var title_f39_2_39968="Growth in childhood cancer";
var content_f39_2_39968=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Slow growth and growth recovery in childhood cancer patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 391px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Left: height curve depicting slowed growth velocity in a girl undergoing treatment for childhood cancer at age six years. The slow growth velocity may result from neuraxis, mantle, or total body irradiation, chemotherapy, decreased nutritional intake, increased metabolic needs, or intercurrent illness. Right: height curve depicting improved growth rate for a boy after completion of therapy soon after age six years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Susan Rose, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39968=[""].join("\n");
var outline_f39_2_39968=null;
var title_f39_2_39969="Audiograms in Cogans I";
var content_f39_2_39969=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F67321%7ERHEUM%2F81989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F67321%7ERHEUM%2F81989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Serial pure tone audiograms in Cogan's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 144px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three audiograms are presented from a patient with Cogan's syndrome and hearing loss: A) Two months after the onset of Cogan's syndrome during initial corticosteroid therapy; B) Four and one-half years into disease course while taking alternate-day corticosteroid therapy; C) Eight years after onset of disease with stable to improved hearing acuity. _-----_, right ear; X-----X, left ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Haynes, BF, Kaiser-Kupfer, MI, Mason, P, et al. Corgan syndrome: Studies in thirteen patients, long-term follow-up, and a review of the literature. Medicine 1980; 59:426. Copyright &copy;1980 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Audiograms in Cogan's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 443px; height: 197px; background-image: url(data:image/gif;base64,R0lGODlhuwHFAMQAAP///wAAAO7u7t3d3czMzKqqqru7u4iIiHd3d5mZmWZmZlVVVURERDMzMyIiIhEREYCAgODg4MDAwCAgIDAwMHBwcBAQEKCgoEBAQPDw8NDQ0FBQULCwsGBgYAAAAAAAACH5BAAAAAAALAAAAAC7AcUAAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmU0ICyIKDJIREhqJCQUiBaeDohKjiAEBIrCyJbGIFLAZr7azAAgjBgIOCiIEdxCwsBuHsAwKs7GxBcnRBraBEckXiA8BBwCzzw4A3Qi9vXTIEBnohMkOsQkBAtHzAQ+y14AVARcBFIiePYAHQB4BBg+egeOlTw4yDPwgMOO10Bc4WgAINPwzYQKACQEiTJQFz9a0XwFO/wUgZgfZBAwBJogsdM7eRV70AhgYxCGABQwWAlQYWTGAgwL0QAVAwCBAp5YBJKozFKCBrF8LoImw1q2boA1RIfCzgGiACAHFAoAaMaBBgaw76yDrIAHXtkZrSSQoZgwQO4AicHHQBBWWBYmEEytezLix48eQI0ueTLmy5cuYk3xDtaIvgLhxM4ueEuzN5osAEKrQKGJB3AB7UyhETRDFOIwpMdYyi5rERswJ8FVMccAquNssUXASIbzAbRMJfgEoIH2tAd4lCKC1WGwriu06ARx46gD7CIL0RDTgFZsE0jdak4U+Ee2Zyt4mao6DpSq/ygAEWBNNVrVAY+BCG603nP+B5vkyizn56EbIALnB0oBxKjzQAALJ8YeCVwtdB8t2BQqQ0wDyIFCARvOJB8sA4qRmSzeeRQiLAgUckFIBGpp3YzIIDARLN/PcEYtZ1LCQklEXMfBcgQikdw4KsUA4izzR1ILgQkhGU+Nx9xSllW9bQtMUfoOsNEIyT6mQjFkH8Jicb9KAAg9asJkgjDXEeFORNSc8E0s3/4GTFwAUMlAcAAqKSYIDD2RlTE3D1UHRmm7SCcACwplgVXoLUonaOSjRN82C9ZAJ6II7NUSNVZTmVshb6h1JIHEOXEcPnnOOYNwsjbYzwgHyyNLqpSXoiA+Ejq7JIUM2YgiAONAWJe3/HKkiiqamGRWVwrH1GFBbfo5OkyUJq2YLzXxJVsSsq6jaSGKanahp1plUdqpjABSeVoIC6zllYaMlUJhAcPC4BQ8BCnxpDawN6DjpgCS0dSOPOplLnXQZVWiUAyXlBOAdKnklbC1nUkrlLIRWmt/EBVBYj6sG7jezCYAaeDOZRiWZ5W+AvHbkyZpyVZCaJ8gsS6EoxDaLjur1utA38nxzzrUimLVwRRRyfNYsrC3YHxTzEtHXlyqUnQJ2DSp5lYQiHBC2LQjctoDaIwggXZHbojb3U0APIoAqLZ4Q13tF4J03CX0NsFnbJahCor9gxHLrFZCPpnke1QS+wj1GHeAA/wMMXMgAU6afDrIC5izAgOsRIyA7AgccgEAwDhBQQALEHoDjAgUoUHuODBDwAFK+yx5pAwt8wnzpS8G2wIWwlFQSNckISg2Rr1L/ywOOIzDAAGMnNsB2250/QIAEtE8sKgosYMwntttOe+2mrJiAAQbsT34C7Qvg+rRjAAWgJUAmIsD4TGQiRJklLnITgO4MoDv/UYc6xNAI6wzYFAcwZX8NSEjdGmAA1DWAdcPjRO8UoIABWENxOnhR31owjxVJcH0MNNECjwUAAexkgNoJkAFSkYB6xcN+1EmA8E63gCY+ICcEWADInERF2L0OARGbhu1YeDDa8a5+pvDdQggQnf8NvYV2rvOdQmCBRey58Y1wjCPRnDAyGsAiKwIbhoYQoscojSgBWQSj7VJhOwXCQjsM2EnpZseU1zVAZpZTwDAS4CRixY+Jz8pTOTjVgNJpaAFBIiEbzXG7BjjAd81TYycERD4E7EVHC1DideKXAJEJgHTOUCLrnMTCT8DGHJ7LwblkwMIYUCcGdYRBMOkjg2WSC5kzCBMUVhKwGuTGGDcUwALVp4qqZO0sMHQZC1iEzPKRgIFn2UqRMpcfyimpcDR0Zw7W06onwaCAMdgfMr3mAmdqCZoAVWY04ZmEaQxAQwmZgQDa1M9wniAVMXCAQ01gTxegLW3+zBtDYXC3H6z/p4MZjVxFV8ApZIYUbjRsJkFTcNIZfq49T4BGp2BAj4uy1KaykaebVkolnaYgSOVEJk9RUACs9SAeNFhoDIQXgxM286nIxKmoAqpMqSqBnS0AnzKHaoIF+JRKVu0qVk8QRaFGVQYUmqg1Y4GvfG6UBadDJkz7CVVljvWZAlXpNC00RxqG9VF3LcGGzFrVGDCMsC/oaAxqGoQquVQFzojoWz/31RMwK692pSpdm/nXIkDNBg3oLHNEKwIOBXWrMTDAoWjI1RKURwYaCexa/dkQVyJzsm6S2goI9oKW8q23dcXsXulhzhbQQ7Y9DA8MbEdTWfWWnywoljKL66a5ugC5/3b8LX2iQSESrLYFuM2UDIz6ObWSCZnmXVN6MQWFU8mCvN45GuP4BQPoKmmmLDhuDKIkA4kKt5/YHQFpZdAUUKGANdHgWNh6O9LzKdCB3SoSAQOUABRRMEArMkaxGpdOlgZ3s/8F8V776iCrOakvu7JCS2lg37XhN7/wVYE1WmvHtJRgXj87FH80xJQpXmh0pqxH7RxAPZCVRCAEspCiPrYhNq3HdVzSyPFEV5LSmTLJAJJiwOLIPTm68XpeDnMyHuAk5n2RduAYMBTI19E6rqqH59QO+XSnHVgYgFOmgJTrXtdE1wkPFko8Xe1qxyFXHmwB5DPKW8ZXgCHujlgP3P+L0j7D6J0cTHc9VNRwSAgwPqvOAcExxR8thMpGlvGR+9qUinQZpySSkXUTE0KeHvuz0MgPLRTU5nV6mEMJgmOjDiXxCfBlimIIQAHBcOH4JO2NCaYiRxiM5e4IgBLwxax941Pgg7tDoeLWiNG8+owBaofstxzASVJshrCR0K5vTUsWsdEIgCLmugpzCEUMCB6iZlFCBSrRFKYYN4f6xx8CnLB+W+QQCx9ARv7Apqjx+/FSGOUNQcVpGFKU2+mCN77I9sKA/Gsf/8iHlFPIG1HCAyAZqXOAIdpufYeUXf+YAsoiIhtgCREUECB5ORSsRS3nhcGL3bbY7xI9xEcHbjP/AwwEP2nkqwMRGXYeec4VMCDA1IZBWlM7A/4qXes0ON4PKCmAVKfUu7p1U4tZSuPz+Ha94IC7dmnIdPpGoS8MN660BDD0FOhNBn9/gYFfELPUxlhPdncB35muI7hvFmTUZUHeC4taZfp2wIlvKDLrzvQeQDIZjt/3ehkAd9HBgJwwiOtyT5r5/CbzBQvugUpKFU3MR55KcG/eh+mO3s0vXQ36fcEDrLuCot5TuS9QveAPXzDku0CrsJV1hPSqzLVTKcBo1izvkf45zj+hKfJeNwq2/oIKG7bv33k9DcM7/rmrgEJpvylaW88DW7R1uqftLfHdhH4P+577buJ9afBm/9clA84BA9MwYABkTCFFD22XXGqmEaHXTysxa5/zT5lVfSbVTHIndxz4gVDAGtKFViOVIQ8oX7DnfitgW/UVUgPAfkmjfi1AgD+QDDTkXiiVdCIGYL+nTPvHUgFmgfrXXtdgSjOoDy8keEyyesdngI53UreHApXld0NgC3eVYCMAIr31G3LGa2YxKVaBIsawOwdDRET0DaMzHTHjQz+kOL61ezrYTycIBOYgIGpFOnzjOEVgdCkQey4gN98BTrz2GdZnAhL4fzRVhePwWZkyca2haPDQSOZAZsmQMk6xHiAzPUz2AN0AD4LiAFkxfEOCPUSyEKdzRwOBELgEZPUQfv+gI2awGIuy+CpNZFoUomaNRVtIYXcaJB4IQG35pkRYlBBOYS6cUhUcciHNI0VedXAvEjyDJjsbRG5XJyDBQEbj9g0WNm4QpTQGEDG9VG/BMXxXdiNNURUKwInxMyTrsY7eQDp1U4wI8Q2qtSywMEjjoQDRwUL8A0qqxUNAwHcAIFHLFA2n4ScSdB3rgyg6pE2fAQ7xRyURuV1swRZokZD+5iDUFif8M0SmIDtykz/gwHAXJkDKVpFNEYUjQAygcj6ONjhEBDBBhkcT6AOHxHzkoBveuCKpsD4AREGq9RmzgCL70z+p4JFxwlQyhEKzw0Kc4CT8si/78wmSBAoFoCj/5/Y+OYEo4pNt55M1ZvGVdvYZCnRD6zNE/FNLUqY7+nM71AY8iOI7g3MPLLQ7XiWTDGAKZlaM4mcDNkhDT/KG2qckE8lMg3mBiDWEUCAPeMKHj1IVsjJ4LdAAP4gCNLgCI0h4TxgDUwgdNEB1ufh18LZP+ddPJShelecCONhbKukfUTAblNQC5oAdfsgC/BMD3fUCSbhchZkdT5SCnZk3MsgCl2WTP2JHJzicbtKa3EJ4vlWZ0OFbc+hcMfWXsHVSYoSALqicKaBv2ilXNAV9WrdiNHQNThFNQRiEzLkmp9l+zbSeKIh/pWkGmdkCw8CZITUNpRecI7CaLNAWizV5/zBQnzugD/fXW3KHeUGIk+4hnTDAW3LIWVHQbjJgAP13Ah6En9oJd8xjWI75UPT3fu0pG+R5X9MhTv2EedDpmso0oibgn/EEA7ORgcrUm0LQeLVCA4zoAvGzVCFlDQMmO6l1odnhfP8pnrpZoivQZUiDmGsCnxB5WxvYgkFYiK51ec3En3R4DfSwooZDpIL1oZYVUgbRVGLaVSEVWzSVOzKwoz0QP6ITY0BXiuwFgP6nTHBXeFL6AufWTF5aC1Y6BPfXlwVjoyPQcy1woCuogirwPi3YXIsVoitwmUoQC2uUF4QqC51QNueDFgvkkBMXcu6TPwdTlH6UO0U5Qe2zIv+dCmcEGoefw6CPEk2BKgTmQqHROX1x46LCdHotRUGG5YK16h4zUJuVCg5W0yYlUTejMz3MMzqHlCP74kpCMhAa0kmc+GR4tI7Zeg+Qcg+cSCjJUFTXem4JYTq+tBC5smVdhiWzSA378q7vuhA1uQQvElqX5aYFI2cHoDUpMTvOwAnTg0tN5EvURGQsxDzj4Q2UZEBZQZlkSG04Eh0dOW6GNA/kk2sDlLFoyUMHUWi2k1Dm8gCqBWjwsBOdeJVO5juAlietg0Un9JRNBJB0ZDVRKgKgiCjYtj5hqbNwBg7JyavNWXyoMGsrch38QzsSSwxd4kIK5JXtQyJ4gp2O+H7/p2AzY3AquZkPxaEho8NLdWkNSjEPUWRzIBsnoEQs5hInGhI/o3NuaiEQFJcSIfQAwASV4QoPQvKK94gQz9NJKVcRRbU/jaZae7FQzJVqCeBf43E7WPQ6L1cSPHIKw1gSnZQwSxEjQRB+K6Vp8qBjArUfvIoPyNKIsjBROgGsgVW6NCSrdapMWgoFi8ILvKEjodFADXRjGQGmJICoiwp4cGc8S9VfV3APWaFW9uQnFFiJiXoghJktSlItbiINHlKeuMmoOwUG7tUOuZtYrusgTBgDXmVMvFsMJ9gWczijNXgD3Lld5kkNkLIhZFa0ynuV8dNLTmkLAhIL4gIpINNJ/1c0WOp6JF/rDE75DFaDq/wXrOgpBQp8YCVQnIlavo94TzB4Ahrio8cHnzAyAxB6VGohqZ/zgDqXD3G0GRaCs3LUTbYQr3G0Ju8bR8YgwdEbqU+Iiz6ghSx2UopKUtt5gj0sYxdcAiRbBMEhqIc0Aw/An3h0jysAHiFMW9Z5AibSIdWECtpUP7QTlFuyham1YkbKBOOywxF1Ur77fkJon9gptF/DwVVbft8LXDBCK9E0xLKQdeJng9Nwwd4AIM9wV1e8bl4hM3acqfFJo06wv+RJw5j5vWfch9Q5mXZ8qGkaxqtxnho8dkczlisjCz6CXDvhumgRWgzJAvXyPVMYC/8EgSMs8D438lgwvF9g3HlX8MFLysP5icnCx8Zxs52kJZAy8KpI4BagZ4GACAP3CbtnpcycGcufM6xbEcdqSkd9PMUUqcN1w4C4eaaCBXiTvBW8nBptOgOUigRh6bwyIjxNREa8oz8jJz4VIUAHlDeeKgv4oD4KFHIuFHK3eUj90z8IB0q0k46hNUq79DqnwzphFFkOCMO2cFFjLJsrRkJfcCoaQT2ULL4ZZQzrAW0b80XMSCxZFDqpIDuPdpQoHSE+JGes2mugagvog7s6pIcCgigHQyw3rcV1M25V8RYA3DyyU7CfcDq/aMjrO3FAN33AOogLaSIoHAvYdjBzjCL/zZOOPP2OnNBJBUtzzgBKCxEdoCQ8wsMJrKNwY5tvXtU/FKuP+ggj9WAVumeD8vCt6sZXYnaO8qqkTTAiW4sgFsKk1NDEi1sVowMpjkQ6CBsiVJmJbtsNr+MNRNJEVZYwmgiuDHOPR0YkAdOufJUQkEJmIYTQBAJM01E6RE06GwRKsRAwUURmzTNFA1Fk2AME51gSOnWIIRwaFOwJAVY8yBS7Rq1cUAzTtbDbphcDQawFWfJm62EMnTpAI0dB0TEppCdyQFmSGKmr/fSnIyCkP/uz2tSQZpEj2vTcntqpF9lDr2WnKhDHqslw1vwoLPh6yBZRJwiavQXchpqFbUOn/4CK3NxMUfXqA0M1C03sdpmcWCf1mxx1UlikddydNRG+kvsdTTbgGnvaWwG+Jt9r1FcHohthyMkNyQMuTLMNyZY2J4ysAhHNAra8Nsr7Akb4oNsZ4V1DTLutndDLUdCcGhW+hMK34drdT5EnLNL0AiuuAsK8BH1NYKxnxgt+gtn3ApKkdeuteJa8W3qtAvJjPN7UX988LbGrfP0k5IZCfZ3M4UuV4weQ47nIRjPwyCkw4ifw4ixl5jo8mT/cXHP44LJm1CJA5ona4wLMYMhk5uL8OecQznZOog5sHI1OHLvd4lbHeuEs4qw34cPn5FUIWj9u5l+u4cgUx+2rHttB5/8mkOcSPQUPvOrIjMvi2+OGLOcf8oBdKgO0jgPBYbs/tR1fMr6pJ+uX/uTv2U8EwpguQOkroL5nwOwsoOxzznrfC+22Uck2HsnNSwTxHejysBehXhABBlEDGru3I75qhjjlKUMUOF5brgPWqCSxNgJL7nNrbN/GZOaAhNxwN+Ge0O4pkCJrZydAl9Qo+jklGNPaAg6SNj7ZFrWlQUbGkBA+lGEZph3p7SuIflLzfgJhvpJV0IkeVixH/quxy1Ty+cTbMb8MyUBRe5E6NJCTBUNZzlL8Huk3gOoLgRLv62ivQwC+czDq3M5YMi2UCY9q9AnAQ7LTkDtUSdTCc5W1ZNX/9Doe5IbTMtdFY6sdtrM/43FnjcY8VsIfeARm1DN8Ltxwef1GQCZFBb/XwlZN6mvXRFISnAgkREI6YH9uzSPaTfQfLFTVvFNo0VHUMhIPAOc7jcZyzAPXhyQoprRlS3E9eKQhyRBCRhEwHsQvRLIv/0tk+cAU+IBHm3IkEVM6ewZKoNhw7j1djvqiA+lNTSrug/jdtH9KGd5PsooWsxHeDuRDJhIMg/MZueKFPeRgOGYgNprrCxQgsOLvOJDErTyUv4UOPKtNT/s/x+KSjcaWz1ZCtnMspvA6Y61wVxlL/JIVd9M8ZBgn2pEjajl9vC9gZhHeXdJD7APdjnYdp6BF/wMAAsiRJEWCAECzFMcCHAEhMAFALIvz5AuDMBoIR8CWOiKTymVyUQQ8l49AA2AIOJAlJjeh4DILX7ByUSUnRWhlYp0SABbtBsHdyLqPgle+708FjTEJ2BDYRAEgCNqd5W31MdT1KfA5tvWh/GkWGGmiiZwgKgUUpHQC4uUF+YmuTfm99g08wOXFxrUq3aqeevomJRTVVCoRHZ4qNLpR+iksrgUQr61CKkM/owUw/D2k/oIV9eY5N0ujkfflku2uCTjUurUWSUqJoxF95x8F1KoflS5J4M3VAz93WFnLVrDPjj7uBrA68McAQH1gBMDDhI1Mg4RkBEDs82DhuI1gBv+YI0MNSTgm/sAsIGnxVzh7awT6achwYDaTXF4yGZnTQM5LfTrOBGeTDLo8Ofws8MnkIKZMeQzw5JgVSgCrR9hBW5rUoa9gfhhs5dJA7BIsOdO6ZDtKIkOjeaiO1SV3iY9mUpc4+KsX6rY+BjyC0dm2SEYHcJngy/sNaJfHZQrnUeyGAV1VmN1EzhOgs5sHpEHv3RROAWUmB7yucWxQcBKhDGWuOWzwcRGSrZU0wC35z282n12lBGc5iTZWwsm4TVcxHu3az/XN6hadCYMXnLyG7NPiT8Y1QPwcmL5mvEjLTzoRYoh4OBcnpFr+MRQ+dvKf84NWd8RTfchh0H7mEXX/1mn0gXOAfqMdwcB1XDgA2xEh1VKLAnVkOMAMejA3IRMo+UGAXW6cCF1NfRCwIIM/1cTWE4RYlRoSBRyIRgPlZeMiGA+UghFIQkKEEQAYQWQaKwnaQo8t/b24zyEvXHEEEQm06IUIBSAQlRfJADDAEwl0R8JrDmCpAAIGfIHAmAVwiQACBRBgApYCjBHFAQcYAAcBBBhwgIf0PGFCCwvsuecCIixKlH0DJHOCIg9ISMVaQxShgDEBTBFjpjF218AIcxqQYHluRpnXMVB0VoSYB3THWgAKMPDDAQ4UQMholLwWlZw5KMAlM0XMaYYcce5pAAkvGBOHRBLBaYUia34h/6YNtXaEgBc5ONAAJUVwEk2tPnTbJacsoFqEAwQEEY0TCewx6wFrcRXAABXu0YCyaipygDN9FTccnmtFA4CSKQyQCZJGIgFHP/+1tVyYphiBJMIgJTCAAYRWUScBGg/gocYGhBySm6UMkBEcKTNnI8UhbWxCqV0CwWlvAacKjURjpuLWyin/OWSYOHJ1JKAU0VlnAaWSgAK4ezjAQNMKJEpJQTG0UeEAErUYMp2lSsIpiEkYaTEVR5b88Q1wzjBAGzQCACefgfYJK5xdajwrAfjm4O8KxgoxRQ3HzXRFp6RwYQADAhhyyggT+cFwHqiy6GMXUC5RAMQtF2E5EynmTP9TFBACkACTm3m+RLBQWahSgCk46EeffoT8B5n0hePmXrjV4Jcfa+bkcumEk4HA5mkcTzEcRCQPgAIihh4ebUQRQdLtBKYOXOvKsSLxPtDPxcr23A93fXx/aAwV5mWArlQz3qdA+eTgJ/H8HwjQH6WnOY7YsJNrqMkg62vC6aBBvB8dUC3/Q4PU/pAeBhGBNa+7UAHPMT4mLKCCTGle/DjoPOGFZhnCS4QH6VMRzeRBAOrR0QWlMEAkVOgsE1xUTlZYvPaBI3++KIIG1+CC3+HQNfwDgxfQ40H8/U6HKbgeJuDHoNEp8R8vtFIQpZA95nhwVmepYvgmscBsTFF2VEj/WezuN0EHXBGGNkxMFDX1uzACAC3NSCAX3Bg6FSFOEwZo4Sj4yBw/sgSQ+4CjFhnSw5+sEQz6Gs4VNjVEKISkOf94JBcouYQvkiFhtONiEnQDCeGxxnZRLB9ADsAj0VjyjzmZoOn8sDRYJHJEp0wMJ5PQQAbhBEamqEF4xOCHVvbBlL8roQe5xI38kCeWoetUHMUSCzeFh44zmSAUBJmCBmAIRPBwWAoyuIRZxgGcLjnkT+DIiln542xig4KAAkACBuAIFK8xHdUkcgUbfCk9c3uNmnwZrjBhyUN9CtraADKjBMnMBCPYGA0Zo6xlcYYiCdhTAuhFMC51Q0IP+FvU/4pgHyp4KhwZpULGiGWCoLFMckio0h1V5NKuGIIl/GgAA9j0AzXZqkU7k8EIJlqCFkDEUMbkIaDq1KeRmY5kbbhnCkjWJ5INIFd/MmbRCDCnOqXnBNvy1wuKQAJ67smdN+gBAmaBBXaZkgdqcgFOD0CLKdAiKmoSlZxAoS1YOW2EoumEWNQVR6vAymhvKE9GCpQHQ/AhQ4O9wZ/o4hZlee2n89zY44QS1RlQJGUh+9MN2hCMIDlMSEcqD86KZgWltYASmgqpXiUTgw8mUmwBcFQlzqYHIQkNJBARG9D+tNmVbUxZXPGa0kCCNBLsMWUFAxSdNPaxlBHJFJYJrWlX5v+nkPxJbVDwbB3mJrcS8EkBAnBTWRf1q+50JyoMUJOlxEofJ7AGkwDoVtxEQc7CTSSNerCmFSZIAA9CShO11N9XwGcEkgDql6m05YKR8IABx0++TLhvS5UgYX14tEEpeMdK9dvNC1v4D01xw2vFU0wnJmCUJa5wW2IwWy7U4Bj0EACF61djJDQAwgbzcBx1vLp08LgrxOEvemTV4CTsCSo3FpA4VQfHAjgRys0QnpR/OUoGRQINQ9xbk5OQY/FFJCc8jiEklmwKIh9MMsF4wQPMfIQ5NcPMAqAFVJyoOCtDRXhmcaUTn4gf9PE3y+lw84uP4mYgQQXEzOHxdt/b2iP/ADMPwjxsn9c75V9mMYpu/UMBpBm60i4BAV1GwgKOfE1Fs4TQyhzFqmuD6iOIlzitVk1NXk1qHZeaRaNUgI73fNgoFiCKBBglJ1icuXywZxymNpiqWaFjXLFi1kegw5CHUwA+AKXYUHBSrIM5aiRQk76fdCUIhcdSwzw6KZ7yBA6cjZBoDyVKDiA0owXNoCtY7sX2uRF5kCm7b2vB34ahHTW1bewleDqmBrfCwdEAcEA8fGKyQ5+AI56OGMWlaGDasBH6pFIlEEIZHbrYxK6AAsaxbFDZ/Ri8oLANZW3Mp9+tU7W0sbU58akFMQsZluqgnyOVZoR9nm/DWUIxcBBl/zQkSsGw4V3J2gUqTFm47KA2BrKQndxeDA9TyWZXp9FCoQof59FuX9iPIKHNYR6yglN361lTkkCFvpXZ3KDg5nPG7TmEKKkN7Eexj/2AS4uixLhu1QIe9qBgOsCoqEihOwHAalFNq6ucbhUmVyUAUeBNTwtyLhFdARROMaPT0gyFghp8QfLaMkBM0Iu/w3g1xlToVjg2Jav7sDb36VY3O227GCh8gXRcGcF6tZX5DaVnZEVDOUaeOgPGMa4NUej5n6y+MUBVIRhfUEDK4HS3OjwvqqWgAuu/UCoPpadOc5KyQw0lURydACTbCMbLsZoyLJnupAa1gb8gn7FgURbVyP+JAhjOvV0LF8jJFaDFKQjSLHWZp40CHFmeQ0SRcImHXu2eusHLOrWFKYwfSXgFw6TUYi0S0IXFkjQDwAXVCq0M1yGMKUQcPziQrf1B9cCALkHSfpVIIdmBDBIIDQ4ABHYSVHjQHkxEBs7EALkYV1RCVEEFwHVCcIwDDa4LenAaDc4OelhcZjQHqMWRh61IPPjVXUhb/FCZ8AyII4zQAJQQ7vwZE1BNCqiHEE4bFIKLJEGDm9Fgo0lHmDndcNDUFDBaHDXYdxxJawQDzglfNvDXpvWBr7lBGrqBJz0iEmLYPtBhE8DCsnVOOiybJmhdMBGHxXEYg0yBOW0Yqs2IKVD/TEgVjRHYSB7lQZUdlvB0Q+SUUEwVXVPVxBY6DyvQYGmF4l1wIg1iEzDW4CemUCYuQQmigROM1yG24rrhQyb4YDaUoRU40flMjo7poixYokVshyY82Sd1hMvIYjy42QLEYDESxx7mgbXwkiZQmxhqx6qJCQ/UgPcUzCSYm/CoAYuM0DcWnRd62cPJgGiUimnpzB+WRjBmY0LmhDIGE1AIDkMKQBbhzGoQiIDt4C814gidW9Hd3jCCXIn1Ap0p21XEDezE0Roc4yMSxztChR69SHAFUTB4lPA9wATZRIYYCURcwW4ZwYf8xLJBYjxMpMClgy82XEtIpMUR2Sm0RsXg/xZ0pRzKbdsbzNh+cFMVDhwrfKJJjoW1EAE57UFBiImUOIAP0EqtEF4OrFebWUsQeosOdAvV3MF6vZhsMcZXGV+XBFbRoITpvMa0vEZ64IpOBsoPtOValIIxdIMPCIOsdMqm1IQzFAHB6J6nHE6MjMQOeEtgNM4uSklrEMLOGIWr9AA7Zp5VUQKXJJ077VFSeQcLlJ5VLR+ebGbp8AnjsEnpQEh6jF7IwNwIxKFXjQCaRJULnACfIAC7FM0e7RGXOAibiEGX1AlMlRUVwIETHIlpeBJjbA28HNfR4Fy7+V5eLNxPFMRsCVk3wctzPVeRvMHEGIKOaYscjiOIhI0RLP9NqXjfd7VAKUxBY4netcFB5gmK2qxFUOEWkWRTHPmkWNCYU+HKEppmLLKTy+3DjCnWVcKBe4mMALRBVG0Wy82XDaxdaXJd2nigCUKDhIVodQFd2QDN2kFBKRDF48DAGbBAgIlJqW3NQCWm9yXVeEhkXrhYOMwSeNbLhTBjh8ajTLTG0E2lQRCZjm2YaTIkdIyfKNCgOS3IPc3SCFHTCHEpNb3I2QRD8lhDobkBQd5ELwAFIUScCZAbK0yQIx5FOIpOGPoQc7DCTFrYG+5DO7JCDBLaHl5jUmQehj0cN87po34pq50FHFHqGrDAntqOl4ojQsbgLMnKKChqOoyiWHL/A0VmA0gZZK6lg63h6SgshXs5hfDM6l3w2Fo60C5aIo0tarCGgTwQUqqiak0SB6vikZOCYjAG4ymlE5FFnJg8XE+KEacBqieElDK2SKHCAhn8U+9BARSeqmhEHJdS6VjQqbZy4qRa6j5sxCI6XGnlKmjAUVK2Q7aC4tm4CSqmQBSNkFzozrZ1xZJmAyeKWLISx92hyF6xIku468OJyRAxRh/daji82kga0C/1mcaymEGOgrCKBoi9gq4Ij5zGQ7uqqkEwrLq5E6fcwqbGhqEGhTigIyyio5lxqfyoIahG4hNA6VecRcTxV29467EibWZoglPORNToJBT0jMsYwuc1/4xmlUztuIl4gU2pvIbylI4YaNHG6FaYGNbRGckqZsPRyoImTJrPgkMiaN0pBKOxDkLDrEh35UrM3YD1VZPRQAR92mcL2mo8LBAlncI2TQywzsD4ZWNemOw24GGmxFinHM7h3J6LjcRmcmY4fNTk3oy3yF6wyAqsPGZvxs1eEgsPjU7teQrBfGZnwm7syi6iuu3vwSKhYAqnzJlp/MDgrQJrAknmwZPmREWLBNATsMlE6Zx1sp4KiBQiPAAQaIquRIUDWMsKyIs21MpskQt4ukqFPGaOcYaJ+EAD4AgVfAFNLcpoiIHUdFrXzgpKbMnW8AkL7A2bhBIeSobnkp0Mvv8HoUjEoAjUDHyMbgmlwcroEkxsq/aDfH3UtdREQRSI2yApjixkDUjEfPoWSGjXyqTjCbpBJOlrm5rWksqtC0LX3iZdGxRVVGUMBcfMFhjBZX2NUB7JCneo8XgEaYEBhwDdbnENykFdkWTXiLYkcbJNi0jV0tSBDdBYCj8fxcJjCK8bGzzBqxzBuqbtt0JDorIBZzJDN2UYV6zau8LEtLKpqJnmPdHuaZIxjqltJAbZaaZOwNLsOHgCm7oB5XSVR/jdaXxwNgSjmYVDI1Qu8ehvOBiuqcXn5PRZKG2oDVRI2xIRoSZtbLTxUZ6mvEKsI3Toq5nx28oafejKFLCGjiH/8MGubFjcI1d0BxgwQI5kMicgpASWkAFcmWTwld3dcRdfbLj6skxxiougo9tcqihfMoo0Lt4ZMzJ6ojPfwyGYQgmkEg8ige6kBCcj3TD9QdD66nuw6cmiKix+m03kjnqkMoxwrmj0MonlMhei61bGKgqeoDWmUSPTqklqsYZBwpR68y7G8z7EMXS8ZN8G82I8wUKwqEsdXTJv8RvRh+7w7DxTtBsQwpJtJjPFA+bgR7igY6D58whrayYfdEnj0TH/RJO9hzSjbNxYS0cLYwySI5Hxgo6Izb4J9EBnA0KaLuE+o0QwjyE0jzYnxgjRy4aKhvTZqchyKn7sBVm+7Rvu/48bWzNB6zSn+tlRg5xXbWYj96NFQ0h5PBduwY5YcRM2XrVLAALwKWXOdFtBPjVXBJ/ROTR0WGNVTmIrTiM/8IgNGBQ7pzU4tKE51hEbFoxt1AtoRjDnFrLNODbrnkvnuAladESo/E2owAkWZORlY0tcrsX6akPNsNbhLOHsmvZpxwjtibSICWrEjA5L3B5rMI+60HbjyEq36KNj6IAO8MBwsTFO+AALkIAN0Eug3A2ckIDbrBceOHUUpA9ersV72oDuRC/MBgFNYYEZYAGUdURMmEa/vm/+zpsP7MlNiYAIiBeiHIIef4QRXCcY6M56Y6KJCGiAlgwHHzDVrofWhf8HVq6ccP2TQulTotRVrQTKPCyLAB5m5X1MOMieHIrMoNwn6NUtrZJNkUBVnXiBF4DsU5JzTmM49PmW2whXNKhQoChvC/xUl/wAVxDAF7x4FNCVIixOsbUIRVxn7XgIjxZsLnSdkewfUbJoVBFFzGzMjproT5EAnJiGVSnLmrAvr/hLEKxXqODAWqzFlK7BLOAASSfDusQYXYtEDEZkmV9cb0Lg4N4EurL3TOAsUEDlImZRwnpZT1vyCUozYDc0Mut5YOeDXHzWw+5DkKFykEUkf2E5xUgTPnOqOYVQww31G5yIOF81wXSgRQu6uTJHz4Ssn3MHTe/Voyuku6VDoYP/mdpa+k8U7Sh1uMuGubZ6+igMUaneeZ/7tBYkZC7YcX6sNsdp+Y6SumiYOZB9JOe4BBzdYvCAKh0MdqabtCrD4Xqma1tXtDAv0K7/Uq9nlS+qeTagMipHJI9dAY9gc6cfBTX9s4eDLKXXNazxUE63+09okFTvFi9T+yMOnRi2trD7oWgEWdHOUK12ItMJYwm1upvfzA7FOnNc2INP+7NDx7Wz9Iowa9rCokDizhm0wlEXyjiyOsKucjxkYzRyQePw374z9MV5KUtbNSTD+70vgxi6chliu5Tsg5nWiyp6L7tLRvCJAxFsJxvban+29xco1mmlKGdxQsccDY2NuHZd/16QLZvMUoiR4KtaaAIbrvyey1Tv1Z6YwzwXwEHScY3XQBXXEkVUYdz72smamI5hJh0BW11z1QFW3gBb4xg8LMT+vbmgFlLnWCgH3/1GvYiapIQi4CwuSMkCovZpPzBm9salhMOtRM2taG+3dIQxuBiUYUHje/7n515bEv3BPQDLqPWqpGvuve5ZcbXlY/BZ8gAarUp3GA9nXPdqcQU+8JDsAT5coa8wPC/MSiZIWUtJCud7ZIFnhtRsrrQM7G71Bkb40pR404elu/ygA4wN3IIcKc2fUHN23beYZAFQXkS3N4zDpP3ZaDigrF+iEPjTwko98dMABgtyOQGOLACg7P84zyUICBwBIAhA4ADqyrLBSKpDSRCCYRSFoiRvCwwKh8QW4wcDjmBMl4pWIwwGhlnBQDgVAAZuQrAlHABRQRZFMq1m6xPjdEoW4S01aSYYAPSBblR6MJBQMLgQBxdAM0WloBJQcLCA8BLwkDOYcwCJNZXX9SA3J+ryULDgEHoy9mLgI/cw6pIVe5JAW3sbYHvbEEtJGavQdUvwdns8ukSnhPgy6USbOictVKC8FLBAsDVETQQbuwpgKIqwgJ2L7PvSO+Sj8jDr2BhN74uQix+tH2sdDewrRS5v6go2+CWEnK5D0HwdC6AnGcJfLxyAaTEgQLt16RyOEEAQyLuCRGz/7CGHrAG3e7nG1Mtlb9TBXBuTCfxHMmcQeURcBgnJLNcwiaFEUCwQESFRoA0dImP6NBuASRFb5rP6Mmusc1hjPTAW7abOgiApFoS6Am1an8mI/DqDCKxbkAyn/VgXIGbbsUAIoEKh1oXeafySsRUlVeuoZ4oRg8PJlyQ2Kmc7Np6G+FCTFwwUoGjAwEAAccawUVJwAEfSSSOnofL8MHIQucgc7GIZ7TBhmLcS1EQ8uAiagbJzBv5p2Wm0YMqaUZxIx/TzEc/QTQeGpO7e4iqsHWfxG7Fu4YURl582nsiC8MJRJnsckHtl48mTBXdbrzmQEnrwUXIFxCX+ZOfcdJo5/0ILXfI9Z0dYNOWyUjINihLaLQacV4Q2EB4DinwPmdWXGjAQEEpgx504UAA8FSHaXZgtgY8dUnRSGiL3deNhAg5c0cADE0r02kHZnPKDCKsE8MYACiCAzykHHIDAAQkk0MULY+gQiBiDbElllJ6N8KSUDDTAQ2eoHcCAOS8I8IAC5zAA5S+goGBUNtfd+cBfnIGGwCA70HPXUHN06CEt8azwI0OPINJUZsQFUYIJZmRBIhkD1DDAFVd0iUCmZ+BzBQFY4FCFDYuYcFdEkv5UEVCoKhVpGotQMYMtRxTKFyEGeFKFHlWosMuKJrVyqYCEFHBDD+YgwMAC6znwLCoOIP+QZwIMNOusAzyQiVqUU6ZpwAJhIkUAAt1SSSUXwmR6AxY14FBDAVFwEYgBCmDZ5wLNQjtmA5LoeedzguI61maGyBHwdEJWAthzDzTgACpxDPDwvgc50IC/F8dhLih5/nIEZ6DUmfAv5zxSMispm0WJJHLOmScqQrZIcM0234xzzjrjx+gyACAbaQLvblqDlzoYkFoCUD6p9JStaGKvCgeIIaqfmEahhwlZV/XEHSxkbceqluaxSBadwiuqFFMOIiU9OADQLJpMrtfZAoNAxEIpa2tC5aWX5gFAejsPTnjhhh+eliO2AIR4444/Dnnkkk+uDjcR+UN55ppvznnnnn9XDnrooo9Oeummn4566qqvznrrrr8Oe+yyz0577bbfjnvuuu/Oe+++/w588MIPT3zxxh+PfPLKL898884/D3300k9PffXWX4999tpvz3333n8Pfvjibx4CADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serial audiograms demonstating improving hearing with corticosteroid therapy: A) Hearing thresholds prior to therapy; B) Hearing thresholds after corticosteroid therapy. O-----O, right ear; X-----X, left ear.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McCallum, RM, St. Clair, EW, Haynes, BF. Cogan's syndrome. In: Inflammatory Diseases of Blood Vessels, Hoffman, GS, Weyand, CM (Eds). Marcel Dekker, Inc., New York City 2002. Copyright &copy;2002 Marcel Dekker, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39969=[""].join("\n");
var outline_f39_2_39969=null;
var title_f39_2_39970="Early stage breast cancer treatment in premenopausal women";
var content_f39_2_39970=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Early stage breast cancer treatment in premenopausal women (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/2/39970/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39970/contributors\" id=\"au5565\">",
"       Kathleen I Pritchard, MD, FRCPC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/2/39970/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39970/contributors\" id=\"se4959\">",
"       Daniel F Hayes, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?39/2/39970/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39970/contributors\" id=\"de8229\">",
"       Don S Dizon, MD, FACP",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/2/39970?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Breast cancer is the most common female cancer in the United States. Finding and treating breast cancer in the early stages allows many women to be cured.",
"    </p>",
"    <p>",
"     Following surgery, systemic (body-wide) anticancer treatment is often recommended to eliminate any microscopic tumor cells that might remain in the body. This type of therapy is called adjuvant therapy, and it is a very important component of breast cancer treatment. Adjuvant systemic therapy significantly decreases the chance that the cancer will return (or recur), and it also improves a woman's chance of surviving her cancer.",
"    </p>",
"    <p>",
"     There are three options for systemic adjuvant therapy of early breast cancer: endocrine therapy, chemotherapy, and trastuzumab (Herceptin). The choice between these treatments depends upon whether the breast cancer is hormone-responsive and whether it makes a protein called HER2.",
"    </p>",
"    <p>",
"     This article will focus on adjuvant therapy for",
"     <strong>",
"      premenopausal",
"     </strong>",
"     women with hormone-responsive breast cancer. Adjuvant treatment for",
"     <strong>",
"      postmenopausal",
"     </strong>",
"     women with hormone-responsive breast cancer is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/52/26437?source=see_link\">",
"      \"Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DEFINING HORMONE- RESPONSIVE BREAST CANCER",
"     </span>",
"    </p>",
"    <p>",
"     About 50 to 70 percent of breast cancers require the female hormone estrogen (estradiol) to grow, while other breast cancers are able to grow without estrogen. Estrogen-dependent breast cancer cells produce hormone receptors, which can be estrogen receptors (ER), progesterone receptors (PR), or both. These cancers are known as \"hormone-responsive\".",
"    </p>",
"    <p>",
"     If your breast cancer is hormone-responsive, you are more likely to benefit from treatments that lower estrogen levels or block the actions of estrogen. These treatments are referred to as endocrine or hormone therapies.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ENDOCRINE THERAPY OPTIONS",
"     </span>",
"    </p>",
"    <p>",
"     The goal of adjuvant endocrine therapy is to prevent breast cancer cells from receiving stimulation from estrogen. &nbsp;",
"    </p>",
"    <p>",
"     The options for endocrine therapy in premenopausal women include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The drug tamoxifen",
"      </li>",
"      <li>",
"       A drug or surgery that prevents the ovaries from making estrogen (see",
"       <a class=\"local\" href=\"#H6\">",
"        'Ovarian suppression'",
"       </a>",
"       below)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Tamoxifen",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tamoxifen (Nolvadex) prevents estrogen from stimulating growth of the breast cancer cells.",
"    </p>",
"    <p>",
"     Tamoxifen is usually recommended for five years, although the benefits last for at least ten years after the drug is stopped. Taking tamoxifen for more than five years does not add further benefit, and the risk of side effects such as uterine cancer increases with longer treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tamoxifen may increase the risk of the following, particularly in women over age 55 years:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cancer of the uterus (endometrial cancer and sarcoma)",
"      </li>",
"      <li>",
"       Blood clots within deep veins (deep vein thrombosis), usually in the legs, which can travel to the lungs (pulmonary embolism) (see",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"        \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Whether tamoxifen increases the risk of stroke, particularly in women under the age of 55, is controversial.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     For most women, the benefits of tamoxifen in preventing a recurrence of breast cancer far outweigh the risks of uterine cancer, blood clots, or other long-term effects. However, the risks may be higher for women with risk factors for blood clots or stroke (eg, prior history of blood clots in the leg or lung, history of smoking).",
"    </p>",
"    <p>",
"     Tamoxifen may cause other side effects, particularly hot flashes and vaginal discharge. Premenopausal women receiving adjuvant tamoxifen are discouraged from becoming pregnant. Tamoxifen does not cause infertility. Premenopausal women who are taking tamoxifen and are sexually active should use effective nonhormonal contraception while they are on tamoxifen and for about two months after discontinuing the therapy.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Ovarian suppression",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ovarian suppression refers to any treatment that causes the ovaries to stop making estrogen. The ovaries can be suppressed in one of several ways:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Surgical removal of the ovaries (called oophorectomy) or radiation treatment of the ovaries, both of which permanently stop the ovaries from making hormones.",
"      </li>",
"      <li>",
"       Drugs called gonadotropin releasing hormone (GnRH) agonists stop the ovaries from making estrogen temporarily. The most commonly used drug in this class is goserelin (Zoladex), which is given as a monthly injection. The treatment is usually given for five years.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     All forms of ovarian suppression cause a rapid onset of menopause symptoms (hot flashes, night sweats, mood swings, vaginal dryness), which can be severe. Treatment for these symptoms is available. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"      \"Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Aromatase inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;A class of drugs that is used for endocrine therapy in POSTmenopausal women is the aromatase inhibitors (including anastrozole, letrozole or exemestane). In general, aromatase inhibitors are not given to PREmenopausal women.",
"    </p>",
"    <p>",
"     But women who are premenopausal before treatment may become menopausal; an aromatase inhibitor may then be considered. You should discuss the indications, risks, and benefits of this option with your doctor.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ENDOCRINE THERAPY OR CHEMOTHERAPY OR BOTH?",
"     </span>",
"    </p>",
"    <p>",
"     Endocrine therapy is recommended for women with ER-positive breast cancer. However, it is not clear if additional treatment (chemotherapy) is also needed.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Most doctors agree that endocrine therapy alone is adequate for premenopausal women with low-risk tumors (ie, those that are node-negative,",
"       <span class=\"nowrap\">",
"        ER/PR-positive,",
"       </span>",
"       small (less than 1 cm) and lacking unfavorable microscopic features) [",
"       <a class=\"abstract\" href=\"mobipreview.htm?39/2/39970/abstract/1,2\">",
"        1,2",
"       </a>",
"       ].",
"      </li>",
"      <li>",
"       It is not clear if endocrine therapy alone is enough for women with higher risk ER-positive breast cancers (ie, those with involved lymph nodes, tumor size larger than 1 cm, or unfavorable microscopic features). Chemotherapy certainly provides benefit for",
"       <strong>",
"        some",
"       </strong>",
"       women with ER-positive early breast cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Two tests are available that can help in deciding if chemotherapy might be helpful.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A test called the 21-gene recurrence score assay (also called Oncotype DX&trade;) may be useful to select those women with ER-positive, node-negative early breast cancer who stand to benefit the most from chemotherapy.",
"      </li>",
"      <li>",
"       A web-based assessment program (Adjuvant! Online,",
"       <a class=\"external\" href=\"file://www.adjuvantonline.com/\">",
"        www.adjuvantonline.com",
"       </a>",
"       ) is available that can assist in estimating the relative risks and benefits of chemotherapy (as well as endocrine therapy).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Progress in treating breast cancer requires that better treatments be identified through clinical trials, which are conducted all over the world. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. Ask for more information about clinical trials or read about clinical trials at:",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials/learningabout\">",
"      www.cancer.gov/clinicaltrials/learningabout",
"     </a>",
"    </p>",
"    <p>",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov/",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      FOLLOW UP AFTER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     A summary of the American Society of Clinical Oncology's recommendations for surveillance after breast cancer treatment is provided in the following table (",
"     <a class=\"graphic graphic_table graphicRef77225 \" href=\"mobipreview.htm?9/63/10236\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     There are many options for the adjuvant therapy of breast cancer. Expert guidelines can help to guide decisions. However, because individual factors strongly influence the choice of therapy, you should discuss the options for adjuvant therapy with your doctor to determine which therapy is best for you.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804571392\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7260602\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/19/2357?source=see_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/62/11236?source=see_link\">",
"      Patient information: Breast reconstruction after mastectomy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/8/8321?source=see_link\">",
"      Patient information: Choosing treatment for early-stage breast cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3492?source=see_link\">",
"      Patient information: Ductal carcinoma in situ (DCIS) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7260653\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/52/26437?source=see_link\">",
"      Patient information: Early stage breast cancer treatment in postmenopausal women (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39386?source=see_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24138?source=see_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19194?source=see_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link\">",
"      Breast conserving therapy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/33/41496?source=see_link\">",
"      Acute side effects of adjuvant chemotherapy for early stage breast cancer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-4-CANCER",
"     <br/>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.nci.nih.gov/\">",
"      www.nci.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Society of Clinical Oncology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"      www.cancer.net/portal/site/patient",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Comprehensive Cancer Network",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nccn.com/\">",
"      www.nccn.com",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Cancer Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; 1-800-ACS-2345",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.org/\">",
"      www.cancer.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus\">",
"      www.nlm.nih.gov/medlineplus",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Adjuvant! Online",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.adjuvantonline.com/\">",
"      www.adjuvantonline.com/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Susan G. Komen Breast Cancer Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.komen.org/\">",
"      www.komen.org",
"     </a>",
"     )",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Patient support",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a number of online forums where patients can find information and support from other people with similar conditions.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://about.com/\">",
"        About.com",
"       </a>",
"       Breast Cancer Forum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://breastcancer.about.com/forum\">",
"      file://breastcancer.about.com/forum",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?39/2/39970/abstract/1-7\">",
"      1-7",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/2/39970?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39970/abstract/2\">",
"      Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007; 18:1133.",
"     </a>",
"    </li>",
"    <li>",
"     Enrollment information for the TEXT and SOFT trials summarized at www.youngsurvival.org/research/current-studies/clinical-trial-listing/ (Accessed on September 22, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39970/abstract/4\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39970/abstract/5\">",
"      Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39970/abstract/6\">",
"      Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39970/abstract/7\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378:771.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f39_2_39970=[""].join("\n");
var outline_f39_2_39970=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DEFINING HORMONE- RESPONSIVE BREAST CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ENDOCRINE THERAPY OPTIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ENDOCRINE THERAPY OR CHEMOTHERAPY OR BOTH?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           FOLLOW UP AFTER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/63/10236\" title=\"table 1\">",
"           Breast ca surveillance PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f39_2_39971="Pyrithione zinc: Drug information";
var content_f39_2_39971=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyrithione zinc: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      BetaMed&trade; [OTC];",
"     </li>",
"     <li>",
"      DermaZinc&trade; [OTC];",
"     </li>",
"     <li>",
"      DHS&trade; Zinc [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Citrus Breeze 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Citrus Breeze [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Classic Clean 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Classic Clean [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Dry Scalp 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Dry Scalp Care 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Dry Scalp Care [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Dry Scalp [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Extra Volume [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; intensive solutions 2 in 1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; intensive solutions for dry/damaged hair [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; intensive solutions for fine/oily hair [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; intensive solutions for normal hair [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Ocean Lift 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Ocean Lift [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Refresh 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Refresh [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Restoring Shine 2 in 1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Restoring Shine [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Sensitive Care 2 in 1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Sensitive Care [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Smooth &amp; Silky 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Smooth &amp; Silky [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Itchy Dry Scalp [OTC];",
"     </li>",
"     <li>",
"      Skin Care&trade; [OTC];",
"     </li>",
"     <li>",
"      T/Gel&reg; Daily Control 2 in 1 Dandruff Shampoo Plus Conditioner [OTC];",
"     </li>",
"     <li>",
"      T/Gel&reg; Daily Control Dandruff Shampoo [OTC];",
"     </li>",
"     <li>",
"      Zincon&reg; [OTC];",
"     </li>",
"     <li>",
"      ZNP&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F216166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F216154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Dandruff/Seborrhea",
"     </b>",
"     (Products should be used at least twice weekly for best results, but may be used with each washing): Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bar: May be used on body and or scalp; wet area, massage in, and rinse.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo: Should be applied to wet hair and massaged into scalp; rinse. May be followed with conditioner",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F216155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F216145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bar, topical [soap]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DermaZinc&trade;: 2% (112.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ZNP&reg;: 2% (119 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Conditioner, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Classic Clean: 0.5% (400 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Dry Scalp Care: 0.5% (400 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DermaZinc&trade;: 0.25% (120 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Skin Care&trade;: 0.25% (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BetaMed&trade;: 2% (480 mL) [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DermaZinc&trade;: 2% (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DHS&trade; Zinc: 2% (240 mL, 360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Citrus Breeze: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Classic Clean: 1% (50 mL, 420 mL, 700 mL, 1000 mL, 1200 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Dry Scalp: 1% (420 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Dry Scalp Care: 1% (340 mL, 700 mL, 1200 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Extra Volume: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; intensive solutions for dry/damaged hair: 2% (251 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; intensive solutions for fine/oily hair: 2% (251 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; intensive solutions for normal hair: 2% (251 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Ocean Lift: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Refresh: 1% (420 mL, 700 mL, 1000 mL, 1200 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Restoring Shine: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Sensitive Care: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Smooth &amp; Silky: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Itchy Dry Scalp: 1% (207 mL, 325 mL) [contains aloe, benzyl alcohol, moisturizers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T/Gel&reg; Daily Control Dandruff Shampoo: 1% (250 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zincon&reg;: 1% (120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical [with conditioner]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Citrus Breeze 2-in-1: 1% (420 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Classic Clean 2-in-1: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Dry Scalp 2-in-1: 1% (420 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Dry Scalp 2-in-1: 1% (420 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Dry Scalp Care 2-in-1: 1% (700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; intensive solutions 2 in 1: 2% (241 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Ocean Lift 2-in-1: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Refresh 2-in-1: 1% (420 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Restoring Shine 2 in 1: 1% (420 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Sensitive Care 2 in 1: 1% (420 mL, 700 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Smooth &amp; Silky 2-in-1: 1% (420 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     T/Gel&reg; Daily Control 2 in 1 Dandruff Shampoo Plus Conditioner: 1% (250 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical [drops, spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DermaZinc&trade;: 0.25% (120 mL) [contains ethanol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F216138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F216147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use only; avoid eyes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F216146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relieves the itching, irritation, and scalp flaking associated with dandruff and/or seborrheal dermatitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F216170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pyrithione may be confused with Pyridium&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F216149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrithione zinc or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F216141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For external use only; avoid contact with the eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bar",
"     </b>",
"     (ZNP Bar External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (1): $7.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (DermaZinc Spray External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (120 mL): $18.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (DermaZinc Shampoo External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (240 mL): $8.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (DHS Zinc External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (240 mL): $7.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Theraplex Z External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (240 mL): $6.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Shampoo",
"     </b>",
"     (Zincon Dandruff External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (118 mL): $3.83",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F216150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aeroseb (AR);",
"     </li>",
"     <li>",
"      Dan Gard (AU, KP);",
"     </li>",
"     <li>",
"      de-squaman (DE);",
"     </li>",
"     <li>",
"      Desquaman (CH, LU);",
"     </li>",
"     <li>",
"      Dos Ele (AR);",
"     </li>",
"     <li>",
"      Fongitar (ZA);",
"     </li>",
"     <li>",
"      Healing Shampoo (PL);",
"     </li>",
"     <li>",
"      Min-Huil (AR);",
"     </li>",
"     <li>",
"      Pirimed (MX);",
"     </li>",
"     <li>",
"      Skaelud (DK);",
"     </li>",
"     <li>",
"      Stiefel ZNP (PT);",
"     </li>",
"     <li>",
"      Z-P-Dermil (PT);",
"     </li>",
"     <li>",
"      ZN (BR)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10237 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39971=[""].join("\n");
var outline_f39_2_39971=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216152\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216166\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216154\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216155\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216145\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216138\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216147\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216146\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216170\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216149\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216141\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299970\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222666\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323768\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216150\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10237\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10237|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_2_39972="Amoxicillin: Patient drug information";
var content_f39_2_39972=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amoxicillin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     see \"Amoxicillin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=see_link\">",
"     see \"Amoxicillin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Moxatag&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Amoxi&reg;;",
"     </li>",
"     <li>",
"      Mylan-Amoxicillin;",
"     </li>",
"     <li>",
"      Novamoxin&reg;;",
"     </li>",
"     <li>",
"      NTP-Amoxicillin;",
"     </li>",
"     <li>",
"      Nu-Amoxi;",
"     </li>",
"     <li>",
"      PHL-Amoxicillin;",
"     </li>",
"     <li>",
"      PMS-Amoxicillin;",
"     </li>",
"     <li>",
"      Pro-Amox-250;",
"     </li>",
"     <li>",
"      Pro-Amox-500",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701511",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amoxicillin, any penicillin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Extended release tablet: Take with food. Swallow tablet whole. Do not chew, crush, or break.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696558",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet for suspension: Mix the tablet in 2 teaspoons (10 mL) of water. Do not chew or swallow the tablet whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may crush the tablet, melt it in water, and mix it with chocolate milk, milk, or pudding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699444",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) at room temperature or in a refrigerator. Do not freeze. Throw away any part not used after 2 weeks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10888 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-3C008BD0A1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39972=[""].join("\n");
var outline_f39_2_39972=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134511\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134512\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015876\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015875\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015880\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015881\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015883\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015878\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015879\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015884\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015885\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=related_link\">",
"      Amoxicillin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/49/34583?source=related_link\">",
"      Amoxicillin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_2_39973="Pentamidine: Patient drug information";
var content_f39_2_39973=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentamidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=see_link\">",
"     see \"Pentamidine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/54/37734?source=see_link\">",
"     see \"Pentamidine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nebupent&reg;;",
"     </li>",
"     <li>",
"      Pentam&reg; 300",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat infections caused by",
"       <i>",
"        Pneumocystis jirovecii",
"       </i>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691909",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702705",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentamidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697291",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your white blood cell, red blood cell, or platelet counts are low, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696431",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only as a liquid (solution) by a special machine (nebulizer) into the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to take this drug as you have been told by your doctor. Do not use more than you were told to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3473616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep family members away from the drug. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11407 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39973=[""].join("\n");
var outline_f39_2_39973=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207948\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022567\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022569\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022568\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022573\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022574\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022576\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022571\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022572\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022577\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022578\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/43/22199?source=related_link\">",
"      Pentamidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/54/37734?source=related_link\">",
"      Pentamidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_2_39974="Developmental milestones 12 through 24 mos A";
var content_f39_2_39974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 630px\">",
"   <div class=\"ttl\">",
"    Developmental milestones: 12 through 24 months",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 610px; height: 786px; background-image: url(data:image/gif;base64,R0lGODlhYgISA9UAAP///wAAAOrq6oiIiLu7u0RERCIiIpmZmd3d3TMzM8DAwGZmZhEREe7u7szMzHd3d6qqqlVVVfr6+hAQEH19fU5OTi8vL9ra2pycnG1tbT4+Ph8fH8vLy15eXoyMjKysrDAwMKCgoPDw8GBgYEBAQICAgCAgILCwsODg4NDQ0Pz8/AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABiAhIDAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjXASkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wmipCAbW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1cC0Atna29zd3t/g4eLj2QHk5+jp6tzm6+7v5O3w8+ry9Pfw9vj7+Pr8/+/8ARwYLgA2ggjTCUzIsNvChv8eQqw3kaHEiggvYhyocSM9gwA6etwncuS9kibjpVyHcmVBlxZhJmwps+DBmgBp4hync6eA/54jgeIU6tNhUX5EfYJMerRc035P0TGdOHVl1aJXlUZleXOru6w7wXoUS5AsRrMw0bpUu3HpuAkT+F0IUEEuXaNeA+bVNoEC3rxs6VGICy6wOAwB/Gb7EODDx71fIcfrmo2AhVoZLsC1W3dchQAExM3tvM1wUG4TbFkgcJfg5QvnPEyAzQ7ywwsaalng4G5zhgAYBHwOfW5DhpfwKNTSoDic8ubaEDfvYOEkusu1NhCfh/g4a9JQwX22RZvg84+UNVuArYHA5n2jOf+VfE7fhOoTX5/TAF6b6cffWDBBaBRAt85vwanD2HbeAOVBYgJgoAE80vFlYGTnvMbahPR0l/9ROJ+V55Vb2yjnwTZw5TahcrlhgMEGtZz4WW4b8DaeBhfEp1wA2kVYS2oE/EYAB7kFsJ4t2sVXG31SoYafAKOxZgGMxxFZSwfbzGikcgMKsKN2Oyb2YozCBZAbbBwA16Bt3zCGpTZWBoAlBzCmRoGUVAogIGu1VCDkBBt4CVycbwpAnThAsXhcNmMGcCIG2GUgHWLLXVChALKJqFeGAVzAGpaNPhopoWXCWGNqAcxG128nblDdlwzyBGKn2dC53pQcwAXjimYCF2qZtRDQaAXSXcYBa8fdqKlDlAmJYlwdNHaeemUS8NkHD1KA4HejebhBoIBWK2RusSJWgZKlMdn/JIq2ZEbXhgJsEJcGgf7mWDbXPuemt4G+Ru1ww2lDQaBr7rXQpdkIeMFz5D4Hr7x6xoWgAEIOR68AF9ubTV+IwnMBdgFkdl+14TIKYTa/UXApf+GRAzKHE9QloAAlY1xvY8Mh1oGHUdLFGAU/a8ZhfbP+KABjqTnmm6Pn0SzzBA8uGu9sJheYmHIEYI3wNyQK7OizFAN33neCYpBzyAHfN9p5w9013J+EQRltn+j6py7RKD7Zs8ydolpLc8M5TBfbnWp4l3Jmg6aNcVyz6Y2bYCO7meB8fyyxmkLqHDLNt/g12LJLwsNBBjCS/VxrPt5ZpJgQspYggC4HQOdsfNpC//bGnQ/3Hc93CdjBbGGmqtCsIn7W2eRXt46LZbotbIvKiQntKrB9IkpZruth7N7lGEw7MsCgdbctXd1u/u2/oI07AW+pc4u63XfLmrc2e+vZqQbrdxN4YrubH2huHECftRTno1jBDzDg2JOXKKCw5zSQf70rXFxMFLbQwEhx+GNfwvpTMHdkQDFTEuDIqmav51SIdCS5TqceVJcRbuxJGdTG/oAmJyjd5UF3gRxLiKeNByWNZnHJ18lcKEM1CUBKFZqb5742mZB0A1J/0wz3mvarsyWrUjrKDoGykz7QxKk6n4HRud7nlPh1bH7ZqN9r4mTEalFOUDwKDQ5VdkEZEf+wAkObz1YeEicNcIBU7uERBCs3s1ytSnHKwQ8bMcCaeyHHHRiYW3siVMcIRUo6HxMk9PyygQttKnbscRQUa2GpUa0ucanh0GVUdTwjDkY3wxPPLdxzq/XB5W+CUswoE2MLLKFKOxVCGm3mtjmbOLEoM4OdGRu3Fc2ciJkIpEe0HLkPFMqvJojRoDIbEjCqzOM9NemaTH6TqmfO4z9tWeZPHAfJdllFnYXBSDchIhRwykSc8ExXPvWoLnTmQ53+rEhAvblPfO5znQfVpxl7ckLhec2T2kgm3gYyz5nspW7XJMfWoiISiT7FoAUFxwVuBNGETOyT/DDh5m6Xk28QoEj/GTCgdNJUqGw0LUBxUwlBKioOlq6LIfrhKTkwesZzbPSjGcppU0Caz4cIKDgS8shJMUQQD8XEG9/KRgcuJB1kceOm3vBoRv8hVI5ARD8eI2NRNXqyESV1RJTZB8ge9SMvFqmmEWlTDZ+lATBWinpZe57XctMXGPklVLWrAKlY1EZ+iiNcADRRiiwgHVSxEk+bo1Oq2vpT1ExAUkU0k6USgyrwMFZNv5qZrsz0yG/MRYteQtUuH5UaIJFKSxbgEgHiM0qpxfMcysKtbikZozBpy65XElSRMPDaOBK1tePAJJIIgNnjUApIz5nLkWBLzs38iiIui8tcgaiibBD2XRG8/wA5a6hZOwELR1KJq1w2Ey6L3YyaSPnGRt8zvgpErVZG6oa+WAsoAU7sgVYraRnRAUC4eAB/QKwa7yrwsHmBBqwT/SqSOKA11t1pc9ipwHPSNKGYRezESzOnY71hLsb0R4o0C5R9w/YBIdKwA/Gp2VjB0WEK2NhNAtSPkBA8YtaabIwchO5h2mquCsfYjdEL8JFdHGETi1Wn45AojDczTcqRDa32e+mFkycszlrvmAB5ZarINhy/mTmFj5MTn+LynrTdqnnj6ZJNBwlE0wFnYptBFoZXDI4H/a4DvysxYSa1OTX2bYJv3nGJPtOB8fSpq8V8qHZrFyzVQrqkF7kAMf9F3FY1D8htoHGzj8f8YST7dK1F69MMv+NnKMIGbkcMWXaNJGpbIDmWRo3eqL8MGlQHlgLa7XWfzgMXThOws+GYmakjjCDdobdyHgDZ9nJpabUWRr70EBoQBRhDi+I0OPQlTH+LmCDlSO2NcBEgBYkcaYWeI00T0IBsvvYe6UDO0ZZznoKhuQ3chEY6FKyaV0sU5eoQ0dNlwq+9WTxIHYqbvn59af7wxWr3tfBJkvZGwqHcanLLroL0RraRMP1raC95k7RO7/dAk600UXaQHsL4P8N7cTpzr78kjpcEq0VvFdcH3ILhEfIEOaRTlkWklvZl3JQVpg7UDr57bnWEf2X/SMXeNZewJkduKJCmk/cbQqsEeCANu0NvZAA7iiGmpCDo21xq15Lk8TQufzsrMca2Ft1TOqSZvshZk+8uvQ25N+Ru+Lr8ao5CWmzDS3X4JPOdrX4J47Xt5zymZzI3fvV7GL0LMtApGaeCkpfPw8bcy4jeSDDyVGpKt3YIyT2+aM6PUs2d0AXDZJptX4k9L3+3gdKzIVcOR67yiNJ/ZCsdwA8I0v/RXaPzvvfGNxlmqJqS4RO8+L0/IECqzykjGTD48LEF1pe8/XxMf5nZv+pC2Rm/+F8/ofZHyvvnH36E8j+a/4d9/ed/8MRUBTiA+XdO9Ad+/ZeAZlVQ+1d/CAhQ/wvYTxPYgAdlgBSIgfBXgUzigC3FgU0VgQwYfiDIfXu0gSZ4gSOYe/jHghJoMCoogCJYgLRgDTiYgzq4gzzYgz74g0AYhEI4hETYDDdYhEiYhEq4hEzYhE74hFAYhb9AC45AhVUIEoWAhXughYPAhYvghYoAhoSwFFUYEmUohn+AhnWghn3Ahll4hl9ohY7ghmN4CHQYB3eYB3kYCHsICH2oB2R4hXBoCH/IBoVIB4fIB4m4hXFohoL4iG/YhnY4iHPYiItIBol4iUZwAAtQBQRQAABQAARwBYdoAKMoBAcAikMwAANgBproilfwiW7Ahq9YBKmIiVEgiqzIiHmwAP8H8ASBOAUP0IoAQAAGEAAM4ABckIlGUAC28ItRwImeCIqiSIqraAudiAQHYAAAYIpDcIurSIy4KAQNEAG1kACnOAdceIzImI5KIIttwIXOWAu/WItEAI5DABpd4IUHcAsIUAS6KI54oIXsmAD/SAQIEAAH+QQLkI1U4IvAKIdRcIzEuIsREAFYsIuOOAVcOAAG0AANsADKuIfSSAWyWI1WABIOEADKOADQqATeiIqqKAQaOY6haJAAUJNcoJNQsI6/+AAJYATwWI3waIhE4JEgKZIbuQX46AQ8yQT8yI1IEJC8KAQG0IoJgJFNgJJfAJFOEIxSsAACCQAPoJVCsAD/7GiOAdCK/RgACdAAxsgAAfAACRksbumWAOAAcsmSUFkEA5CMQ7AAtVAAA1ALBvCPdxmUDsCOnSiYAWCWEGCWAJAADuAACRAAh3mS7siRQrCSLwkAbckAEFAADwAaoGgAl5mM2yiXnciKDTCPo+iYkokFINEA+jgEi4mZyuiYjXmZAfCTtdCKrJgA87iWdQkapbmWoFkLDJAEPgkAFxmKg9mNwWk7oHgAcnmdzHmPzJmQl/mWDeCbv9iWbxmXc2kEWviXypiP3wkA4UmPDdCcQzCMoUkEuWkADrCaAdCJtYAAlomZ/+iYxUkAsrkEUTkE7/mboUgAu8ibk7meABCZ/wkqjgn6iwWQmv+YnGMZBQQpnJR5jPhphgPgmxDQliy5lxC6i4lZBA46nAVgogfwmsESitg5lmCJBAhwjAXwmtAolvYZooEJiiPaAAfwlgEAAZM5AMbonwahkfrIAAT6ABFZBMlJmUsZiq34pJ8opZyYkA1QBPEJnQsQpoSZkxGgmdZIkyAao6IpBMY4irJ4lQCwABGwjQ2QkA7AigMAigTAAF7qBSCRkAs5mVJalhDgpwiQjHQKmlB6mPGZpzjppk3aikv6qAaApEqwjue4kPFJXapIlDsKpVh6qUZAqgCAp904AEAZoQxgm0iaAEp6mCuJnlR6jiM5ilC6qof6oP8j+qCmSgQJUKh1+pGoephlOgBn6qc02Yp/2pe2aAukGZS7GpCHigCJ6gDD2KcIQJ9BSaXS2pxlGgGxigCPagtS0KGTuQDBSpYY2aRCSo2xKaV+maW4mo7Veq0jSq5t6ot7WozgOptW6IYDsAAI8J1fOqfiuJib6aPSuKQgMbDwOKlWKIoO4IwRMKhIgIbRCRLbGJyOKIreKI1/KadDkAAQsAAvipHsGACiCK9pepR+ioXwGKejmIrgaIqs6Ji1kJMMQLJaUJu3aZVwagDg+KI+mpAmChq7WI7muotJSwBFep4ZWwREW605aTtDCacFcJxrGbXyioqXSZcgIZY+GhL/CUmTCxCxtHoEGysEoli2CjmMhImdoBm2ROCNxnizo3iYK/uiM6mRI7uhRXCgZ0mMChmQRXsAkemLQOkAIemW6Qi3CFCNrPi0VUCQ59gAeMuNEoumFfuYC6mibpuOibuLZzunnHgLC3oENwoFZbuNEBqYbNmJxuiqSaq2qjqx6fiiziq7btuuX0q00JmlowurZOmQxkgEDyCaf4mV4oimKYmKEfClfxmfmDqzpzmKEfAAt7iSDcCKZSmUUvmzQ3Ch/zicwnqviuqhEPCR4Qia3Dirudu+B0sECjm1d/uTBnm/UEoA3VoASPqJthm7tICxZmsQmgsButqqR3q7quiF/1pYtgXQrqO7wKz6AHopmfcrBOtalt0bAMFbsM+rrDn5tcU4vvh7j+NrwdSKqMkYn0FpAPKJtvP5ravLivRLm3crjh1Mwbt4kpjqti8puqsrBOqbp604wJN5AOFbvpsZsFTAjtyosxE8uye8nG4Jlw+cl3ZZwZvau6hYkP9ojoRpmMS7oHySAGNqCwK5q0r8n/sJvZfbmb4Zssw5mm56mptqosI5ADKKmbbpsVuAhX+Mjve5m7XQmMw5ismpkKYLogaxkshpCwU7nSlsldAYrM7IAFCquWtZmKbJqPTomzM5mYN5nKBYoVhcnls8uCr8xSAhiqqsxMZLyj+qm3xslf/+6ZuKzLKSDAFsbKCbOL6qTJUOmqTsGqGLjKDiecOt2MgGPKVWmbAgOpI5SalCWgtVGrpnzJVzmsjXTJPnGKPzyI3enI8SyQj2uIaTOAVlC4tqcLo6/AbxGc3RC4mI0LphSIl16M6CGwbr/ATy/LJsIJgAO8+VuM9X2ogJHYmK2M4N3QgBPYvpzNBQcM52IIbv+ZlOUJJl0IcejQYTnQYjjYeGkKOXHAZeeQUh7coLrdBLILxOXJV+WcpQ0NJigIUyrQQ43QTbeM9DsNOSiM+CgNKsWwYrfQQ/zQQ9DcVE/Y6f+sTsfAS7+JRL0NRfANIOKdIQXYw2DQZcWJTkqwT/Vi0HRr22o1sFZZ3UVYDV+pwIXDiMCAquxhicF4qMgxrMLmoAx8gA8+i4vvnPQM3GXBss2Mmy10ycuMmYZOmxaFkLasmWmcuZo2ueJpyb+0mjDKCqjg3ZE3qSGPrN/ZmpAEldMiy1ncmOb4qw+rnVNkmda3nIQ+CdWVw7o3ikk6ycd+2nAhrUwUme9UvZ9omitqOh3ZiasSugqszXyPjXCXmMCXCZH2nbN4nXCYrC9vuN5nrMqQ3Oh721tqPd8Ambon2m1Fij352XjI2/JQ0HXCihVYuRojiUrSiuQtmkOCmnBdCY3NutWV0ErBHOSyuqhJmvRECaoJm2jqqoQvqW/0Vqu8Z7rk68pLNavlzaiRN8wvrqvWA7BCdZ30qqrIdJ2gdu2kx64F/rjWJpp6gKz3nMwcI623zps/2qnJWajOF6xh6eyg0c4VTghQvwtT+84IvZiovqpiRswfrN3wlJAPH5i7/arzneq2ft0ml9xBae4J2KpTppvajbr9oKwi+e4VtOmAju1hUN0+TIAAewp3I931EdzuSolhLbjbH5iwP7uOgIqHPetH18qregp1Rbs744SwxLu4f5sK79lRPeykKb4Kv7tIGr557qzDdrz+kM5xIZk3bO2qrI6a8Nj5sr44ULx6DIsbNEuTr+4qc7sECNmxaLAE47SyE7k/gouf8qjucECxIj/qKm7sxHi93oPNOJG9SEzrWCTuqoS8U8e5Voiuwhu+jD3t5v4IUJ0KoRAJjz/b+jWJM/Lb/EmOs56ZCuvo9hzMUCLqVKvKxFYLwPsAA5XLiQXrs9LtgkjsaOjszvvrrx7uHjC7Eui8PESsIprelLieAcHKOw+sHBPQZa6L8wnsxCcLYJ3JA5eepG7L5praLBDfEQbu9gDJBtLqX97o3b6+FJbsPiPrCn2+uc2JoBr6oY2b6XDMCsaq2AycHPvMYpasK0zMQA+6Yuu+76Lu1OHdFCEL67uqCevKfdLo45ipl1vvLwvszmfqqQHM6SDLV72eZjmcadCM3/h37FwC3cBv/w54jhp9jIkryWwNyOaLqLm0zwR13iarvYhn2OLhnMZ6CFTS/bEw+txWiYGJ/0lKzq0InY5EiRZT/HteqWTJrbCinGRKDczUz1Lf+PL8onBhDzUZ8Awi6RoCzaW835nXjYv7n11+iW5GyYgbyW0Iv6BwD2zpnmcM3PXRgHzZrSbf3VHw0FAw2IUSzV6ujOJiwHb53PuC8I1N4E7AjytdiUfQ/8zT/Iwy/8T0CemB6Ptq/8T82HflD9Dr/8at7O4r8GYe3789rWW43RCN3PD02ISVDWQy3h2K/U6h8FD5D/ywgEAEBAWDQekUnlktl0FolGQsG4WCAH/4On8nAtFghb8XBcNp/JaDU6una/21gtGhFAvNXxZf0Oxf+V9IwOqIwCwsYQGBoADAICEvoAhaIEJy/L9KacstS6jMAwLTFJ/UovR09FlzovQ9nEUpNaZZ9aS1MJy26FBh6EDLQSIphqlypVk5s0DRgCfjsXHu0GEh4hjAYeDRAImp8BHBwDvITAGgoeww6mDxycAxy2jJXd6Oud7vHP4t4fHapdA5AuAJUpD+JZ42YIQMAAENg9QqduCIRDCANokRYgwsZCy5A8mAOgAYMhddRBgnRkox0HChE0sJZxmrcwCwYcDDDxkJk4ERM0OPDtyiMELwMs9FizSARsjbRU0/8p81GXRwWoBjjwBNk+r8yOEslCgMEdbgOooE1SICc3B0QK/Pr0hYBasiWxLejya4w+r33/5gmMqgrfhmk/liRgc2BUYn7Uqg1l12RGAN5iMnjLiFIsJBAiNDBwADQZWmEYILpcthECtg0jHEhQpJWBm23DUPZZpMFDAAkGDG1QRx631wMikO3D67c8qL8XMH4wG0JlIdMBVCdw9Vjnwco0FRIbvNBZLZuKDH2UU3yjdeUGEmhpJ4peB+kiSAL5/Y9f/mn+s8eI+zhCoJNNtFEHvXEKYuhAKkKZL42I1BmAgWAAzAeJkg5ASyTT5ojiFQB0aY1BrKRJoK45bAMAJ/T/JMykiDp60au8MLg5scSGRhIiAefGCQrGEGl0kUgNMwyQMCnaywICA4Yr60EjRgMgAvY6Aw6AB+AD44HHSIrnt63MIRNJJQU7hSozmZgrCXqkgS+JFsdAbxA5i1mrw/MK4AOA1NDTEonxLoMQmy8Zyg7KI7wZgrMzjUhgkQg0M40vEVV7MkoEBM0GJ74SOEAmLLcEczchesMGOF02a61T5XoxTAingBkJPeyqc3RL6kxC0j8052G0SS3SYUBKPrPZhlQitoOkSwJ4MqChbQ7AKJJgAUCpqirPsGKfNhi0Ak8z1NrCzUGPwBAYdxZxgk4xNuGWxHEDMcJaA5EtFtBC/5Aix0FkE4wWQIzimUaLCBqEtAhEcyXjrUMwBSUAY4+aaQGLJibgYQKAIlVgGdN7JCgKWaz4kSs82pg2vtQtFNWZtkIYK5i58g7YSfyq49F6DHgKZD9vxrYRNvFgrk16k2xZiE3snFO1LZoW4tz9gu6PFJ3/06ck/Z5QZOdTuqoaj3vG6VEVj2DJ1g66vHFGLmc+IpEoHoewZrasgoO7UIT4KULesb75RZyTSdQ7iwQK0ZanMDDSYnBy8E7U75HAGKfsjUw1wBrNsjoAgYUK8HkTMB5HGl2xx76k7ADvkcZUMR6IG2ybUV/j19pP1xauxdzaKbXG0oOSuE56Sq0aVP9/Z4uxvoGpCfCwBpJrAcUaq0a/TijDrKT7pJftzXQpX8wgKrAG38UIcDXJgeh6HP2geT3D3Xb556c//tvtT5LqMqYGTwig44Me+hgsPTcinjnkMwfdkYp5Q6PNstwzrwUyJxrT0IoFGdOFBqToaXpoGRiYVggLKa1FhMAJJe7wgF4VwX0lNN0R8Ge/GNJvhlULW/4AEz8z9C8ZUQAgCMXTG+cMggqbOWB8jhemIUYthw7sBQS1xCUhPvAInUCUEDRVhCiWYwDw8WD4mDYbFkrLb2FAX/rCkRNZuW+LOsShG99YM78RbRLyIsUN46iw/Y2Bh6rw4doQKMDCVSVk66H/G6bwdgB4HICJOvwbBJtlgCsosioU1ILACNYNkV3sEb8zhd+msQAgksQRCbIMKCERE5hxihE9YyGEFrNJOOYxT7SU4ykaeUfa2bI7A4LH+mgmlm0Y6EaULOI4XrgKN+woMLdbgKzqUUMlSbN21ERdHMCgnoI4gxgLoJkxeYQ4glChbGC4UrYW0Tg47JKX3ytMERZADEVmiC1bg0BQkuch+H3lDcz8i1+AwjX/tVN/BJWcQU+HwKF0QzM6i2fhqMcW6/FmX4GUli+0V6n6WVNseiBQfk5IIyJoUyOx85wFB+DCfxqUoz1kKULrBdOExkcXn0NhSAe4nlaYUnwIdI8B/xxAoZ5sVKYzBUUXojIbIlTpnGRZxBR9pAUurVQZcdLlJfwh0CayswlZZYJNoyk/sJ6qqJ+kKfnIaIcTVgOqdPMToMQ4GcQp6mtpamnQ9HCvjfxOmEmZQwL4QkmtNCsByVySKt5RV6td4pwCOugTzuktJYzVpYU8ZRUMawQAmoGyW5XaNGTnBsmGlS41TSsC9rqORbZCX9AqZSjqQKZMOvauN5PFCZ3AGrwqI5epA9kSRpQms8aHCcGdLBmfiItBEMEiQ2RCb9/Q2VkOBZ0+y6M+cFtNrsL0tmZLgj/R1IaW4Euc3PFHPLxJyEIGZRxPAwS4NueAZvWkAIJNGElgFv+RjyxgHAizDDjnGwY9/GQanSukROu2kqwgV1vyIdzvwCs0ElUCAhu5AvHs1oj1YM5BM7Hu4IBakYfMRFoAjossBEHdtzhgcS66ioEpxMjA8YhC0yMItGbiXbI6IbvX3C5CBaEI99IyCrA6y7WQJx/DPHSeqPINcKDr2Oc8tBcQekxeeUVceKZlZPgMw2uqnCQ9hAKNdDkkauoyG8p2ojoIUARArpAA626VHdnJSFneTDw0b6J8DkJMpH6BKMsc73MRxc0eJ2zI7Ok2fXhxkYyh14p3AMQgDPDeYvEhEzoutrbAEkSP/zBa0pbIPL2oyUdRq4Uiqa1GUa5fBAnRL1j/7hK3dgjuCT+BGZTKWsxHiNCRfHpEMIQUuXQrUX3r8CThJlorx95TGkbZkAv1iFBNa1Gj6qNqbqDU1SmWFmBd3I79Eqk+jBxWtlo0nw1CYsg7boKokWBHJZBFuQXlLhLaVafQsg6LwjuW2u7gyYEgtSFiDJOqGKjMCKLPW5JBxE7sleVbayHXUBKTEBpOhQH7+lBZNrOwCcCwYvsiO3iuVAEYoGMJ1xmLJgeIFjBFAINfptjVjhu4BX0dYmjq4i5DNHUVAYErrqYPjRZTqASZhc8hYui0yWwt1WC0Jsj5qp0O7xFe8j+VBAXELM5x2cB5OARbeOApV7i+8GWOiaVG/6+dfBpQGuBq4QZJk0mZtZXua+CJw69RgmXkNjQOwypKhGYfhzkCPweJYm+M7HZW7MrjQHaQi4YmhoQMsorQ9TQkPgElXmS3kUDdkhMoKeGeGSETNJqkZwG00cKYwJetuYnJQ/Iwt1uDweAQbMT4OtDkdFkfWxq1FacagY6NwTdh6Ik6yeUFeN17j9Dnd6v8W2XEndXF0MVXA7/TrswalTTiFJfr+U8rQmBksMKAvJCpj7QF/nCFXyScXBtKHOQzSndKnjIZF/rNuyyPqQ8fwKXdPC1A3qWBuG8S0IbfrI8QnA3kWMv8pkD+2O/pcgj7GDDzxIhGROOejM/pZE6JqP+IR9rszfgP00BC6r4vfzCQtJJButBgIfRoH7xK4RbuAUpQMyCQL3KPT6YoVHqv6t6PndpFW44pKRzg9VwrI/wu/8LtCk7QtzREBfmjBfuvnawQ3ZpA3pRABhFtHxrrqvzvWmoP2jRGHXrQZVKPTKhOmbJwMD5N1d5QDFPQu6LQBWnopV5p+zSr2NbAC6EuMIKLCnfsAOsIG+hNCIcwyFJj1YhM6+ymAZBiIQilcSjkO+ZQyngpDspG8+BpGmLixhYQv7ZhkIrol4AIIVpsvG5pjNxmWpICAbQJ5TgiHGAicl6mKvRL667BVH7EE/fHEN8AbTSt3jKRnxZR64jvOIj/YTwy6j4IEA/l5xhtMFA+cGlY4ywqLUkIDUry6ZnYpkUWzSy0yqhoDnq+IDi4gSwcQGeY8dIiruS0LLlKwkqmxyRw7vnc6d7sDchuRvR8S/5SCrRARKimIBoHSob0cGluhOYKCBhQy4KShNgWCNWibT5IrRwFT1g6g6RMC4VOZN1UBJ6IZBD/qsLqixjorxX1kBoFsB4AsrgCMIc4sGc6BUSyyBzmDBm/kAkIEQFtKQ5C8Deuka4UAQGaDuIWZucszrn2r6dKpQg05ShZ0ueWKmb0D6zs4CZrZGEk7mlIbkvUz0KEoSgDsSWHsB+bwNXuMAnuabGM0BYJpxJBMUEw/xHjLAiQfkwJftLdHpE3SgkYB2LtQrEUZWZGHKHzBkkr7iXaBCYdmkEjH8sqYTEYPvIk+oWTMoY3aCa4NiZXpkgwe4kfXVIah8IZLqwa6ktkKI8J9QZvaoIK4K5twCFMHu9nSlMTG8Ucm4AK5W4jsfAMpK+j0jI33bA4j0A4hicSUuU3sET5DC4UpqA5oax3/EYy48cR30gopSXAyMAbgkpvzmuIdG8wG2R1Zum6ygA9rw85ZQqPikoPSM38iqSL7s9gsks6+yQK7LM9IFIKN1EKRk7jMurLusj30I+ioNKz/vL9jNOP4nMvCUo+i2gnOoE6c+Juei6JBgIRseLJIP/INgE0KAVULhvEkCoSPyRhSnjqNydTPZdAGDkL9qTRaRoUdfrSFB50dpZL0eYA7igvb6oCbxJkE2bTP99yRG+0UTJuCN4BWnruC8zkQd5qMWZOwkg0RsFy36aP2WZSSePtacBsGqmETMaUP3LUO3a03h7yO86UD5e0OwHPYVLD7+6FikZn7ZbwS180jmRBRs/yTxihzpqLFfi0J6kEIfexCsvUHA5VFdI0DdaUDkmES5UhJjUxSxVyQo3AwGRPB/1FnR5nHD4i6yaMEiCgvlIOKB7mEODutziTkD6VQLZCnSKCATziVpupURsDbxYHF8PhlyaRmICBYwxHNceJbrD/ZVJtsKyYNW02NTi9Uh4xhMmigxu2Jy7g7zEI1daIAUMvFERvrCrRqFq7CdK2R/1MwfsM4REqa10cFR4pAx7hyTCYcWtkDjolQTEiFT7f0z2lNVoDlCRBch1kUy8w6F30QPh4D7b4EyfksCsZtNaWrlIfTahYzjtkozZ50omAQyQdrMA4KPNU9ESMBCcmaA54ql8lNGATcAtGBAZ3VQnixKpW0GXL1YykJyejBwp2xlQzlrjA9RcwFFavI8taBH0eLScdjRJ2Ri9fsilm4y185kCfT/t8TTbaxwCgpK06oUpZVi05NRnV5uHoKGb98C6TILESa5oWkhS1QsNSCX4y/+lxCOAwi6BdgvYV4G5jXpVBPVVk7kAvtgQUb7UBZGYmLJVH/8di7CxjXM/tFkZwMxMYvKAJ56C1wvZZccY968BskQBtry4JQmh0XZYTLBDjHvUKxaC+BBYtydZBtc5s9Q7HSpHDCkn9Tiz1EOCcvEbyPIxq4M5yKOJmB9YJUMIpu4ZGE/IJ2GFR8vBfxfZ0I1RtLKhavrIbh7Npl8dRG+UBcHD8/qyWMLR03XZsZTd2/XF6j1cMCBcPALFzy5YSCO4khk3bpK1lVg09SGpoyuIBMa+X6jM6xsd029dZkQD0zMBFM1VsftNf+ZE2ijcJ3vcN4rf/Ppd+0chLmHKMKP/qKRYEK6WNCnLw5Xyul8q3gM/XZTF1ElqYcfcQUZ9rceX3H4vtgVv2gIFnCSrYDS64ilbXFDJ4CESlMwmA8yzO8j5rYlLV1Pzq4PDSX6YE6o70hI1XU0+hLdk0hgP1CRgYTrEUE/RzWQE2HQtOIHhPnWa1cC2jADZncEFxWBMsEpiCQWkwbf1Su9DXZbh2YgiiHbeuAVrsISBGHShkCtoWJ+SYdRky0YLCwJgFqHQVeeylLV4RwGZME9PYkDDHI3ANQhTJFwxpkklihbaEPQ45k3uJcxkZeNDP0fTiGc31GV/jSozMNRxjCNAsUvu0HkANKNtzj+OFWFDmAYgDKnT/4/8czmXqqyTQIZdbeTpBFI0OYSHYVYsAYjZ+BDM2I5+4WZraAJbRVTOUMg0+eSCIQZZ38keOZ5tn7Zv3g5VR0FHpZgLLzSBLaDVjMzf0z0QIElN4ebhulEyFmZxuYiu6SCAlJAp4bYwdUCUJMpr3s0Yo1vI2VlZEgi3mSYAWSJCkjAINcoQOz0gsNhQM8qIrWaNNwn0os5bkWUmPwwePjjSg9wZ5djIGYCrL4iYB2veqEkZfd0kN+tEaYgFqUuhMpT4uzFBcpiRGkivnuVAwlJqf1BAkoToe4B3SOYh6zqNf7Qdp+muwjRGmSpSIi2eh4KoZIKsZYKs7tKVXuYxh/1EC00JkahUU6Y6NbY2fBzMyKxdTVMaO/RSHXtqN4uWgizouBabI5rRIC4G/hKByJdqRBTmYglXmuIM3jg7zRurz/HP71lCvW/VgCsIf5uoVMklxO3Wz1RANJRSC19eCFZWqqFePa3uyCps3I5hKdnJTcxuMzwBQ1fa2iXOPm0A7CTp9o5iG9fi3lw2BjTuYifttoZs05bp6p3u3ojsZXrhZMeGHm1cNtJi0nBtaXza7bYu6vwpqkxOPQzeIgVl1sHOLxZtj/LC7FVG5ZwG+C3BylTe5oxe9Z5AJkhRCVQG833UNxnugyhsox7Mm1Cm9tAJYV/hPtDUNAho4KVW62//3NP1F88TCwzxiE7YObsmoN24zqmkTGoZpFrlJLpUCFOEw89pFkR0hxEacKYCoxkbnjcONvYlKfV3EMA4EWzWDySztSk3XJqRlKQxZb/jrEfxLC2Y1VzuphgO8w4UnIT5QLP6syAi0/LrxOhN8aawzHReKHd3RMW55xqXUmfMRVrIBltBj0kbnYHIiG+f7fuQa1TrBIHEKZNMb436Br+jxG7lMKGbDXNPgmqPatjv8RlbS5tKAxBGI2MjcwJmkI8EOrUAStDLSzaUmJSPIG3akoXuqYlk6C0L994RcSkmOZ9fK4LDWdOEBHPhTDvGT4q6gUfJ5QqzBp5+bw7GYVXb/Ih9BxGUgztLjQ+ScLMWVVJCYKitPq1N0es9t0KnDIM51q0mBqGKZmZ+vvf8a3N3uZWMyKbWUcNCVbTV0heTaCtd6XVqS9hfK+SRaGdKLnYBAvJ6pQGaYHQwSj2uxSMm9O+mU5TJdwnEhU7doG+PISPNy3O4CiC1Aa9WJhTDJ/bqf4JdtaFYMIzVkxm8XSd4dMq8TN7Mf3cf2OMLw4NLedMOldzCGM8j12335u2P/QLi9W99v1OXVACUgzL0P67y9gj19q9yNFrsBgeeLHsCxuLqNHnZvnumjntgH2uqtPnYGVukFO7YRyxmw/es/frt3W+q9pltS9zhffeZVIQyf/x7rgXrqmT4ss9Tr0zOCsc8kV764Bfzq3Z5WmkMqk8N5DMiSwaF0GJzj+TFlbjwJfdEBhlUnYrXZMltbhM9HJP/xB9zvddjtpf5HriPPkXIk0AJfZ+N53qJn22/j217vfcT46rEj6pEZu3dX5JHvZ/8eiTIqZVi7/z7r3V70s6MjsFfyVRsn1gqCVKqy8D6MZz4KVlLOROkAIPoqooZi+f43UNL6S53oBdrn517qpV7wnboRTKJJvWFRxqI92qhh8pvuo58RkF2FIIAsnZOLjzb3wRIIHgDAgwEZMAaAhPARGUKj0IC0ar1is9oqdev9gsPdMLlsvo7P6vU3PRAOE/9KJ4AQCBgKQ8NiOBgQ6AFQ2eH1PSixYXWlKTo+DkJKOo5FBBQ4GOA5AEAwADQEcDok3C0ESjWUBhwAFBBEOdwReIKKAmRubjVOSvL2Akf9BhOjFR9rpSEwNPQuCCUgEDMiV1sNWxdjZ7Ntc+9+93qHQ46TU0o9CDoe3EUjU58fm8uv0dcn44Pd6xv3i/8DuAYVtwMGrg3hF9CLwoX5HJJpeE7iQooQuVxEN3AdAAOtjhVIJCxhRkUWS5LcskCkw5PcXOqDmVHmRZcEfWmBkABjJJRqaEI0t3KmzylFHx6NmLRMmgIHkjy9BGDAHQPSFtx5ZYBBACGvCGztiktTgD7/VUjhQYD1Uq4AsKCEajay59J9dcV4GVozKdCJd+3+ZRilwJMGDGCFhBKSAANpdazKckUALILIBYQcMCsl8YAnXS5fsSolXmCkpRdBWetUDwIqC1a1enBHydon4fpqO51Stz/eCBXDan0nwACDsw+sI0jlqyAqBmBltkJWapfnoR0bpet79PbfjB0jB9AawIInTykbliWXHO5pvNv/g9+vKaxQnPa0igCo8RDlkv3LQcQhtsXBUgDNgOaHIHFxp113uz2YUnhDhDfeUK21MxwBSBjAUjbyCXQaiPiMWA99FHLFClV40JaVf8yRVAgfS7w1BFplAWAJJmRtKIhOPJUo/0+QftXBXycHtUOeEgMkAIEB6/V30G18vRfhXFY6eMwzDUipRmINDskelruppkoApZB3x2FEDCfLbGIeFaZ7Y8r5zZAZvsOGQb/V+dKYWd7V509V0vmnoHMeWk2i8BBa1KKPPJpbod2RZmWkc4pIpW6XBsMpMJ5qBOokouK0qaaZToolqfZAGOGqkDbq06t4pWrpg5W6amisKM0KmKq6UtrqrcCi6uiuw9ZKaAAKMNuss89CG62001JbrbXMLnutttty262z2XobrrjWgjuuudyWe6664qa7rrvqtvuuvOHGO6+90+KK7K+mxnlssMny22s3xJYm8JUFE5zrvwYPCv9woKci7PB2DANGsRkWM+XvXvzu27Fv+VbUMBmovKLITeVo/EXJWTjAFXZn9HWyoqYpEt3MasgckHw5zyMsGIhQqGaNGl2cDhxQPHB0f3qsHMaeUPA8MNK3LDXGdB629vIQTV+hH9F7DOehF1Fn4ZHIWw/XSl82X5H110F/QTaJUTxtx0Z2+uyFJh4+sBMbf+QtWBQ/2sFJk1KQPDQZJcsNcxQMJNgF4GdXwXXGeygBltJYWF654o5H0eFjm2/ReIhTPdnAApysrVnPUiQ5NkchQ1G3RIzPziigX+gFRQSuL0CWJcQBgGcDYHH1gHBunXkmLinel0UjcRUxQFwFZFX/B9MEIOBRhp8MYVgUiASSoVthkS4yWGCleYmGUekR/B3DK2FAKQw4oNr3tQ9nJiu0diQRT3HFU6gylVVAQDLdO8D+gnaJPyTAKe5ogHEuwRUCHSyAKBrEm5h0hwSa7wCogN/z7hA9CBbgK+gbiymkFwUkRG8QpdiJ/w4gPqQVR02xIMsh3lSbSKCQhADkH1xgU7wJooJJ/hPblGonJbv9UDbE+6EDz5c8AkKFK3pAi2hYtbsodO8SDXDKEHrXGiOVUQ9KPEACQpFAOVAmMpNzCwAO8wxfQaFJcojAj8J3GJIZBBYGSKAUEuAAJi3BAYl7TGWAMoY7rklySjAMYgaw/wA1tpGNGixPTwbpOSLspBa+El0dlmMbKgxAjUwLZEcIORhYMAkBblxCcazCGAe0BkqtIqXd+oNKVRomgQsQYQEo6QpLki6W/4HMcjDjOp5M7Uysg8Vh+taJTxgSkYb05GaciR78HcgosTTml9pQhdiB8pqzhGNI9KDJ+NDtiQHIZZRkCU5dSoaRlinMmtq5JAwW7YtQsCQCZiiX3vnBb2VUQnQoI7lTNGcqifgMARyAvQho7TfjQ0Io7rgit5AsALZho1hwGJIBLtI/sBpCisQiSfEMhzhDaehBrBOeLpBUaSXTyzxHmYharAyVmWOaSClUCp3CUgnjmcowWSOlnv82CAqk9EQDhidU7S11mIFYHnEsKlLsTA5GkbDpM6MqhQh4ZmsE4CkCEHHST+Q0dNAZZkw3xADRXZWrTEQN7B450aVashCcUN2ZPtdECkkJAqi8aw41xCGW4I4kJdPrdHKnFIFqQS8PiA34Flq8PoBlnYCI6BtS0jQy0uyafcAeBNz2R6bpxEDY8cQDWvYEkiVQpRpxUn8+Ec7S2ic1DAVtTWERASGEcwrYKUACrSlKc2LuMUoIqkS154rYCmO5SbXFG4vj1IRktBGiA0stcXHVQAQ3AcQM7mY+Ut3/RDRADyjrwfRCmJ68wrmfoK1ts5vHOSzASbpk31XZe1m6jUH/v6IlQJO6yNSYxCIACYyAQsEiYMR16brWjUTJDBygUJ2BLEjiypqE+9nHHPFMx4uom3qZX3dkFJpwkfBUwok9BrxWMlzyoFRmbLih1tgtEV3pcaFwGB21OCqsmClxOwLjHF1iFRxZUQ0BeDW1kgRwiduxlF/5XuNV6KnhlcKVw6iJ6iaxKsQsXooOIMU8vVeshKgKfbOD2CdTtMrpVUKXoeaOHpowbEAUYJuHWEVRGNF4SZSD0CD8wqo4IBRvkqIoBD3QWUR0ZUo+wI3qXLGE6QsS1rGGxWjCzUncka8eU9jEApeyV4fYsJ2CmBlUMwk8xdjOtpJYYEDWal7TuiQY/+vNrlcdMFA7wnST+9QWOjcJVDSkRKYTnFRlTRScWXY+sgLdGoapbcwWSxInM5sUln26Kzhb3HqINjE8Mm1wyFUR5NbdGd592GzMG96X67Z7TeRqjql7C+YeVbOt/QhoazThyeaIvV0Yb0PjDWrZvkLD/fRtGUO8DN529LANXQg6OiUJeDhTKZ7UMhNCbYWv8N9BeOxKlCVEsRDAHsgJMMZZcJB4+xMiYrnSBxIinItqyZ5GvxeZjqzViH7cKFlSOZkVUs5+AcCf15axntqoBoUqvGJbPL1vJ3dVEwaIXmsMigopLqkqlYGe0F8XhY8L8n4OMIjPJRpBMIdltQX8iv+GVNN2KqxpQvomgkjEt5Y+BDFtSyRSx/H4QqY9oTU2Z0ArBpnqtzNTMojs3lRUGSLipbJImtcDY/zcSj9W0okNaE3LKolwzqSVr8EcwlKfw8kB5vGQOzEkQVTYSC9KlTYRYF/SoEDPlCjT95ZxJsyXFocmEIj1AQzEN6MXksvD3u1VCL3oymOQ1YtinDSWw/dZf998Kgi//wRiHw5H7U5EgEsHgAAfG7MM3dtTmAxUKOMTdqPtwdQeSINTeBVGSZxkrZVStRyQEVxKrMUdSMYDHohVFc9R6VXtCIJHxNRojdVwrJvDLVUAIt2FpIFbFccn9N5kDBm37QF06IFHoNH/VDBWT4SVCpIEWTXfhlkH+9BeF6xE+dRVBQ1AAYYR0WEKFPwf0hXParQg4ABWU7XgyrxCElaHB0ZCa/AWdPnRAaQSIkyIUzihD9oQViSAwUlK42lhGSEeANbeALoXam3YchAAHfCWlk2cyHQBHQCHHhbPQRxdQshCDFHIFh0I1VgXFXxYQuBTdsyeLaxdAh7Q4DBAbTHAbfmNnAFfC+aIECCBZRFYM9QggABYDjLY8xFB9FEBl0BAIFwYfuSISDhFImqfGnaeEh5XeKgH4IgWLh6IFK7VGg5CM8jiZySB4yUAM0QA/ngCAtyfLt6Ceg2U151hwsgIG1aHG74ZdrwI//eI3QJuWKn0xM3hgY7RnFWIHSJmz6bxz5tsWtCtQh/oSG98D2FtxVo1mo/REijsDSZG3ZPN0oy9iY6EYkTJiDQOEZeEnS70YPac3XAgwIp0SDZ22iyWEh68IIyZz5II0ARlJPrxnUVCGSa8Y08o1iIS2yleUxm10OSsiHop1tSZIaIg2zG8k6Qgg+CBYxYgFJxgQSagWvqw4BaE4LZpwagtoRfgpCJYUsZFDBq+3zEIR4nZJE3eIeVcwU7emxVg5RngWg4KZaltgVEm5RWM5RoY5VMeG7CVTa7Bk97E5AvtVQMaC8Cxmhak2xncJe1l2IF9zL+FWxg42Ma4TWi85f9AxWVO8gqslcHTzI0X5GUZPCbnBWVaGtsXBGYWVNzbYMFZlttE+cFheqWwKWbEFJwkROZeMmWv+SVp+hLOFcD9XIVDFtEdVB4srETTWRwQIVDoyF37LMDykEVIzMGbMJtKFtXhdYQmQA7KoR29seYSQaQ0SJiE0Rx0pE0gtEwzrITQBYJsTOUQAM3SvebUyVJ1ugJsCgM76tArLJDQsZxVoopTDt7jHdMrfkdHYId+KeEPVmVxApHnBR951B8z4s8cfWb1FefxLeP9iU4B9MEzIOh3/oUb8N/WKAHokR4zGAF5rJlTGMYY/dP6UCT9yR/91ad+hF7pJYbXII5zuJL/U1gH7G0eajoeZRabjXRZyfzBhDgYW1kHfx7WeXGETTEhARmoRJkPHYXIY30hK3mbJSVpYcJnXaRB7whhT0hgVq0ZchzAE1RWZn7dFnbhdCWVBObTslXVcFSgWFwU2GTFhdBoGipLwiwAMOroAAjYMuRnKGGTDcFRhd7MoH2jLT7AghYoHPwWnj7Jd1qY/eHPj7aCJbWic97NvSGSK3pNHhJIeq2ZYZRhPjofRS4BMuLPmb4BBt2pE5lXdjFXgCQiHcYpWsYnNVYFAAIO9mwFdlQZnljP3uSmkIbOkyFniwnkcN4BW3qRpE1RC0Hqg1Easr4NWUil7PAkKKzCH1TF/4WGTzkGmbsJQvDgqCmAKV8izROI0p2K40Gkql6O3BJkz8p1SKeFUQLE6uCtiJTSjnym1r/8pWiGTmwAKmb2p3/K28s15qqVk5fg60rpq8NVJpXSmtmgFZtJRXS2j1ZcEQmdnCGuVLcZ4cXdaH3Kj0i9iQEoJ82xznE4ZHVsCJOIZFow7Ez2JV36q1TBGDnB4n44RhwdSD8h06yp5V8mxiUdEAXtRIM+6NHYzWSxbPKtH4gBzDLAwjiMa1GuHbSe5ITixcAFKn4s6AYKoeAph14RoVyGrGEggcCaAR9eAdcGlGLQxnChWLNaUppCINM2YSJUVswCDE9FQZ1WQdWu5f9UAJScaq1K9IFQDWbXdgTAGpjE6myoFqIgEpDZ1uVCjV0fQYFOgOmnZoHbhunQyi370O0w+eFyJFAoPOLkyCLUGhsz+KXgbqY0MAi5Hq45ge53khsTbBpEtsgl+MemZaPlhpqNoGhcoC0RPEBmcglf5e4Q3SuTza1tRupvnmOQpUk9Ts5Eum7IksIUzFB1PSACIE9J2QgP7ScgaAgWWZJsLoHByirEGidGNU8bAc5VodJuji9i3m7IVkGTeMITNEn5CsHfyZx5zm9qZIXLUezAZpCNXq6JJgQ1tex92lLmKQbz/ahIhN59WbBjbFxqasrxSV+H3G91/VLnfTD/Poz/WiYNIjDDgfBsfXbGICxJhvYgPkkOMPmsCLdww6raEEgwfrUsj5LvCiphdGxwEpaMEZdRvxluC8tgh2TVH2jrCduhE4emFPuvFNCfISXAa8Qh2FGHcUKgH8xgdtjhBdborCbL95pWy+ZpY+hWPs7XEvipJdkpLMyxY7ifD89lyo2HKmLxFQ9VH7MwJIQw4jjwvmLB8+LlwsYvXNxVjQmBKM4F22KeMIDiUBkYIFfNaqqmFMAuEd/q1NExEhdkisFRrXokHvBH7YJyYtrCbCyPGhmyoIYUjmHtLJ/BIr9dIzss2tDm9g3A4irCY74tFjCBeeUWi41kF6Rr+FjaEBSr/3Wpo+Ml7Bow5s0AcdZupRQcn04C5RfUcJj2r/GdxDhrpiQA8wGaxAulzuoYs2E6gjKjM7/O7DcrnHhMK5kRJ1k+2Rm0TC9jXDr3YIgFdMcSMy5HUC6MXYXk7wel2P8oMPC6kxZ1q3QqlrW5QaleNOJd6PJ83HQVEOxaad79h2NloCSDG2tijwitb8i177FCNOuEL8mg5/7CHD8ftD6PciBHASUpUzM7gUTXYirNXgjfp/bgLNzaMM28mQMY6iHlsumdn4cmVx+Cn0XViFI3hubaLlCHcAffFn9YhVF7BgWTjBLoxwr3tMyOJi0LdZC5xeTsoEewhpBqKQZKnF5d6f84DANaNWkhgwIFapocuA6PUl8SPgMc2m5ZOl/nMJpBf+cwMbELCmBeE/Ei7WgGWrbg+LRZXS5CX1sPSsNhsC708VaS2CGnQo2RoJchQi64VWkiEEZVYzFmnC76Gca08uIY/WItMkYpo7NkW9cr4FowCfMRcijgdjAfP4meqnVn26qirl4MxvNLB3UXy29d35hqJ8JNmwma2GGQQeNFv0JG06bv2nY8CetKaqubGMeZNY01IdibfGQemOJkIvci7UGhJg0UB25zLzOHVuMr8/JNW7epugIqhza8jfYDA7Vpb0y/TkIEQDFyP06EPzDd4Uh0AnjjZgEJNd08Wi5kt83/VpsBO2/3hOtaaXMxXbNmL1gd7PQnh88nV0ufhS5SQd0hzqJCI4ZIOyzqZi40GeBmqcC4KFt4KPcLzVY4YwthSlWlXqHCUBKvGz/szGL4hWsilBtbcEPuiP9v4RliKRL5NmeiP1ubka+Kr3m5d4s5UVab09QrpRZvRacdiyxSN4OCcVMsKyBkYzEDm1POTNFoJH0BMstk0Nb4k7cEmbl06Rj4JM91GECAQVKqoAOJFkCyQDQ5d0t6lNe11OEP3LHvdI6QRnen1aisim13l8cKHOs0ea6FAbWdamgIFTB4/ZYQx17WqBN7ph9sdHFS+p0f8aCXz4roAYrWrNN5rEhw/1u/Yk8sR4gaiYFWNx3ZUTl/GqR397jXrCYiR2anxFZtoMxk+UNJu4z/mhDbhmdrawdmheAZKGdTVNmCTrGLe7nTOKFCNwD2xGxHD7vT0PiBJqZbg9xIhL/j6GRvFzUkYlOXViR0O5ZtDYGHO61L+XfbuZtGQ4JTFza3mcwUuvFIe5J6eB+OzB0+fMLALr1jOy6MpN/Ngq+LHeuo1fD2u1x/fJ0HfP8CehvHDcwfePGG81xC/LSbesh3N2PW3tNxnYi5SPys5G7SHOkNaW+iktpVnac7+YxL7Sg3PbwLPcATvQdO/QwnSMEzl6MeEoAGug0GKCc1BSAcRPH1c4Vzuf/Tf3nan7ZWLjwZaLnUIJY6t6B/GGUXlI8ggCGQfZTdm/sHXikM5trZM/wj4PNcaL7fg/zQ/23h51sWaLmSLjNjqm7rvcjRhBMryv0a91SO3XmROUd+LAnkBDHaozaF90LnZ8fnx3ukD34VIBTwr/jLB3E3Y0U9+kdbEICOoAJynnd4Uz7YvcPXswh37f6et61nHn0kDzvQB36wFb/xvAZtmo+qb535stDYlZ2KHas42mZWLDlp9wNnWoFPdj8QAIRDYtF4RCaVS2SA+BgMGwxAABHAEgKJLaDBDRwABgJgMTBgo8LBIFFwcA0IbRZQKDOJzqre/wcMLOITLDQ8JDz/VFwUSmR8TEpsCIAASBhYiAA4oMIjGii4IyCYc0hMeAB4iLhyGIuaAwUgYKBFECIIbYLkHctTOlNy7CUWTISIaDA4QO5rayyrfUgAgKAiMxvILXK7LYga0GQL9QTkGy5O10NXb991h++Lf0y8YlsItveMwyIf1U2EjZS9bGMQLMCC5YCuWQyNsJsHD2LEdpIYHAAFxdkaPniCVUGA7cy2T2vS9OMXwF+gcxRdyns5b2LMQjNpvhMyqdKlYG7uVMIHQBYekqdSrbKnrNKcVUNs4aKG82bFqRKLJGDQIAIDV04GpJKHZ1o1KgkOfNEWdcgzS2vMLBC60lyjqu5s1kWE/3fRXb2ODmBJ0ABhgFpCs2Ax4K8oEQdpDDi40k/InAYFEJvppyyA2z160/H1PPeJJmt0TQXQIgTPF4WbAA/Q7JZtygV1EotiSTd0L9C71/k2BlwqzSm3DPUWHik5I+TL5TV33jn68elLoNO8DgmhOOrVg3vPDd66bvF+skc/39d7erzsk7sXDl89zPJM5Pu+j319/UH8f/sfb5EFxCDiAANiaglAYRRcUMH8qHKQQeUkPIK9AY345qUEKeyPww4BfFCdEF0asT0PPzzkwiIgUCuiDU+k78QSXdwvQhjJgzERjXKiYjC42njjL4VY28yLABogEUcZb1Syvhl5Y/DJqf+kvOmYZJZBxhoEEOCqmymAOuCAFg1KMkYPqdTPxunQhPBGNjUkYgqMCoBiIdUwioKgAQXbIo85ynyzTDejrBFEJs3k0BGstOJKSy4deGYSV8xaC65JkKToxSWZDLSYTrsbYhnVOHvv0E9lKqKp0jAL4Mc1BgCMGSwKYxFORCk8NZ5cIdlVtFAJzBCeckDN0VR1gs20yUSNVRO9IkS9QxsDGAgglQRcEQKZXB7YDDEEDKQWLiGpEELII8E4wIGsCppwUE7TMRBBZXFl1tDqHIH2m4FMUUUbBhCAgpRfojWwgVYMqKQIT8YqrYCzjmzQXYkl1PTMev3r9Q98CbxkMWT/BpzGAZIMVMNOX8SslghPPrJCTEwCnHhTem+l+GL+MjaviAioMQWCxaagZtqGJhMjggHsNAVTkIYooBKGqZiisIiLfXdZmgmt2t41i0AADLgWa0sVTUiCNQADjk4oCjAcKptIAseCmeqYbcT5M5udLLQYkw2JgMCpZZa75qubBfzmvInZWxAulW438MLpvttqrZ01ZFgjSLIqa8ch1/zx8uq271m/l7C8CMztinzmmUEnhnUoCV8uu9LlOb3NzSUX3HVedOcV661VHmXalIdoLIvV0B0MD+HBEjF1wVd33neMDyeqlEToZJqAp2m3HvXOLbaad3qiv5f6f3DERjUC/1gmCOzmv8cda/GZI/93+9V3/w7mxaKmNIjz91T9phc+ARoOdqUCXv6Kh5rjtSYCKgFg6wqINwLCT3UDvJ8B5xY/zm3wghqk3OQ898EO3o6EnzscBT34vNxNEIUHjI/0RshC+blQPPPLWflgSEPwQc+CPHxhBlVoQiAOEIeKOGJedogfGfaQiBRMIrFmmEIEitCJU3xhABSwRS520YtfBGMYxThGMpZxi1o0YxrVuEY2dhGNbYRjHMv4RjnWcY10tGMe44hHPfYxj3z0YyDhCEhBFlKMFeNgIm9IxUX+sIn2imJNbAicSEaycVi0IiQnyUjwVPKRJwSlAS0ZnhVykv+JS0RlJo24SR2qkpKfLGIsochKIQYxhBh8Yio7OS9Z6tI5nvTlEDG5y8HVJTv5OQBcTBRMY4bGK6SKG14Sh8RA4IEtsQNfdnaULdS8TpIKS8jo/JDM+QiBW9gq1Emktht8pQ1O1/xPudxZhKC4I3Gp+WaBEmIFhREAnjFkGj8/QszrpMEtpxmYIdhyTG4YoAGC6QogyLlMITAAe/L4JymPMDtfiQpu7HxWFEjBPFRllKP0+Us1AoBOJdROCRktkEP0ANNhxAsJ1oTmKVVjALgMtEbZ+YhSujmEBZzkgUUSUmBIQa0HRAY1W+iCurDA0uEMgCtE7UfZ/gRVnp2kp1j/4I6tZkGGAyUvIQTghErMYFQ1jIELXEneuIZgLrd1tGiaSGsoigrWtiZVK3nKCreKNJiwaiyk5foXH8hAMpVQSxMLQBeruHMFLgSGH1sVShQEizYsVEifjYCAjzJbhcqOQQ2E3YManPoLv4KrVVo4UF69AIayDXUINT1QTiKLU1bB5VpDQAaR3FLXArz1FpulJtOsepAouHOvAThqFGQrV+I5piulvaxxvmmTkKikMgT6CCqqMLAFhMINDRCTTtqyr2dCAwC1WABJo6kKwERUZc2NxrY2sYArME5eQojve8vAh0gV5hvlFUpgxPQKM2hCsQkDnir6R64cmnYLCJhC/xkObF4FB4YS6z3QVwYyhaQpMVRr0AJBFjsHWkDmSJnYRGL924pXZCgcGxkxV06aiJRCYDP/etQzulmLbfQXCamBp3ovUbBWhCTD0fIJG3Ja04TQacKiaIOjuBKwf9VpTBImS7QAYLQcn6Y510smPtySGgSfN70GRgOEhyDepgw5F+AorGhsgomubQFT+dinbYNBzoEQuDYAGW1YCOAAy7AidEiIgIPLdZLmqg8b5LTq2ao0BGphIRUEztM+MSHdrx3o0qHgA8pIujKOaPfRY2AGkEU96FIT5GVkdYC5UJPpnL56MmvQkmLRGoqQNIK5ALAHr4egJzRUeSO6zkVCb/+rT4WYzGFCxp8ulJ2To7Z32YY2GRlC4tTNDJSmRrApu6yAU2szIwIguxafEvAL9nmiDdA28R0OcIVvaCUhBSH0HEStaiII5EAdIYWzuwNUUtkW4KVWsjYQ/RXdDMthvmZXARyMJFEZTdGXUIUyx7rpauSWFlVAEsUlRVRSjxwbEfg04/ipGqdd2bBEk/DKAdxyUkQ8waGAgENNl1uNMpgUsLGCuoaN7NxaoSdqIcW3vYAwkE87y0KnuVRSmi0gd6nSoiBAi6I+aQDwi+JS+PCSQ5E0J690LWo5O4rIbs4r41TLDgDaGCgsFJFvz94DCLp/86lvzBztQPyi9Vh1vgf/7dJZ0qKoenILepnbkpfnsQVMAxaDUIQLNgGuHg5jPz9mlWj160QBzAIm0dY0wZzTBHggHLKQ1jAkPuonGX3s1/YJLNT15rAWAipon8zLu8bPyA6DORNi5l5H8yRFwsy0ll5skAymFquHPvIlQ5uN0BcLCCibZ+eaCNFiWxSxmSfTzeYEhI7fz+bKU2w7fRbatl86BSI6cf0ZBdGGTVWz+gX9Gy3BmrnBu7grGIDuSoOHG7nh273qMhv7wgPuWzhauiVISB9UaSUBaT4hIAhvEo6x+45SyiIL/KViyEBdMSVA8Kkj+MDdWQ6DkqIrKqFhAqEbxCZmaiQSbKRR8hVA/zgpZ2KCIISEbTizEVyC3+odXmANApkmjINCRfIO6nuIJHjCEywmXEoCaFGfC9woaSMGI0TCClOCrgFBRpCFuZKpKPwbGhQPKpS7mBoEMPQMRAqly9EFIoxDDVQCPWQEMazCS4qnl+rAMSQdOpQyOZyQhdIol9JCI4Apz4DD+0O3NVyCSNRAH/w9cxquTki4zSguwrgF0RIJTJAMQaEESrCMblqNVRywvpqVGFOruRIecaGWUBDD7EoenEAt0RqXSRgrB0AtIhg9GKS2wBg0h/k3rGoVp6LFcCk76zKrwyg7OQC9QJwMNSiex3iCtrq4r3AtuHAYBjiaWzS+HgErCf8qAqlaqbNCLgN4K5ZKnroygDSwqKm6gjRIADnQvLO6A+MiEqJDkdaqxSpIOmtklVV0uGTJwhsMLizRBKLIwygwmrsrxYZUxyoAB1z0RFk4OVxwAoThEQ1zCyZbKTgTQxt7vHcwMrLYEq5gAAhDjTloScb4sr2Ik7QbtU2QC657SUjhDJOMg6N4PEZUybghCcdzCsrgisqojE1wqFbQOC+AM5FEPsEbH3pinmcoM02DMVz4F7oLM00rgJ5qKtSQkzGAsKGgSCBhOpyIOKE0CJV8ikRLE00kQ6qcE42QyC68tzw0kDIIhk8hBD4YjM7yiH3yt85SNXIrSV1YBlETw+f/Q7WI4bV2SwTW27ZEBEFbUzOexA01vBN4CjeBGTlQowvKRErILAMRxDdOcIXS9ATHJLjNXELGaDTwk659Ms292Rv2EQkx4DPF8oZ02b2/yweBvD/PLE2DoMy9wUQVxEhbCr6s2ApXIIqo+Lu7Mwu0QLn/koemyB7xhMqyy0xToCrQTBq3w4XKjLzvHA5SuLuYvC2lW8qCw8rkygmdfICeIgc5uzvSXLtzIcrvPDsneM+pCbvgK9BswTovUL1QQJoj8YTFuy3jEMHbxBCMSIXAC5UycD2wNI7tCU6+U7HiDIqhKIM2UBXlnLb93ImjGVCO65o1C0uhkC9AuRtVIZfV/zCov+st4wO52BMrPqiMy2hFb3EMBJWM4XM/pJq/XPQa0rNEecA+/sMCcZkVYFQXH2O9sqtS/ZQnP5OqNzAM8stSuzS+ItlGV4g9zqvGNJ2a2GjTbvy+lXkA+AtNB8yM9NNQ5bswhCLA7rowIpjHyCrR4ZyM4rSNlWiD7koAF8WR1pqnUpjS5LE/W8HLQbRBRrhC+iGGPA0gHVSCT00TQUjBV/KD4sjBTWXDXuIFUxVTLHQlQZBVsQqEVNWpJdgOLHTV+ZLCFRRCUhXWR9QkR/Ks6CynJdBVQuTDPayKiWhCxZHUUX2JoLvGM9xEgPIhHuyPRy3AU7qCbJ0MRDwCZf/90xcdViRIQ2p91nRzh2bVVhcM1yP61Q65V0EcD3RtJj2Q10RDTenExjp0Vkcsw2rNyDb8g9qJgxnU1yRgxG191hrqnHAEuMrENjfAgkowF79RMbQqSGv1CjCQM3gkDFfwEac6iW/QrC/NSNTiqmiMQO/bTcLwnoBSCZUtGXPcFkIISFnUK7ZCqsxrRHIwLkxFyFSEAFeULEpbC7DILlYJVwBDCesajn6RAiqwgrOKWXoUTFOcRRqpoJgRymTsPq8wrwL4EjPwWGGTy4xE27goOP6LgADlCCkrM7u5ysoTMMfrSjl7nyLIMK4MhSfTlxT0CSeDszbrMJ/7wW3IEI//6wg800i5tQWIGZonWAO6DMs/CUSlFD8ieEh3677xEjAS/drpTNdjJVvWNNv2aq9c0JO2LdfmhNvROp1Ta7eIvTfe1FuhYABNQziDgzaCs50z3TWRIjbJlKnkdEzbE7h7KFrcMD/VNMx9At6zqZ0deU7IzFZhG7nQzdq9rLSI9YhWu8hOydcXXV/xVc8j6U8zwNjyVd6Vo5T9RAClm9D81M/YdYiXe4AABQuIuTr+zcr7RDjH89BBINcDRr5bqAWupIbF217ScCj2ZMCe08npBVKIeU8+IM+lXNBPAIvICzwuwTAM/k7QHdg5s86r8ooBVp/t6U6Qw1yG7FbH0dMy/53f7tsGrRodhJA+PRVZ3P1fwBjFNEWo2HuGQdXbK1W0Oh3UBwxc1SCMCI6C2Bi+2oFU+VMI6BVSAxZfyF1RilQJ7jPSVbxgNYgN4okK7rMMBviXpdWZM7Za9zUn0iAX9qPG84uspDLjMP1dCyvGb2vg+WjfFr7VP7DKI1jkWRWmHKzVdvjX/hJVh70gTUuAPLspc4XWJUxkuXtkYDhFJBhlTCamWtpBl8BWI3BanNQcTXODOh3ZjTUXdkQnrTqIUlbHUKbETq0iL6RON8xktYGsAo1bFTWDHFUu1Q0PX1bXXFJlVZ3kasYl3FOG1jw4I8YNRoMu7WKsr3sfaOYlWP8q1mXFwSQw2EX4Jz8E1j9w51NlMAYVGx/+T5Xxm45rLjGWPBOUZGPlVlz62ex6ZTPYLckAEjiwxqWqltUa03NpjR/UrcuQLXasrY9N6KjF4XmWWW703zP1PO0yPSodZ38O5nQOaBBK3AOhy+bFKwob3NGjy+5p5zLYHolOMKYzXEzYnzLAaJmm3I2mWG9F6VQW5lVOTguDoOYNNeTdv2zsh8WoaXU75BYuiHETNW9mhdkUNrZQTaGuQWLehUg85cxxJX5FQ3HGY1tq0bCBCnoCh8/jJywOvjWbOPlqGjBbFYltUQu9k7yehPyla7fG1SIo62Ui5xjRNdDztkok2Fn/cFl6Erl1Xcx5Q2t2VmurtiUFPDyvaWOqJQwNu+KnjtPXQrRMbZvIwmnOlsUwCOnwE+LBpkCxdWSZWkiQcubDgddv7bXDbpN2VdjcBtV/vIU2uGxFML+rHeZNuEkjaMF1Rbfm3kDDFuRzJZV4BtXE9gui0+WNEK5nbBV1QZLnNmtZYKwCcKzMSh5dRlqzwTDaemKH09gPky0lrIZkgG9OzFqgHa2JuNd6AEA9IG901r51GiKChMbvi9ppHCq6Uu1R1W7DVjgxe6YFM+yoXCmHuRSxMm8W44r+Su5RCQs8s/D3GddPSNud5jKAOZovG93ggrMQ1+xVBuYdjEsMd4U5/+Bc45jqm4Zwm0m3cPZuhJg30TwZngBP8ya2ptNNeRByxaoyefPk7piEgSFcx/yYAwgZKR/fjEhAUZPxTz7nR6inifVAA5+pCEAWSAi6/tztdmFO1nTOKoPO607dpfnxiiU6fS5dvhPNpImaKbdWJX9LkBAyjiuafSbsSvnd4ipu426Ixcs7oWF0F2YUvMPgMP/lSOYFLqTK9KxillOci8izE/fX0YGCIl/zdonLGTWIyKvLuMs6H+9lIOduxKBfL10nIv6oMqkDGS10K3gGJsZ1KqUNXRf0ETzSPiHc1hYDkPu/0B6NMHN2TY/moi5ChngAZh5kTuPnI4iAxniEpP+kvlrxNUplPUtNU0y1AzbovQevdWRlhL6RZ2zH7clh6FTQ5XzcAn5c9oFRnrYyd4F145xg2o5dAoR3gsJYiH8HnoLeT34GDVZFoAhvh8Wpd05P6SFir/u6AgJIS4TxyL3rSw9E2ITNFnEY+bVVESRgeTHwCnGEgJFPoCr13OB2bujyVZPe+OXu+VVejHA+UX07zOs5H5OnbeASh6Kf3TI0TJhHNpiUWqM32Jt/WFFyocbOwRdsqerGjMk+Mq/H+V0FocXQ56F3mBDOnhGuBulG+WrMY7SblGfPKfuF+n/ULE7OziPY8HfGennvjOMmOa5X5+oWbz1YZ07957KfOFz/R/uzUGPgaeNtT3pv94LIB+IpyE8gdnJ+WnaB9NHsyxa3v/awDtYqFPw0IfywX4LExw3X93uy1/h0ILHK3zklQJjQYoJGfoRVV+5V6hzhouX+biuTbcr6Q0ixpSw/6+7k+eHAOIKTWJ80BRLeXJ7Bo1WATocyJ/hlQ/OEZIJdjNWTp0TZepmwW36lopOVskZcpq7Msfi3mzNktsvU8Mq+UYujVH630zQgAAAKAwIDISQQC8NAgDBwFpmQI4LhGCSQBQKAYEA4AsKy+Xwmo9fstvvtVsPn9Hpdbs/r92s8/w84J9fA4EUEEIGwgIAQ4ABgUGRgOAAwELHwUGYAEWin/+bnKTrqt1ApNPllAEA2MNAQ4USWelDQsBCQACbLNAqn1ihkemAgVVtG4PTIpgRwPHTgKtT11Rsq6Jvdp839e3bl1S3Odj1ujibXKFt5xa5m2gzJ61AQkHiQEKB5zipUzs/Pj5YyCTQ9iNDPFTEAYyB5ibDP0oIEpwCWAUamAScDBxAVOZIkAYQwzKhYwSJtSKd4/+JY9NTyJaBS7pz0kikqJs5sgxyZWQCLUUZO8SiiKdDRH5JzoHZa9NMgX4ABDooZeNRqAAKrs5xsgeCkkAOpC15itGnJSSQAuAJ0YaJl6Zl4bcumjPLE2h45xXLJdUoOsC8/DBoAaESgXZt4gv8DNx6H5wADJ9Eq4VPntpqQsU4yeUUg9aa5po/F6aSTqvRF1TM3VUqA8Aw1wadZO96cQAjiIQ+QMhhwwKtGY8JL17Z9h04w5Oj8MR88KjXr48+do6qk5Vij4E6iSinjYLKjiZTZdmZoFWu+3C6rJy8DITbiK7UQNgjQiWKz+/ldfXdKnXu3vbGcgKQJ+EeACKaxoDfXAZDAAtqRQQ0+aGRSxgIISVYFI1gUBMBBrHhRSHsNtoFHfLrJUhY1yw2wQDMvlvWYgif2c6ODNp64Y4MKPoNKONY9tYlwEw7hxS25CEmPPYq48wxSqYCB42wD5mgGHmOtKCQ1/EFYRG5fGlX/I5afOEUmT0Oa6SCbbc7BEZAOZSkTXxWN5AyFnZQB41EHmGKJSCeNZRBCali5jZurmVHYYU+UMRt3CTQwHHDFlanoG3hwxI+c0OGYKYqhmliHnNKBCpCdZXiXT1r4hSXkA5+1VWJd6AVwVZVCJpopTaOu+Sudb6S0B6KI7KnNgcEKu6yw3k31rCtaFNAFMZOVZUA+WPTDGUmQcQNosqP6Ac6vPS6IRxdgTPYAZgTIOpUl00qWWXhSyMKoYSF+V9V5eijbLKoBq2GhEAMZvAWSxDTQSFWVaNjPIZeMBm5Fn/YaMLMZp0sAGGJkpQoChGSxBSGUYDjNroQkEcbIBWjy/+dewDZ7LoJqKKlLuPKm/MwktDDRFVrf8jjuGlsNa/FzNRtohrp6ScOdE1DUJEWTiSC6cp6ygOFFzP/OvKyNzRgrM7E5nQHjwTsrzMQYGj2kCRlpUpxqIEtj+s0qbpitXAB/DZ0xqk47N4AmI+m7833LNF0LskI0ejhBlTxQlojv3V2dHw9EJMTmczFB9td82y0EWAEUEm1K1a4jj1/ckkU3JEl1UzPmtBmtdxuj6550QIGvOTi3UsPrd0r0BnAAvFvgZUYEexKPQDK4lqXLmQLTfAYEuSXziEifIwnT2qQUPU5KtZMvxLOrdCuyVNKy8p0rCdQjhbtklFhLA/TvSv/677aXKpoLPUAjeQAY9sxwnwY84DcJpB8TxpaYOIVlVQwwwwNesb+E9K41oZKDugzArp/0JRbxklQDJmS/9fDhfwAyw0COJrEIqI1YyQiUXGpoPomoZAAPrOD4/Iem3knqb3QwYNjQIBKKOI89ADDZ2IjhBU4gkWQQykIPNaimDkKqY2FoSIbgMil8jAk4TAiG+UjEvyKijy3sWEVf3KIzV8ACX9KYoxPWRoYrhMc8+Pph4FjYGCMGKxQXLEwAMISXJ4zNHkLAhz4syEPgVLAtdwTZxRTlwY7pJUOWKYvH1ACjI+UQfF/TYhlEhKc0zRA46wPZQhpSOOsUwCiWy+L/Hw8IyOmgoQotwk8jkFCIsWnPYn6DDwMeEB6E1BKLl3RTJlnyk06qYox4Co4l9nGoNGLDlLopRgLWR5bUaYUrO9sKrsgwhicQrJj6U0szDzhIsMXzDF+KgmHqwYBggo4AGtGC0NLnE6O0E1fM9CMmtwhNTjrDk6swIavQKbVsyoybG/ud4LRJh92Fb5u5VE1HjbNGm4UUnhVtJL5sBZ6+lIVeBXDXJrTlAOk9yjeFi59UINCWACbqo3grKcaIRtGBWZRjAOiQHiEFM6CUiAh8WwvEDAY6hHhsZDy0BNDUeL0jAjGoTOPqORbiu62mzBm9QMomurYIWUylqV0rAGcy/1MhtU5NM7URpLmGCgcJleFob2CMG/iaIG4Ez6DOrMMv2wDWNxyCKXiFVCeMui0h0BIoPjEY5+YEkQXYZZ9FNQDipNGMACCuPTwNZGM7V9kMzQ6wixGNZnHXv1Lljg2DPZtXC5gH7YX1lny6I0qToJaViucA6RRSX7YgPQNwdl9OQABomRALnTYnq/Pk7eNedga9drMN1PBrG1g7UVIGorYb/WkjQXjIW+WqFTfNaWhVqD6AjpZ2p7UDyt5wKsZS965i5ZreonaA+HLHh1p7Ano1IY1Xac+dHIyaDA+DhVzkogHNcO/WkKSE8BhGZ+E9aBkW1jAQiagVcLkqXdH4wv/ceQtwPp3DEOGEUfrud6RaZYsmUMeATkgoxZBw3Fg9BstKxIvHHAQflTbXMEhMwQh/q+rgkJLAInu4kb3wmReoBLLQJsHEXQAUYFdsmvqSr7S3E6t49LEcCXm5ofngXHefJmRhtDG2s+GIFd4xBSC9dZ/NwEefpFzYD7dNtCI21M5CaxgtIwmVeoty7FrcmKjMbqJkBkylW9jZJBiye8lDCJ4uIpcCrATOOGI0nfc0AAaUcSgQUAKThbFZDDOBECUCNJsiw7p+rffQ0HWLortgTgPoTbf6tS5ODosMAlNazAeESBkKgZcEHMCc34TQP10FzQR3MxezDS/zvoSZBzL/wcK44nMvHsDEwFLUU74o2GIfLdQt4oRY3luhPPlr7ECfoSorCkQEJm3vdUsXEOrAX7fDLNao8ZFGCHNCJxzojL4UYDIIYV+WXOq5gF96JxvHScdlnN1TFGgPV5hvh/UNaZJSA7KLq2pV01cIYkQPC43QH3ZiQ7iKeG3ZYk25mT6ubvP6vLrgi9LsnuuqJ2hHb357o2gsuVB1A51IPW8Dh5Ez9ZPfmtk1VklRB8WnSijhsDEvI9NBs8FWRCTjPM83Sa2+QY/+AdlwoHsphR5vYzPvt7xuQj4JsHSlvJXhwntUvds+dHy74epr0KhiY9ym0GnD8aRCed4TvxMjcDDr/7v1aU6PRB7kMbci7uK7TIUUtQtSUGuTShSAVy2v+c3ydEhgr8MLPGm/Xdh6eH+77wEj6c1zfZ6vJquj2LKhQrQssjtjORpePtb4aOQA0scPmHhVIdjHZQiVeDCJrUoIHedefLyfskWC023vlhfSvfEw54tdUiCBHkpyDbvxoQGe0DQtSQyIxsu0AkqEtyhFp32nQA3a9lxpNn6UJyrrxjrdUGtmoH6x1WIlx0cRiC73RmPEBxKZZk2AogWRgzaGA3awZlVNsycJUBgRgAVjhH2P1VCWdIBx9lyKAyELeFlYJXTWBBaLY0sSOHBB12KxxBZMsEBuIHkcp4G3hW859f9QF+gF0AMeUmN6aiEazINKPmRCvIIXT6g6XoCAYgcXajF+xYVbDugPI+EFgPIq1pJeuuYA0cI+bREFQTKBttZ1ziMMD4QfL0NolBE1zwJwZrGEvdd1lpcNUkRYW/dhZAAWW7GGQmYZnhVihVIw3GcJhrYck3CHQnh5CbAMC2CEVhYiuVEF4INuXwc/HWdXG6h4iOgJOfWDKAdgc8KGVBYkU+JZuKALTtcPm6hJ4tJzoCgMahFTvRAufkMNyUhEdTNjTOiK0eQe71d+tIgH0hYVcWZ8blNofDIRxNREfhMewTiLJKWHRYgM52aKFSRqpaiKmEaNLHZ5cDeNNxKPFGj/TY2YC9oYNZUAh6YjFrDzDriiT8Kod/sgiumYPlLREV3IkJZWiOY3j2zAeM8Xd/DWVYYIB+zGHPcIchBmcvYYkbBYXZ8He6HXEfBCeltjK8RYOsr0HTR1dyaEP7aQQTJJdRr5BhyJdWLWfoHmkdwQlMJYfKCXfFPFfNLAchfEZEy5fPSAc2c4Rn0ialWleQUQlc6ok9EIjT83kozIW/J3kvS3eztjdPEhIejmAFGTF5DXHjOiR5OkVuKVkxJpB0koDui3TW7HFoPIIB35lV65VcVXTWQAgiLhWc9Hgh4ShwyQGyDUWYiDl+3hgrM0OVE5mULJlUjolmuQWHqAgZX3/3va1YB58FoIN5TlWGNOuB6GCSvMVUybQYX+QkuxAT2ZeRtbGBxIMFCrgJuqiSU98pt0GXB76XOkeSWa4oyp+U6HCJYZSFEDFUFcgFMP2QVwyApgcXpR02fCsS6PlFK44gB0aJyXV4sqqTWG5Cok8Sp4EQY5JS1VBniTEYRYxZyL6JyC6SNrZJUVNJ5QgHzOwI4E0I3xwiecpQRjBGTXWCjPqDF5F359iZThgSzpIolNo41ydAQEajKYKHXD94rPKVIURUlqcIRsdHxdoIs4smdG1lIBmFBBogoOOoA+pYBsmY/OQQzfQTB9kaEPkzaYYaAaB6KbCZ37SVHLlAXvgv+iA9EFBWqCTjZqCrpJktWgx3GfthWOnCaCEeocnOJ9qNAR3mcYoCVslJJawld1vxecIhmd9BMGrccJtGIIBICdapBcY5gXrEdhVapeWPEeeucVKSkLCDBg97GeGaoW3ecWKWEANHI8fnk5RdqVSGqpdkmPbsqX7kepWwlUl0qSa1CR9bimP5Wl6zeR+nmkmEp0qcqppdqqIpqRrAoIDDgHnViebCoOwSdjp0qBrooTyFmNsxqqf2CrcICrbwKsFyKAZ8ApfaVsWeSreDhP4bYTwhqoq4pyydoex9pX9amsuppRF8kGhyetneph8/EbR9GZf4CtOqitz+mjcPhgJdf/FjgHnzcFDb9hK4ByDAD2nTmYq12XLafzCLaSYOvhLl3gT9ZXiyEisBs1rZ54QLvxMv6KFLJgL6klPxk7YaKkrw97d/GqqkVRKEfWLqI1XS4XVV/HmBgboRKyoFpHsA/jPIOSYChmgFBQYjGbFDt3rrDKX+r6J5bBWffFJyVjfRQhSj2bY31ZnCTbpgo5J1RiZ0iQamuxKEiXfdNQtGSlgDE6rATbVkanbUjyhQn4Dj/brLY1sVEbb5hRFhgLPlYjF9IwI6IkhgoIt8T6nARqpSGCEKkmGlRyEWUqhuCzlHNrCwF1AGKbrZeXChDBcmfLsPvAsGJog9LWORHbP29L/7PV+iidw7heBylHVwnUFIO8trmSGq6kKnSVgp1fch//IQTRxbXhYCv2Mj/r+bh+GrkkdVxIgLDaeJ1Sk7ma4Z5JYa6fArojG7ejyxCT0bt4oTx3ewoO1Zp9F22uq5yfSqv7dnDioIjUqnj55QtSpHm9iq7FCr4j6qkKZQ6yiKrC2672hRa8qpk06r7xK7VKY6T9G76C+bxnuKk5AroFzCsGbFjji3AHzIgKHLz5ObWgKqto8KwPOgfghZEUDJTte8GytXhSI49+W7LgWqPK4cAfuawEDMKqqg334VxZ+brJCbvm56Mdqy4XhgenNwTa0j4Mhhu4Unva6YeCuK/kGv+YFcxfEgyv0bseDWBxlHRDoAPETRMB1YNAD5kKpkC/32vBJ4wwXCAkVXUNTtZ98nMYsxVDrCB2qZCKp4iVTyyuLiy05JNkkRBDr7ZiY5PGTTNLXtQ562iL2jiwmbNG8fCFLaol+jeDa2YGvoinyHgKyni/TnzIH3zHppRmA+B0PVPF4EMs1ZQt0sgKkIiiWKqp5ge4a9NlsYYHr+VkYFg4njZbczPJg6yKv4nJNazJEMzJrJYmh3MFoTyD8BFQ6RbHFYSNRqGymQyY0VkM74NhVogqeSrK48RtZjB4OBIPSMzLLwydvQzGJWWt3YxPHagZxwwpUjAR+oLEksKoKMz/vyBVqQPsv25KzqKpVSPHBjXXk+8bwiHqwREszgjcb23go9EcxkzcwvkMVPtcmpgn0DcswBc90Aa9yRrpHUmBq1mXwAGc0feszwe9yi5UuPUJ0ic90hANw6Yk0TYcqwZjMR8NkRXt0HXs0uNs0p9aF5iBDAf2p69DxHUJv/iM1BiNpDG9wPFWuTXdRXJzpZg4MVr5vyxd0CQd0T2NpGZb03qxokGTGVZ91Eqd01k9tUw9Xbz11EDoHFA6N2Rtwmc903X9yxRtXsXr1tySHkSdXnJt0S2d1IJd0hs92IGN2HRN0Hat0cC80wCM0wht2GY9omr9l4591QH92FjN2HaM/9mUzdCZ3dCLTdqNjdeHjciRzdmlrdVLzdWiDdty19qKLdKuPdmEPdeQvdmqPduV/dpljds9Bdq8vdupbdkajNaxbc/FrdwvbaoKAN3RLd3TTd3Vbd3Xjd3Zrd3QHQDb7d3fDd7hPd3dLd7lbd7bTd7nrd7hnd7r7d7n3d7vLd/vHd/zbd/mXd/3rd/Y3Yq9vdr/rdmoLdmfvdW37dy0HeDDPdq1zdMGjuALnuDB/eAC3lXHncI63dym5d/ETeGkauFLPOAdroQbDuHMHc0fXs8HHuLAreIMvuIwzeJ0nNz7t1crbNS5DeCYjOJq3d9uoHpfIAs2Dr3DSj+il66ywP98H+abQsLBGfIZa9C7sfWs76ZLTq5WzRjaTVAeOo4G/cis3QAB9JytYFVDetAWCdM0suC9H7oH08wyvjBKJ+fJlLIAgIqfCGexbTtW2/UGIHIG0VVeU67EIy6BQh7gc34Ldi6rPJimvMPPPzHWBkXm5+Lnp0s3PRIu0oOBCzBC32FCAZtCuTC9yqCsqbY4OYWd/cqQ0WLlbtXXMrYbRtHFU4AkAjZB9JTBCAN9QSfoG+sA7OPr4CEe4/mQu9vXEpZulx3UxmdG0zJ7R8DqKxLF7km8hco+0U4qpp4l8LXqynZBAybceZKGxQvqsrBgQ4rqry5oPzjpfAST8XKvaDD/fbJxbUH7V8Vgk0lxdRPxE2B0QpOytJLwMXiERkhbzqiVC3ZeaCwHMZJxicLSjbCO5JUw6xDEY+VrBsGxPTbRIbtenIJ+XzFk8DaWIcnHcgWKRslJJSDLBWn88CvyCFrLfXyMADH08pWnPFiBRstcRQMBihhfZhnviFOBswIfZM6Q7NYR8et+SZMO0CEzMs98BhrvKhVBoew7LIsQxXI2F7EsTZ9kMDFCarpit74cAYZWtRxRVl9bc7y4K2qwohJ/ZY5Q8fsEyY4ksM5m5fV+d89KEXbrdGW/GfWQCF6GPGsf1nu+1suut2MlR26/V3i2o1MByk6HM51ZDmevK8x4/0FEIBlID55Br4/I49XZlrqQvyhxz/SSPmytwACRwJZQ8PobpPdHMeiIZ5qnoFcJqVAxAwZUSjjYpPhmdfDhMscqu/CDcpjemCWGsfTCuBs92My03gWmBmplEAHdQ8MnGFtZzBDW57VxjX+y8bUhOChQSpwXTiWF6cq0zPz9phEjMaYDQMxHIP5/RirGj/bVT8hAAGE8HIwIAAkIIJJN5xMalTYDz0MVKUQgGI7BgFBAVgeP5mBBbQAS5sexeRBP6U8s0hGAACKJJMEAwmCtCbApwoENDgkhoaGIoE7SbmzyySAgwADggEEzMWlhgDPN8CrAMawyL4AAq4DgITOBif/uDukAE5UpIqDAAdMgcSEzjTiAgQAiM/nQF/jTUlqJMTNz9DQBTAwWATNhMyFzDkl2F2qAfJoqqbEYwJzWQTxgIb4WfhbhuPk4DVoYNQCwotxCYqiBOHEAviAh+GUZskjVxjHMZGBUAWQMEMwrFrGZrTi6aAmElTDTAQANAiTSxqbiOplSDHK65Y/htlWZQE5E0utXMFBIji2ZSenMRQcsr+XLxCrAqCT3mjTQWO+oSIFZuXal6RWAKLBga441O6WsV7Fj03ZF0LZdAEIz4Z61q/VuXkt19d7FwrdvX8CS1gbeazjw4HWFvSqe9naKLqlHHSNmaxlzksqZ1/3ljHn/82e6os2GFm2aNBTUqSetZl3H9WsnnmX7XdewNlrCk3Nr7t2wrGPGeAXrxX3airoo3nqr7rpApWzazcnSWZDmDG/qvusM7x3b7RLgzpsYiA7F+1fD4KMc/1xTTh3m27lnhV57Ov2sm91P658XsPSc+G+930YJThoByUvMLiwItAw+5aCYLytVbOPqPukq0Y8rg3LxJI2GjimgoQKwAwAyAAwg4EOsKGoFp2bi6+qOEeODbAF6VDJnsrcyIQCnBIaC4AgeB+pEO0nqOoWBsN5ZQJdeouLEE3WKeCrHlKgZD6kkYAHEEzNC0dFJrABKpApAhmqwqqsiMQATBq5y4C2F/xoY4KJ9xhmAHgiKWEPBy5xoMY1sGkBJEwBkJKdOVO7MU4llJGNzqskaaBKnLxIo4JQADkA0SQg35JCyQQd5ywswOELiCxKbSHHFXBpANYmGtODCizQS2IPGg1blRAwcj+gEEAQuHcpWjnB9QFUEmC322AIWmeYOa5TIREVeb+1iATH4bOAAR5pxlSgxwxq2STIOXNAhAorNo4kF0N12HjeOaMUAfC5kVQwCmsRoIGMeoBVgh9ZlyFtuPpWrQFNnbUkPNjRFcRM02OAVxZZUnMzVKS2kNIsIGjCPSHr5NJaBPaAL97X8SO1s0DlW/GJGiwZ5FYtYZfapoRk5fUuQ6v+ATeLGKsR6q9NWasVmDk6JhO4BIZMOwydq6Qg3gAd8PkAsrgEo1pop8dAogn1GgUzdrdhp4ss5bjrb06ZzicSQpooLJWwVI7kPjRRFyaUpB0dRJVyLG45D5itYve7sTYDeJC6iBgB8Siw+PuuWSw9Ih9mtG/L7U2ISqDozl1+WxkMx8rizWVYfeEAdljpKJr7VazWD3oEYCFUmy38NWnGx+BRkrtsBoPdSPwxokngvST9MyQGU5RabUgbROApOhfcjbQTZdtfteEcZfvp64bkXkrvLmXbFsFTqu4qRBVEpggPXaEiVS0NiMGYAVo9YG284HuQKsDucrSQQ5uHDwQj/4Id9ISEBDGhABLpgslGwxCXnMdx7RnU6q8XBGuMbxYgaEgF1EGN5LAphE1gBpHccj2GNwZsvULIQfkTCHEbBw49wIrHzlcMaCCBI7+hADzHgpGvWo5KWgLiLG27pYLNxQts6+EScnIka6QNQmy6iN/cxZAE+8oVFNDEKoOBvDlET1aBWaChvoAJyyyieGL11kYONTGylcYIAhUCUd+AGT6g4QE9IYzoPKql/XanZJDbYq0MWRDSBYtcj1yaNFK0jAufhX1YambGWUVIr7NlO6ryySEm0T2igrGRmJNklVXZwEpe0pATXmBVURo41otSQ2l6pnl7q5pe85JAukRNM/18a05XGNCQyhcnMZlKSmHqJJmcMwoXnkWaIMHOmFJ25TGROEz/KPCQ4QeOEVmImmx/cZn2+CcttkvOTwYSnHuXpBFrmJp2oW+cqxfnMdu7TnaCcp6B+eYt5IAFUiDrAW74hjkFY5Uc2cRSYsrZE5RgJFldqiUfyBUyADrSc/uznR0f6MpCq73hwYFk5/KCFVmguW+n4mgQBCIZ8rW5ck4FWF2BhDy+Nb1rJfOdQRVpPgBb1dCd1ZEGbQCSEig5IUllCzpigvbClCA0WmuoKcRE2qjmAbG+MCSSPqtSGmbV0R33mg6iD1lJJga0PbA0LHVgre7SUI1Q9kgARWlOtYv/wCc1rl5cKh8iyEtWttSSaLk6kSizQMSdHGZ2vHPXAZfAunkkgCQLiuo636Iub+mwCLXuiUFhV9VNX2YShtLpETzUhh0KMhT484iKygtBu8WrsWCAgof0U4rVsgNw4A8pMg7jibHV1bDUIwIUvYHYKPppIG9hgLnr+pAAOJMjltNke6LJzY4roLOa6KznjWqEKy1gTXKFbF2L49q0HGWMehvsH+O4ysYgxCOxms4zZTqkTYyRUmdi3t8ktz7aCekskCsCsAzWFSQ0wkhPax5JIyBRkx+JIpyQTYDFQroABOEKWPDUijYJCjC5MMHgBxifgNAUarfCwRJtENGawJCf/m4pwFTgK2kla858gHAMEMmXTMIkRAvSYjImFkshUfq2AzorAJq4iBsm0TxRhkAVElRbS/B6OKLv1WL40zOADP8x2FDawrGhFzwVzYXM6lUvKDkLmLqg5YxeuL0FZVr+B0E0MlzJzLhDgLzrJRV5UEohPBzSK3IUWCQBLgCjkPBAxCXogAwiEEy6FMTLQotO+cdUAgjpJogr5suX7wrvStlJuUpevRLsvEe3LrJQNV9AWwrJNL9yvGq/xy5ssh3KwkLSkTW5n0itYpNe8M/Jm7I8DmGAQ7zA1PFsYYfuSEir+DGVoX+NGkFvC0aqABbCKGB89k1syScK6aWMLlWKM/wrWzCXLtNlbRdaYdXG9wt0Oeg1kNk6J53QCxZVAdW3tMwTirgvlPETAEIFsha4NbKGimNWbJf3alBohEMECFheqi+HCIfgpbdQuhgruck5y4b85a+tmUEAldalLKdmthKd7aOBKsDe0+Yx7fNwrHqeM92h+Lptmm4BXg/u6XiXUItSVaEjUqfGSuXZnt5K43HXUBvBnCzkLqi44GazbSIbBOqim7FAhxLArsDEhGTtng8kLHuu0IrWX8PEEVu4Q2wB7qlPS5mpXUTG5waucZwN4IyZoLOEgxuUd/joHpfiUhPoFEo+T2/sBwj0GPUmED76gyg5h9EJIh5dVig8Gj/91waLNGxG3NI1s43lMj6wLdSz+7vrtl2rjeEW7tawgpOWf0eQZ6rD3HzOERhiQjMxno+Bc3jP/go3SrKj9avv+rVHNck515r0qStYUiaTtJgL/3hcUNcN4Ysz7tR+2m/zW+FGwP4X6y5D7Y/G+aJlaq7qeLCdkyl/eonhmqhZYLbKqgOm8ruHWqfro6QG3CP76L6lKqjAACQ3yRtkmo2ZaazzahwEJap8iUGhIMOAccDf04w5uCXrATK4CrvJSL/Xsrs7+4Fc8cF1e4gHcb/si45quL1GkCbHUKjS4jlQC5LsuQZOEkNnKy/oU6JSW0NS+biXETyq+QPqYIo/KBBb/wmc8XAEVeDC+pIAFyeUo9ofGftAJzZArWs7LiHAKxksFU5A+VlANj8n6TlAP448OWNCw8HAqlKsH/8kEqdB/9g4qwHBKgCPVniI3amQciiYsyMRIjmFavgTBrCvGAMHAGsURYEOzxKELtCxuPMkSlUAhzKkYLgW2jKyiQPF71C/2/kwWO0Ulak8TfOz9SIrTyMQARPHcdgTCmGFEkkChjiFJIkAMW3AgPEURGQxJiqIjmgwVuE0VsgsZmEAaIRAO48Vc3MMVEnCErCucDDDkTBFddirNYvGmboHpmlAUCCYJV3CEIA4Eg2Wq5kJp9odehKTyhAQBYdF5AjLSMAYT/zvi5b5IAYGKCnVviu5wErzGCA0RHvAqvBINOtSRzmBJjfqoJt7iV3rvi/hlII5gAFWkEexFCSIh7rjBjFqnowSlEBvw3Mpm6rYtAccG3R7xHM8RR+BmajYwFsNHs3xi1/xmHosSWCxEEoXyFXxia5iFRDrB2/DOIKio68TBDLByqojiFvNtrJ7MIb9HkdLgWPRwLZbgHt3H2G7BINJSls5AEMfQfWqLGyJhRvJF4TbhKa/xwpAt0nTxrWZSBNlmc8yg5eCFSwiLJ81xgGwiLIJOsP6gvriSbcwlAegOMuRHINsnAh7AQoDnDupmsMJuCypoCIrAJImSOGiRNalAtv/+SmMys+qScDTsqw7ySSYA7nX0sCP/JRI+030+biOVoHh+k5e0Bh5+bRe9kutkiiCIhwtS8of68i5zQjpDEv8I88mcQh5SYvVy0jsFk4P8iIYUwmiYAYesASp4wzKTYBOhD7I6Ux8spIbkYoWeEv3McjYH5zXx8D0hqCIsM5AUCBdXLPk+bBYOhUy6wTyYZBZXqP2yYC5Fsgq1ZLO+yO9uDCiMkUw8xBPQcBDdBwwN4DqbsfmmMRqss9tKZCPIk9a4E/94sTfisjWHKS82DczCgCX2IIAsklPaR0fLA2Pky9JIgRGmz0JzUwpHaYqa1AkIMCukVCa7kUZzw0Y9yqT/zqIY9YvtsIpxPI9scEEr40Ar360KQBA7KKQwr0YTCrAObSzmomBSZqJOq3QCR3CkdPM7pGAsA+NPV4lHawo5CyDJeAP5NCMxq0AHsSPJ9vC8vu82bDNGrVRPuY9PIw1KFcsJAlUvPLWDCGdBFerPRoZPwtKIFi9NZgE7epMi+VAKPouf/INStUlGlzRSKTBTyxEKQPUufLX6zvJVc5UOcGM15LBS8xQFMVUUmWCF2kYWynOG7DFMyChfPPERHAofsFUSdcFTrGEBCKdKAJEzJrIBTw0eLCVdUqwaBVEP9MD8VghZbdVSl1VXX/IPFNBd/FCxqJQgM00eR20R5FES/4kCDorAAXg0p27rUq+USEZmkO5l9vaxahbR1/J19ijlVpvTXsFvsLAQJ7FSWlmFATCitShH8bBAFLyVUVQWMLFqDrwB0OSNdzZ2RNFVczhnXYy1NDfk4tA0Y5/NZukSMa7APIIQUp9gXu+uRQ/M5VyzkHp1RcJHgepnMwPB6g5IfkQz2yhmIgbV6U4PXe8iS10wgibozshuQ9IJC2JtUYOWG5W1U7RvGriuGUTUzayhJBotTj9W9TRBX3014LRw7Kw1ZSuitk4Esu7zWq5B38SViXCPWClzFiCSDuJy5ZhwKo6gj7LoR/STO6RPVeEWT6+UExynOEc04xxJVmsuO//6tgJlomwPKA9hNS6kwjsUY3ajQHDJ1WOH9jYXy+UOjdlqkRnQTxn3JAPDplY/6LNM1SlEKHqbcb4QccZObFidVHb5YndntGGnQjm4TMU45XjhUyiwNRM6Qlu58E5pLVKB130Jj+NyZl8RMluiNOUERyBWdYzyNhNM0s5SRR0RKhkYDdNIhNGStq3mz3bDTKJaZaYEYkiTAO3kESUF9iSr8mb7D36dsOWoC1bApxLo7QxK9mC4BJ4eawnUKCgNzxoIQOIIoCZpdoazd4HzLzAy5HV9kxxE4eIEgoSVEmzMSy/1rQPp9kYXY1PvroMlteW4AAJkBxJaSzNAq27u52D/UrgamKANJhMiYk5W94dEeo4xz3UO809xNg5GlVhpQ8UNgxc+X5FE7C7lno6C7eVq9yBfsjaD5W6D63aJ31Bu44gjUKglKwH2+qopziiL70ZWoTi2GiK2mC8Z7uHvDmD02vSMKRAy1bj7pHAxuxMXdOEkVCv0sLF/8eB89S0wE5cLM++PEySQga1ex3a5PKiJ2SWNXcFshsYWQSVfI8oWm3J5yeEam5X/LONS1th7mcUYMSXadMwaTC63qEn+cNiWBYq40DhsgA5YQm1lKpRfwJnz8FE8cdNV/IwZDYMYSs2yRIZkIsBkQI3OwjmecnmdsxmatpmTd9mb5QB0GgDh//AgVVW2nD0plL3tIZoXn6+OgDenwQDzSD7HoAUaFSxXAhv6Dw8CibtjljVXJJbWS3G5pPzZWYyhAACLNhcnFEIkpWdzkFare4rHL0lXS/FmGc9iV53wbCnIASyI5zLIrqIW717puDraOj5aAkFxvGR1pMESQXepny1nCa5kU6x1kNQzmE2UjDKTcUsolWt6aWviTz5jpyWVj2qsyFhlFrIa9IpJowWSo8FCh0dWN/7jrHuWoKDwLHqXYY3aTotUe9kOMywkr/OZg+sVcgONHmQ6JcRXooKrmLC1xwyORzqFHU5VDzqFVHeRr7smpZXsxHoMeyMN3BZUUm/ZEroUR/8p7HOXIckwNE7mhAqaQrP3wFAkAxtXBaOQxKEJUbFTOqcqzxvIWQAlqJ6V+kICliHVRR3ziQwSptuQ07NfGLRdLYEFNoFxs0d9KJkBW1mrckqQE2BMJCzIceOyLR26WxsM+yWf2519F7zjujXDgGaPJl8M+uJAJzVUWHJYFoqmBrojq6bh0rPPA7QtenRmmGVreK7B9Pu6WcInnMIr3MJRg75vWrzN6+mw7H1OBGjRCEwN+y8FHKPBy6gyHA/BdnMHSKUxeRFevL+rAYEONbMHYDINVYrQaCD2gLp7kK93MCzIYYM4JWvL+Gv8gL2bV23yC8PX4Y3BIsq9d64Fgrz/9+bDhVcx/XPJ5W6hc/zEr3mfi1q15/qSF69iLiK1uiiQVnqyWdmV0yaSscU3eBzzyOTA4dMTNqUn7iFxM/n5UDuZnZxoM+Ow47fKsYBUPRyM2iE8edxQMm+hnWIJDl3MH2l1ObkOXO1++7Z7N3lLUZxTk5kUIXtEVOEXkSFhG0wuyIRJIkLGXlhBJyoTnVCf57uWJ0SrWVt7Px12Q/3So+AETqDQf5sTs81f+tjK6vHYf5PqSHK7XtpHbcp+U7uBUzzXJ7fMj3BWQwAEMgEEQiAKRMAETEAE7MDCRd3Y5+DijtiL5MDipOqS7LLb7NtBwvU/N7pj+0nF/5qofJ0s/zOLX5N4SpW0yZ1gBCR8BKCgBEiABEpAcrfiyXHzh3zlAK0sOEEzjfAq6p6TG3RO2iWGir/71m+536cwUgHeeaR64DWcK9h0lW4hBChc3JsABSYgBVJgAlBAbOtj4qtc+rgQ1etzDkj11S+ijlph1lMh3+V637E9vPlwdy2nacJcc1tevmcC5tnpFr59wkEA4RceAEZA7NVd4ov9lKzemqP+d7P9nyhbKEZEtwkAsqU11bug7gmPplLxGQeiWRFF6bQV8BnWLSu8CRRgAs4dAERgAhRgVn0e7esA66W61lqiyZAoSqoZtLGVVHebmfUd6k333zUGI9BOIEj8uIvpIv/r52IJ2NNYkmdccoGIm8qAivYJv7YpvAkevgka/vFH5ee/t84iAe3opVsYwhE4ffNJvwyAFF9xFdfZ/u1ddi9Pv+p/2O7x0kTyhsa5I6Ngb6HxG6pNpHFwPwm8XsLBHgkQX/GRgPEdn9+qJfKxmeK+xjzkJonsX3yABSmBYDEAAAKIAgEwGBKbzifUGYhSq9YrNvucFrXeLzjMBRMKAGQ4neYipg0DJPEAPCLFBoCQICLr6v9Wk0FSxIPfUwMDRBMX0sKCkhnakh+EAUACE52dJdVYV1NIwCjpaEgTSQlUCQlj1dgnWCwgbS3UbBmR3CYEAwICg4MQwAEkwWXTA+T/QkEbwBvEw17vWdKS7aytthhR9vY3t5Ph07hTLhq406MaG6mZg0GAgQNAREDBW8AAUkPBKHK6K2PiBUiAoN8/JwdGMWjQiACBf5KsDUAQz8AlBwlGLbBYEGAgV05GlBo1oomCCSKgiDChoNsrkWsC0pQFJRcAePLoLeAIYFixPCAdMCjYzN2zjQEOVFOiCZC3mlK5RJVqFaaTOHkC0EuwyNzEq+zETiXb5MCecFidhAAxCsQpVCVLgug2t5RMtWbJVv3mzGzfvbWoCgaMKECDBwwGOER4L89EiwcWBmCgkKHDUUOWJChQ4MBiMwAGXStYMCdBSJ4KgwusrU3lJHpd/wekHcU2a6hk//LNXXutb5qzvGaKoJVIIoiSDgwa/bVJoudEIioxeMZOIgRaSydhUGZO0NXBB4/38gn3N/RSygtn/9s9eVDwt816MKBhgAVzBpBSfiaAHcRsNAcRvDVgzyhO8SGbfp8p+FBz4d0230wUigfcXurlZaFuVFgEjoRWacghKCOSuN4TvUDiDwRtIACAd+fE8ZQRyClCBHM5TXFNU3kw0NCDC2ZCh2oTnpiFiYKddxeTTTr55B+fUPbYNjlmWMWH34RY1pFfENblWIctwh8e/vzoHz8GDKCUaDgypFM8CvaICYGlLRiRPEXeAqZAfMrn555nXQKMdIBu6P9EllXqyaWhMf3ZaJ8U+pKFfo5CeiiJSbInZUZc0aEZMZj1lB9qPpm2RxmwyeNYEqMGGJ8TDSh1CWiPMTdKAUXZwZ88CBxT1Bw6kSqWpvN9eWmk8B3QJhWUWXchssX2hixwUw5xzEHB3AhAL78EUwB4kATQnX9JLWEGAb4glh4UawJgUXJnDMCcr8G0gQcfA2DrwBTgErNoTdK6dyy10BYcKLUCX6VwbpzSGSopC50l2mcRinsnxUOMmuB9amozyzAWqarPsu8iY8St+uA0hcXTHowVw8a+bDCkMQd8sMOEWoJvdER0C4xGQygDChLnMHGIOSB1KA4nBjhED45mZGn/hAFMRaCvaFMMOTSxM8PsNcJgY1iznzYrqRAy3T5ACgKUNTSqMf9cXE0ZeI7imNOkPLV0Ex4lQGtRS5U8NQK8qrnyVgUB3J7XBIsdC044S86n2Vd+U2l5lWcOtuOcP0HQvKMkcOAQwOB7pOYud5l617Y4++LmYmMa7diNP5GLQ4tkcgwdBK4+OZisLyz77C8Lb9ijnoP1LhcDQFL1pMED/3vB6qGDOvG105687ebskTsmmzHALPbVlz09FVU7cf2Jx7Pmfuvwnx1rPKEXhAf4lKPf/v5U4MR+suZHPPmJSHvG8wI8AEXAdCwwTAkThyYSUQ3QFWAjk4LbT4awrFG1/8lusmHcAJXXwNZRam/le6D+zNcECETgDQdgId0yVo8B/CwYQDGDN/bBKNmN8D09LGD2foiN86nQRgfYh31iuCCnlOwMxdAgDp+gEVzt8HEizB73ZiZEWFEPhU1IQEMiEAy6pWUSNPQF0IbGjDuoAxI6vFkQrxjHOXqxi9tLBicsU4187IMiP/EJUYxSDyolzgDkaw0Wt0gfA/ZPi420kCL5ZkU6HjCLlQxhEe14qUgyMJFyxCQo76hJskEhUbWIHPJCOTlOIpKSmyRiHfumNECgUnWTdKQlH1m8iVGIlRWSXiZlWQs01HJ5nXSlCn25yCek7GLraNYhx6NMm6Swjv+ySsgUDdA2guQKQKWax1n6YwBgKeEfHtFHEwwHu1/y8JPtNAc6EbCHwDQRPtP0EixF6a4PFWAzEaBXuhxwr10grSn7+kQ/i5mvKHmye/fkIh3It6OKyKMgG3Eac4oCCbdd5n6/CoDv2BVM/mUyZJcgyD0GdzKLJIF3TSBm1ogBulqmzITmaSguH0qLWDzTFUtoAwESwRQ4MKcBbYBHocC3O23y6z2xJGkdK3GJIUXNZN2Q5xwKWoBFIE59V9PD56xmUy3oVJLJxCkRHiBRp/xFm05s4iDQAtK+NW8BiDvmUzM1Pb9lRCkLUOlV4QQ1IvAKcYZjTP3S+Y+xIgmtq3T/bERKN0+2csGtnykZv05Xo2cEQHdYYyRDR6pX0eJSlWdFZq1INdG2vuiyesMEFcPp0ZjiVZQntK3yTIvCsoZWt4biLWiB6dtLVhK47Lwlbkeb19K+M6eO/ePifqtLmZFWKlaqYm6L61iinC4L6uvldO05PYW+Epm7hWw0sUDehoV3YNMDnWCv9i4g8QE08yrKO1LTVjTZd23o5Ghvm6tdVxJEYqNRztrWNIpFIAF0zRlGZzvrj3ENr7rgzSROCBoB3pWDD9jxjrz8VYz9nsMO2EoEUiGa3ce6Mhckbo4OdVg00Tx4COjUYboqvFxIjpfGLT0paNbZlJENwGIkDsuU/8Yl15DqBbksVqWLK1uua5yjXDUGxcaEZ1xLjbJRnwDrw/xwH/Kh4WlfFNoCHIIAoqApCTu7hZCpOVxSblnO0zGDmtmMEypPBMwJOICsbJzWV+k4uRyqs5GQUz/BcrZQ6EjtAfBkgGXII0Zh+dQo5BlbBwr4yZ3GSU/GOeVrTYSPzhL0MyY8y9qWV7iGhkICwbClVHb6tHO2cDW7LN0ShmHWtlyxrWvdvR1fmNi4NvauEX1T8+7a1a0GlFsD6ORgT3vYry72tanQ0yu4CBzRtoKyyerOajP32bc1N7i9wKOAfJvL5C5vuBvLbAXm89kehBgDOLiENw5Cb6qiDqNPBf/PUSShgpV50cbinGhhby/eWHC4tEnpbIk7YR89w8oSsgPmrchJa1m1A4VB/AQZD+Grk2o3zazt6Xe399xQFeUU78EbUFxDCEI4ECk6fmChEO2DMQ/LEuCq8LCx3MvBzTaydc3jkroRH9tiI5Ux0oAcNXUABPL4JnrehHXImCI7A8bQQ3LrZD9X5RR3udGbIGkzuA3n/WTCpE1WUR2NawoBX+J0JNKUa/hjnGFH0djpnctjI13p2Ea32RPf8LKX++wvR3zjFQ9vxhMX8ktPuuVbnkKIp3ve9X48xdeLpVVLk/J0Nj3h0X7oHofBlIjarAAZPnnPpx70yhWl6D1E+nT/7g2ArQw8ETnvbmCnfeLFFwo51VmEjXxvVn/0JiP+7aa7KYUpiu3VR5k8fMmfnvaYt/3qMcxUhNqYXPvU5roCse4lSoNbenxCQscvbu8LXvgpj3yzDZ9rxNW05yZVAgN4jE/1XqswAezV1F09HOqRHf1lXq6pnuDdGUx4Far1QdOoHUjsCJNtFR1Mw/uNhlglYMRxX9rZ38IVnfGFXx0Z1mL1HF9lBjq5Ar9QGGFR3yhYXw3Kw2cN3i7VHjCZINERX/5B4OeR4Pf94AIWHhFS1xEOoRDOHvA53vEtYQpW3hN2XxROoRSqYOH9VbswVk4Uxd9VATWYlRHWXxI6YBUe/94WPoEXjpxN5Yh8pUESmSH+QaHsad7tUaH+EcEbVhyqQYHvaYF1mAgQit2AZaETauEehl5/QIzgSM1EcZDafcamCUsZUFH2bd2m4VMDbl4atmERciHiWdyN/NXgTNSjVNn6MFlyHBTgNdkVlmAoMuIikiLF/dxfoKIkBsnysE9z5OC4iKAh1iL1HGIsomAfuhfTRYKZ/VknSExpdBcrvhSBdJulAUf6yeIZBp8xRqASxs4K6h2v/Nk1bYSC2EMHXRoRYKKZZOOfqONxzSIDKiI4qiEzNuE90iMafqIt7mMj/qMe3iIeKiM+8uGmDCRA3iEW5qEP4mJAEqRCjmJB8v/jQYLf5YWjuoHhr3UjKPqjRD4gRubTNS3FaFgQPfjXEHzGYvhbf6hkYSBjD9ajQ+ojG0YkOLYfNXjMAmyYNqFYARAadURdtgxWRzIkLYLkQi7lTebfMBQBSxGDJfZHmSGIKibZBx2lFZ6XUlKkVzKhKOmkZTRHIbzZElGdBnKL07BXV46WTB7dReJkU4JjSQ6V6LyIfxkBGnhEnMwgAeTlGDpVTfajPX7lGoJl5gWjKD5k+bwlD2okREYmUyqmQDImSTkmZk7k+2jmYdqkW36jYS5jQlqmSHokErZlZ4qmOEImU5Jm+GUmauajasqla87mMYJmaYakeNUmQi4mTRr/pG/apm9wHmwW5mfGZm/S5m56ZmrG5W0i50jmZkY6Z2sy59IV52AmZ3AQJ2425+YpAHiGp3iOJ3mWp3meJ3qmp3qCZwCsp3u+J3zG53i2p3zWp32uJ33ep37GZ37up3/eZ3/+p4D+Z4AOqIHaZ4EeqIKiZ+eYpm4KJ1tap3ZWJ2FmZ3BOaISyZmhS52V2J4QiZnR6Z2VKKHVhJ3Aqp2xyqHRy5nV6KIaCKIq+qIg+qDeG6PYBgq/FJIcM4glaQe5h13DKyfxJBWVqpXcF5h/84TxyJR1qAq9wpJ1F6X/cYK9F1/yoSnrtBY8iDEEYxHVJYIaOxmtdyfopIAam1VEg/+kVFCkJCUreWQHKbYOS6sV39dMasA0U1KGmjdEQPWYUJBa3mKQt8EgxVpzTNMAC0ANu5OiVjgswmNCWpkOkAp7HJAChVWKQOoHHHIP2lUWZzgki8o67aAObFhqOIAN1VEGcUsGnWsGc2lmdQulthB2gtl/79amJPGUELM4CEASCaJDoNED2/ZvABZKnSNt9DJa+mdPynYawUBr0+aFPKFhnOYFgbWI2jWE7FJwyQNGUGOtgcVStmAGILQurOFFLEhyodt5obEYC5AIH5cKalKQm7FdGDUuAtSuOqAsRxBU36cpPVN/zvUobMF8DZGsXXINKTsnCHUMc4MsUcJSrYP+axowCoRkASsqX6cAR2rwptS5Cwp1rhMWBZvTHa30sJB4AuMKq9fUTvbIKvUoBqEDBUw5JqsZHYHgEPjhIBvXrmPqhGcwrWiiVvsgfoZIL5sibOIiOosJf+cHId/zLvaQIGgVDjDGLhsGinQ7ApYYEUAHDE0llUyStIHxFvLzdikAAjllGUFYcOyZLpdoVEkRPGegQWpSSlBXVUUmSAEaEvWpTQN1LTxKDunQX89CDmmwtyDnFiX1LVsZiughqF8BBgaRf42YWFPCkT/YOdlnJUAbt3L6INq1tEWhQWggpx11tz/wV2Xpiv7bsvJzu2t5tsyDGhDEI3F0L7HVIYDj/j6aNjh8ywZBAwDYChTGgH2HJLUwQ6oI4gD9EAJJGRQQsrkyBCoQkQVB0jCY00Wfwmab+WFchhaOoyjJAUVM4L4Cs05IRGdBYRpadL5usq6V0qbB+RgeNAj0gakF8kL36GN8yQbfkrdSsVMjsSADWKxcIAUpFUdCVQt1AS7rwB9RE7IAAoJpgpfZ+r9hCj5rmq0z5jCqWgdC9Lxfo77teA85xDKntoso+bwfnxXdlggkTQJbN8G08bs+GD8fhapIejRkQ7+kYr1AQrWFdHd45kZluHRO07bpQYM9tTZG4lPt5iwN47xd9HOJQVaQAVTIsgyRIB89KAb8YZQUJDaGh/wHXvS27CiBkpAvs6IElrJPzQIcRsBlmbeNxbaqa5Jl3ABZUDsOo8lzlPgMcaHHC0tBa8kGh5IWoutV5vDEcJPKZCgIh7Mf4AJG1VmsE7AGffZ0vFFQsOI/VfXDVkdoz4mAYD2k97AG/PIfzFFTynsVG0Zc6HM0e3CrOqgFBXEJd1vK/8Jyz1C9M+OVD+NezsOup3uUg9VMLPgSeJECa/ezzuRGpWetFOADixJyVggIXt2NRdEY5gZQy6wIVQVqovAjeGJTeTapMsDG84oq8ZgJDZGWo9bE05/GY1jMB+LERjIp3wCACU5E2HzKmGQGvNCwySINDwNY9AHRBz2AM+v9sQaBztQKp4dCD9/adL6QzFxBvbMzgrcSJ95bjARjzCwOHppGKR/+zqq20zwns5yTEnuJwmJioRdroH9TTTmnDU2KJzSxQrAEpUv7mTY/oh2qBTtthGPS0h/x0YTA1CFnoaRrnjE4nTl+1Uavoaz5XT2yzB3/hjfaoGriekUbBq44Gkv7o/X1Dq37MMNG0KouUNrBzWR/paJood9lCt83kT+0uXPopFpB1m1IKDmqqkG0bmHIjLWxbW/cpIFzPXjfWdy1TFSC2FdD1YKfBquooYE+hWtsG815BY39ZlgqMYJsqFpz1ZhuTYlMBZu+ZrB6x0kJGGGC2WDu2Ldg2Jv//wWpbjokSBA0D0jVToi4MFgwZgckyn7UGThUL2rM26x6ATqKNrMBemcCVJEgsgMDC5LPGrJxNWNAqxSJMSWEn3Hfog40pdzx7NzJDzOjcEMP6DKElQHODDspiEHznnCrD1zWnYqmMi8FNyo6I9/Ptbr/s8ziRCoBJKbj2dTwkwEVNXYKvSFDdbqY+wwfaRy+zpPOwzcpuZmcPYS7UkEZ83KPYhxsnkSoWAblsne/YiYiJC7msFywIjQfuHISZ3x6Y0uCCxuXGOO0eV3Ko7inioBuj9TH4Ucgph92ebhI3WvjcEKhK0K5K0BLsGeiSuJTrNmnrwsf5t78slHztCOge/3m7HbjecgXlcpofvjhFBRUDDBUEpLnzEgDpZih9uwt9i+V1+IjoIkDrcraJ5gL3MsePPQoL/ZU0NG1oXw/6Qq+dtIwzl7ZIPCXVFKD/lU52l85SOLDF2LCc8cq48BkL8xKSi4ad0A3+PkNPvOuT/4XzbPnjegUzHMCu7CCfFbqsuy5t79wx+LdimhFBizCNCRma+9iSzeOjFw5F9WtrTYaPOQJeZKh99BNo5LBeYm+xLztbDvoPV22JZx0eJ0J061Faah38HZGgQXHPbRzCcAGfm+OQFPMFKnF1mKUOc40SeLWRYKOdm7Kn/NkKOQ3YwXa7e8W3zXEAEa0afTE5KP/CfWyGvqRFJ4N7w5/BIiOzn31cNPaL7wh7CG8VwUcPTCDBHWvWSRtQ9zY7Wr/VO9juX3YtZ/sMAzwAUdgBn6OBJ69TKvs2ekkrqTCaPJ5Z1nUBMR+xSduJpM1NmkQ04JWwwJ6aCz54ds9zQfuK3Li0Wrzjv9M2Sa9PpfkKqlegf6wJr4hcewdzIIHzQa+QZZhZxtWP92LQ2gdtgqgyHwnWOdodcIO8gpxDZZB8F5j8a8WvLCY9y1vWZLwWP6jahXNWVwzBhsuGRiOASXe7i5JFoI+gLUC1WXcqr8toilrF1EZBUit1Fpz+6DOpVBfG60gpTzPW66M+jNJoLUg3NFH/dhqo/mg6F3TGKFZvJ4uKPvGXaObHaKlqwWnDSiCl/FGetVV7gVqHKWsw6lcv3u+HX2RnLlxnwfLvNBHMYWRC/1yqV5tsf+mNh/WzObUVtRpMv1yvafcH9u6Bv/wupxsW9svBP/wDAUA4JBaNR6QxkGQ2ncbD4jkdLqlXbBZptWq932xX6GAEAo7FAHAoAAyJAMNxMJSlDkPA4AAEIHozNTCsrqUBOD+itzi+BTOpATMDBIKCh4AGRIPBJKsDs4KCA4aBz4CEBjrQsggiPDMCAwKANITT0wYtsTWzgIOGAli3PIbgM9pHzjDFwNe9oczASoDDBkNECOWvXYDogAFn/wfbvAQ4g9S8gAJWaknKuoAHgNcAKceAVk5ubf4rrn6Ag3YtkCckzZo2BtQsiECngS0HCeQ9aPUNwLSATQpRazOgzRCFtCJAYIAAgZwhBQbEmnUIAIJNGbsUmFWglbVsCUpNIiDHVi4hlkDOqnUs5DJoDLItOODxIgM3agrYe0DSJMqMnYhglAiA4pADCYZUctqH49msT7i5FNKVoi0CDRgccAOBDiWfmFKunORgidAoP/ntS1vY7GHDiY/schAsAoKDbNzMYiN5sqyLm6xgVFzF8wA1nCcjtCxK1TeMB2FmnVlzli0hA5i2Wd0HwVDcRQ0KIkQENq0ovZZgZkptdv9Qup2FiMGIORY0RwkIEDDDxyzoix+VF+F2UIjzSVYmATBNO2YABKdXfhxOGRKDowK3G/43vzNhUQ/sJZwV4YFkvzKZqCIhCBBrvo2wEw0z/6w6CQ+6IlhPiK8giCmg1sibBScAdJKsNvRSKqjDX3SCrQEDskFKCGv4SOCAr3KjSzYHsVKOuQPdyocI2Qy08DZDQtPOPsSGYKvDAX8br7yXzoMpwgnN0skrKQq8EAzCiNRnOS0T2+WSUxAg45SEzEggvV7UCOcwFC268TMhmQkTmXra0SNKmE65sp8MaRLCFFQ+dHIIeggAdABbQPFil0hO+cWYTYib0Z5kECSiTXD/8nhGiD/imK6jM4PMrssiWUQkUz3EEe82JkFEoFGFMFqCulMWsCYQZbIkdVEud2XtCsz+HNJX7ojFUrHftjFW2WX5bNbZZ5nVNVp/gJ1FWGp7zVYtZKd1wttttQ1Xl3GZLZfbUs+dAlx1i213MXXZ3Vbed9OtV6t7txA3X3z5ZUKMKZ/AzrAFqux3XHqpTbjdXeQaACp/7eW3voj1rdhihJIomEfetNi4CbmswxjhiheO14g09kiUEd9CzNbkl/e92LOZlRhipG9j6zitB0aE91yYlw2a5CIckBDRAGoyOAvRFBv6WYprplnqqRnIBYIdO3QAtHtUwkYRotTwww9N/6gRGw6xvIkJggNHDvdpX+GOOQm4OhT7D+qo+foel91oRlORZZI6aqrlVphFiOUCIAJbocLOCqfK+i7sPtRwabXHZ2GAgMtjqs3teUummghdVyalci4jp6kkN24r8CMdCzOcWMIHH51mxduCYAFRWnlc51FzE3u3Js0+jCbVPN/T3XJn19L5ZktP+qIzEhTSsvFenzwz2W2X+GKTp/HzcCGsplCphy0XOxcFh3wxk+G9asVC462gqcK12/5Zi6a7T2Lg+6yIH8VxAk36lysm1O0PfoFTdiz0ENYVKEcD8t/MalezL/nMKxoU37Wi1QWcAYAk3TgGdiKgjvYR4VCHyf+TATbxOw21MCY9+xdIerG0JBzwV3I6EwCVYQvX7Y8KYjCFm5BggOQcgSl0aIIBh6UN6aUJMaISXxwi2I08oGpTO7SgzDBYBLZRz0UqGksbxvdBsDwxIGFxAhtDVsPvJLEIPtReABWhhgQcbTsLI+ISFugFAjbxU4ILiGC6BD1SXbCLl8LEA0hhDWAoqoNPMgXEdgWwnfEjUZujmxk4+bF+IREsZSjAygjQtViUQR4R0YOYynCMLd1Rb4/DVaFGoQ5exEGFnrSG2RIgCl4ugZXZg+OfuAABMKnvlzTxBl2KeIBpVPJWFnEiGXLhHfn0Ix2ZtNQXvye6IiSAbQMYSdv/5DJIUWAmRUIDp9/MQJKagCY0EYyFmP5iOcZpMJsgwWMaeJM3oXSDkypZ56WU8pkzyYWM96RG1kb2CRH6YhIhOwSrCPAAsZBEocCpxEa38hd0/kIvsbwdIg/pxUUS4QEPswZB7JS0KuYjLPGgXTtF+RLhyDNjdRxOLwrQGHwE8Vg8bABoGnBCM4wGp2ma6YiSdR01PLWnitLILs1wgCImbWDIEwR6rMCUSiTrqL3QUDR1gkNzzUcnfQOISZ+HUvAZgSRSCAYEgAiAzYlvnKQT6lsj1oWbtshI8uiJ62RlNyOIAoGy1BkTGRhQwXLHdR6FqkAXith17XIIDzSSIO6X/1GrHeNFHT3oGjbx2EHKhZOLnY9C1QhF77k1bkbgUCRyEQwG5NWMcVEIIl7bTX8BNom39IVfkoZK9swDEQQxU195xViztVCY6TDUK2eKS7AE03i5DK1yK1VMXqi0F6/ybFwQMSMzQbMNlXQGSDGC0cEQCZn/SYts7aPIuN7um0A72V+X1ZD4FuE068DHPAA3jlOYAx2rKDAnLUOf2Op3v8FtJ9EoTKyTAIW1YOFJXgQkP7jIhS4puktPVFVUKYjTaRHWr30TWeG3wdh7KjTPcmAyi3quijxYrbFtbEG/FXvTxSel8RTomIVAttULwdop8IJMhSS/iQrRkOMTHqwFYv8yTxkwfLGAe4weHSmJVTwunm3Ic7on53fIfk2jkbl5hSgH+KVo5bBSm7xdL2EhzlRgIrkUUWUe/ZYJV85ClknHhJu6ecJ59nKZ0RMOMe9YUDaOqIYhLGQJ74LQ/3szlAEN23mU8NNFYPKVj8zFKeyZ0YrOwqaB5Vy4aoHLRFaMbKS8yDUTSdPwgIQ7vKHTqaw0KX3AFWh++cxfB9gvcqwkBCyRtITAQQ50sIPZIjm9ezh0n8YA1Ttz6QsioLIXNRlFJPC2XlLO45WB03JZ4eHUXjSzD3/4BDkUTO06AaoBtJqeKEjBN1gXSUIvsRpNxnQG4oit2MNzsKBRbRgmr1r/zZkW8DkgspcjgUYlIowAig6AtbFcAwEbXaL+QE0NTf2itCwZVUgY4hCIyLMNhR0ptJLCuY4UgORJLOwczZgPi5A2ni6tKhEM2BcxYAe+I7RIiOdSF5hXLye8cYpNnnIbQ0+NewOQB/JGlPCQ1884HSLjrUeX6yCjHbjYmox6sBmJcwi0KZYYwFiTip3fMKUB0fEgSY1Uki5gZBqYqcxHZME14VADPp3280s5J6S8D1c7rMTl+DZTypwC9TEHK2tyO0uLrv4m0kxyA0SNQ/nd7jTr+5LFMwzumBuD3u6iWsKPl5fmwrG4pI0OkCiP1jauPwB2VovAtE8rKsG+yEh0/37uATqueI8Knj+L+08bAgSaGG3l9sy66+bal3yeR3BjVb/W5SNr9FGXyoniUjpoWahjJgUoEWeFROofeJKAM+qXQfGgKN7noeMTuzNjvPqiOExrMQGTIlipu1MxoTaoEKiQru1qlBfplNVaLMojPE9yNu1JhzMpIvW5tnOQIjnDLe+LEwqUI3HTg9Q7jGiyLjA5E85bvyLBDnmzgtHDKinSN1oxgBYMhjrIvyKwheS4n+Y6FAmEoT+wNLPLvQPcPQT0L/6SwqywNV0zQFzDwrOTsbm5sKyIuD3SQnBSuzCMwnA5I5s5AlejtYnJrHchwyaUQji0Iyg8w75rtzYLO/82zBd2mcOhsiojGgJQirEn3EIz/IJT4wc0xEO2o4JE3DA+dMMhuiQo8CNYagIdirWHk0Mx9J5fwzcp4MF3MyUF/JpkMrBUURICOLjGIICBy7Cp0TdQpI5NuKU2+LVeYBtcObk2LKNLuLZZmK5UoROaGLeuAcZkq6DsWo7dSYbHQRt3kg0z2JGuWZPswoVUoilbrJZCdEIoZKM/sTips5t6YiAfyhvVqaeQCTPxOKUROboNOjQSmrqoE4dzGChj+zxwtLletJKWmDmoWAId6blAOwyn6Il9vDTN+oOHuYqtERvNGSRDksfYYZH54wt7OifyIEB5zMJDdMK9OwVDMTz/0+uR5LJBpKIiYBo38FBFzUMAP0GiK3q/2DiOyYCJlfmGt1ODkJQOOevH4OGbJWiPzHgw1DsMoezJO8SQSryq0miK+KHBh4mPwwCPIfgNk7SxnJrEbpyxK+igLqxJAMGEizwsrjOtUDOeSuCsthgQa3Cl/mODligGd+EQD7E+TICJ88s4n7FCSLyCKJitMqKQrBHIASHI8WsDvci+5VPIZeSUkngQGDIg/XmOKsiFipxHcmSP8+NKj6xDCtEgGtqKFlSMQSw6CzSUHTSTfUsu41KFPFDLBxyvNXGEOrio5vITDulIWZSi1SCuEmmGd/KkpUwrd6qHRIMC5ivDOhJB/7OoTVDowTY4IZ2DlNR0TGMKN2eMSt76BhIUAuq0RmPCxuQCTs+cuI8MI+oYoyIAS4B4xPPMw2bBgzR0AstksziagsAEnU30JtAcQzGEJEeqO0zgtlGhCUryJLABPVtAGw1jxXFTwLv5hnWrzyJ7FmzSuiTIoi4DiSQ6OlVCxXpIRmIMh7IAw+f6T68E0I8kO50op5sTHzqYhYJa0KLgg/ggOjyjnvpZCH3S0HvxQwE6zkqYDqQjD3mIgoSkGR2RCwQIo7/0T0P8zCkdgpUKLZdqFJgyowJbAzjwmYTLO954SZQkKxh6SQuNRCt1uD1MNBokyihQSnm0SoJQrChNqf8ugc8URU8VnSvy8IPuQ6e9qoIg+j+kwaKyQ46zdCzaKwI77ch+hEXy8dCUGCQpUQP9aMzLRBL5eQrzudMv6DNKbILTfE+OHFJObNHa0gsTRCfeOgSqGk8T8SnxCpPX1JRG9YrmStMgHazQ+bNKPSxaSYAFuM6bUQdr7Ape9MYr0NNmPdXe6EopTYynUkY1XRwVyTZis4gFSAekUoNtJKTtmMl96oYGdId58wNjoIxeUC9rAr1hooRns1bTqjajOpV2bcdK+MV1HTYrNTZv20ZYTYT4TFUVLYxqLUAqTAA+mMgCWQLe0ZtUQAV8FNfOWMM9PZK9QJ2DtJqDAiszUjn/YMAnlqPXepQn4IsqfcWMjiUChnWJl805jVQJ1eFGKmVWnO3VtrCOqay7lAS9NZCCHPtOfrxWoA1HXPkq4Yi8aOqd46QJNvU7tjs82aA6lZ2c1Ei8f1WJUZDNnNSpTBQiFj1YZQhbJNhPqdVZbNU+RgXawIyFzmRKjYFWLPiccj0S34uf7AO/aZALnwyY4DFZvCyqfIwNeXhLMrBUxtwsBngAMvAdIdnLOCnYCxNS7OQHs1XD5YxWLzzLaUIUXHVboa1F67JYlKHbK7DbPzTXQFhANoEUO0Gi1IgJyluAzE1bELS2UzGuU9ID3WIR2IUG0VKfUQHOFKLcXrRcetWG/9sVsM212Uj9VDSa24ywW2flzyVL1A6VTy/k0yrVGGf8mnC1khCFlXcIUXp4XuRlGJWK2iu0KlRYgPOik1Y4RX870erCJbW5SmP8rqIDg66JHihwX0K82RVtFN6oka2R2Yq1EnsyOox8rCRVX0kEygLWzLNqhVEwJHWUA6tzUgOZ2Xy0XjVQYHQh2/wy4GlVw48Qhfb52sE0C/U4LMKj4BO24C8gg4DbMKwsmKvt2awq0t0oijRJHo7ZqUcFr5wFiNWTuLH93iNQ4O+7xBgeDig5rCnJVFDtry3Ttp+0y6rVm7FIkbjjPys5h/PDHx6RBxPOmRZl4h1e3uTtRCXazv/iLV2eit0omRUzsWE37t5BgKSH07d72JzP1VUzgEkPMoAqAc48SYAr4d17sGHlVdi0aOLLrVw6xtNrvd9JRkWVAYRy0AOgUDHTVVsozkZ5MF8EG2U07leAe18V5uQVVVurU2B2jIunKyhVS9t6qeRNLEcxUAmnGzEI6Niew2Q5VlNgPuUV/uVKReIZzYwcNIj0K1ejzdnDUo8cFErsiWNL9l6czUTR6OVR9UI/weUkgb/kMGW5xQ1BSgK0bZ1wLiCiqJNfJU0uydsczL77I1c6FOcVJechMeft7eRr+WRIY2cSYsKftLMkOKO7+pOlUWZsNgZwc9RVlF5tmOi/NEv/SThUehYF5wRCgMY9g/1egg63az5oVB4EcqpnFE2s4qRoRQDn1R0ANF4Aduu85tlkZhZDVfYunlivdg3LbM7hk17WRZADYDQ6aQMSEaWURH7qWzA5AXqYwLHfWBAGU/mbYbxqdauOQhHGUJ4cVowK7E1hgZ5WYd7IhiKtpWjpPXzpfP6OhZAQgITgxRkewLBd1pmElp2eC2w8CjETB+jgVpwGBD6S2CFsdxQRz2DHydFRtRbbWtbkj6Rhnwqrr6Jr/ExqpCa8qdBaM/6dGv5moTyemq5gIoiAhhCOIm0abLJK+1lF2GMyoswxtIa9/4Vizf5PLP4nnRMt0JZlHB7t//7oGS/2k9/J4mK1uJJgzNteXe+wCbb0aR5pm8c2Y+QIKClxy0e7QMWiSkhd4jnebNdcLsZOL6S269FuLueM5t8ZVrry3ZGD3epOq9OQQTBBDxqEht0FHNaOQTGhLrNuBN/FzTkxbyB95vRGYS58Qy5OblqG8KB+4wun8CkE5Mze8AyXcCq08On1cAyf8BAHbhCv8AvmMwq+3tWdgoRF2O1T4g9PcfRma9GeVMB8cdQ1bBlXO9W94RzX2WZ+ZxVn3w7vcYH5cVR1ghlPiyH/4yQ3cqBGcRa/69FIg6FO3zVIN2PTDlr6hndNg3hN14epDvB6aheKA2NQFQc133TdV//vbKVPVNBt3F/OrXJoXrQd13H45vEtj+C/mGARrqgjftgdg6SNi2lu/VELbdmQmApaeICLi4+NC7qI49q2KahDF4sp/+0i7/MjVzINV/KfttE9Ho3AyCk6MqqfDQtbSwdcsgI0PZjVlhTjEFP1cMGPUA+lbKqvNeI9H3UOL/WivfEsR2pDHW4qkdw52om0VK1ZAFz1u2YxYExdl40TIWMo8fX8HLiarAK/EBk1LnZlJ/UrH/E/h5oEPIVVt+8vv6pXB11AoJADqd3DMPA1h91tX4CV6YiQBnc9Tk3fmndfeOQa57x0P/Z1N3EOT/X5ALAtZveGV3Jkf+iLb3EtRxb/jo7xjQ90HA/5Pof4EidxLLf44OZzk192QS8CKut4mo6WemP4E1f3U095ibewI5Cc9575ZylsXr15h895lY94njcCGK9roBdgGyd6jH94lF/yFgcU4xKDYzwv/N1GOq8kXhQ2xCGPqEZkqRj7lFAUht2sCOA3ciOFUyQUwLmHTsv4ZU1pY5/6nb9gMD7HCFo6j6UEio0nlqvRDcMajwO5jZMQxU78TDqnlSossD8Lq1PsIejup19xnBfxlqf6u+5hH3ow70CPNCBiafj1L+VFEfMIYXPuUpBt1ueRccMapsAoBzhKPwli3HiOaaH7ii96zcf7pL/rve8YgvT7zEDj/0tsGrYyzgQgPpRg/ex+fSEIVL91A6hITA0RoTJ2WQrafanvL973ZczPey3XNzrK+qv6jka2Lq6IVWyGwNPG1PGS/qCwomrH1FaQzuxH5L4BAochYHAAAoCkcnlkOp/QqHRKpSKr2KxWe71uv+Dw0isum6fks/qbXrvH7zi2La9X6fY8FK/Pd/uAUXyBeoOEZoaHVop1iYxujo9qkZJsSZSVYpiZYJuce59ZnqFMo6Ckl6hypqpwTa2QsLGyXLRPrKi4pa26tq++tb/AncOaxWjHwsm7a71vzrTQpH/LwdVz107SfduSZAcGDAELAA4JRAgN5wEHAAbnDEZIB+IFn//dqviZ1NmL/f7/lPnSp+ibgQYIAjgoMADAgAgPEgCAwMBdwwURjjRgQAAAQ04EQ4V8xC/gKZMn/418hvKbPXcEhgQIUGBBwyMIDHQ8YC9AwpkBblZauQ+lK6JDjabsh3RSyyU8ywVQJzTixIo6AUDUqHCa0ltfXzUlGZZZwLGInio5ALShuZkL1M1sJzMBgib05oIs60ppybJoC6otFngV1JdVstoqTIixnb9hHQOS3CwZZadrEVNRHI2vksssBX4F/XjwMNJlUBv2LFplKtaq48Qmdmy2pSicr9muPPq1592Yz1o27SQ3GAPtyMKO7Jsv8DPPsdUmzsT4suipmbf/NordmMnuzZkukcvOHTwH5Ae8NXA3AIQADBoiYNCgAIEB6yAAYKu3Eevt2UDW23LfDVegElZRZBEAGB0gURIfPXREQzE59IBH99kzQAEb6bdAcqv9ph14tIl4IGGm2XRJTjtxuEAACcQEVE9K6FQEhgNQWEBCSXxYGoF+haedicJNdyIACWLV0VZJDLBAAkL9gt9L9uUIAAEcdpUAiLL9R+IdQg5IpGtGFpkEeXTNZNd78BHw1ji/JJRclTo6NBNyP46p1pdb8GkNmSge+YgB+vkHJHdhBnmoeGUCqsiLNPnh5YiTLhqggWY6V6mifoqyqaPAdGqWppYWKSqYpVZDeeKpn30KGKWpIiroQNSJSSqnrg4JKq2z2vrqgKwiEyump9WqqJ4HAqXsssw26+yz0EYr7bTUVmvttdhmq+223Hbr7bfghivuuOSWa+656Fr737rstuvuu/DGK++89NZr77345qvvvvz26++/AAcs8MAEF2zwwQgTHAQAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     &copy; 2007 Chris Johnson, MD, AAP Council on Children with Disabilities. Adapted with permission and contributions from: Frances Page Glascoe, PhD and Nicholas Robertshaw, authors of PEDS:Developmental Milestones; Franklin Trimm, MD, Vice Chair of Pediatrics, USA/APA Education Committee; the Center for Disease Control \"Act Early\" Initiative; the National Institute for Literacy/Reach Out and Read; and the Inventory of Early Development by Albert Brigance published by Curriculum Associates, Inc. Permission is granted to reproduce these pages on the condition that they are only used as guide to average development and not as a substitute for standardized validated screening for developmental-behavioral problems.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39974=[""].join("\n");
var outline_f39_2_39974=null;
var title_f39_2_39975="Etiology, clinical manifestations, and evaluation of neonatal shock";
var content_f39_2_39975=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, clinical manifestations, and evaluation of neonatal shock",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39975/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39975/contributors\">",
"     Lisa M Adcock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39975/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39975/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39975/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39975/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/2/39975/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a dynamic and unstable pathophysiologic state characterized by inadequate tissue perfusion. Although the effects of inadequate perfusion are reversible initially, prolonged oxygen deprivation leads to generalized cellular hypoxemia and the disruption of critical biochemical processes, eventually resulting in cell membrane ion pump dysfunction, intracellular edema, inadequate regulation of intracellular pH, and cell death.",
"   </p>",
"   <p>",
"    Although the underlying pathogenetic mechanisms of neonatal shock are the same as those seen in pediatric and adult shock, the etiology and clinical manifestations may vary, and at times are unique to the neonatal population. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=see_link\">",
"     \"Initial evaluation of shock in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis, etiology, stages, clinical presentation, and initial evaluation of neonatal shock will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is characterized by inadequate tissue perfusion as a consequence of diminished cardiac output",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic vascular resistance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac output (CO) is the product of heart rate and stroke volume. The stroke volume is determined by the preload, myocardial contractility, and afterload.",
"     </li>",
"     <li>",
"      The systemic vascular resistance (SVR) is determined by the vessel length, blood viscosity, and vessel diameter, which is regulated by vascular tone. Changes in SVR will alter the afterload, and thereby have an impact on stroke volume.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Shock can be classified based upon the following underlying pathophysiologic mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypovolemic &mdash; Hypovolemic shock is due to insufficient circulating blood volume, resulting in a reduction in CO",
"     </li>",
"     <li>",
"      Distributive &mdash; Severely decreased SVR due to abnormal distribution of fluid from the vascular to extravascular space results in distributive shock",
"     </li>",
"     <li>",
"      Cardiogenic &mdash; Cardiac dysfunction (failure) causes a decrease in CO",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologies of neonatal shock can be divided into the previously described pathophysiologic classes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypovolemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are common causes of significant fluid loss resulting in impaired CO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placenta bleeding, including placenta previa or placental abruption (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35032?source=see_link\">",
"       \"Clinical features, diagnosis, and course of placenta previa\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=see_link\">",
"       \"Placental abruption: Clinical features and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Twin-to-twin transfusion (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27594?source=see_link&amp;anchor=H24#H24\">",
"       \"Neonatal outcome, complications, and management of multiple births\", section on 'Twin-twin transfusion syndrome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Massive bleeding in the gastrointestinal tract, brain, lung, or other major organ",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Distributive shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are causes of distributive shock due to the loss of fluid from the vascular to extravascular spaces, resulting in a reduced SVR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis &mdash; In neonates, sepsis is the most common cause of distributive shock. Sepsis releases vasoactive mediators, such as nitric oxide and prostacyclin, which depress the autocontrol mechanisms of the systemic circulation that match oxygen delivery to oxygen needs. As a result, reduced arterial vascular tone and increased endothelial permeability contributes to the redistribution of intravascular fluid to the extravascular space. Sepsis may also cause myocardial dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5449?source=see_link&amp;anchor=H15#H15\">",
"       \"Pathophysiology of sepsis\", section on 'Circulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other conditions that may result in excessive loss of fluid from the vascular to extravascular space include hydrops fetalis and toxic shock syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/9/10393?source=see_link\">",
"       \"Postnatal care of hydrops fetalis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/52/8010?source=see_link\">",
"       \"Staphylococcal toxic shock syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adrenal crisis due to adrenal insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=see_link&amp;anchor=H6#H6\">",
"       \"Causes and clinical manifestations of primary adrenal insufficiency in children\", section on 'Adrenal crisis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiac dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial dysfunction in the neonate is caused by a variety of conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myocarditis may occur as an isolated illness or as a component of a systemic illness. In the newborn, myocarditis is usually due to infection, most commonly viral infection (coxsackie, rubella, and varicella).",
"     </li>",
"     <li>",
"      Several conditions, characterized by hypoxemia, metabolic abnormalities,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inflammation, are associated with myocardial damage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decreased function resulting in poor contractility. These include intrapartum asphyxia, systemic bacterial infection, and significant respiratory distress with severe hypoxemia.",
"     </li>",
"     <li>",
"      Complete congenital heart block due to maternal antibodies to",
"      <span class=\"nowrap\">",
"       SSA/Ro",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <span class=\"nowrap\">",
"       SSB/La",
"      </span>",
"      in mothers with systemic lupus erythematosus and Sj&ouml;gren's syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=see_link\">",
"       \"Neonatal lupus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Congenital heart defects can present as shock in newborns because of impaired blood flow due to either inflow or outflow obstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=see_link&amp;anchor=H2707582#H2707582\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\", section on 'Shock'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Congenital heart defects associated with inflow obstruction include total anomalous pulmonary venous connection, tricuspid atresia, and mitral atresia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/51/10040?source=see_link&amp;anchor=H9#H9\">",
"       \"Total anomalous pulmonary venous connection\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Congenital heart defects associated with outflow obstruction include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Left heart obstructive lesions, such as hypoplastic left heart syndrome, critical aortic stenosis, coarctation of the aorta, or interrupted aortic arch. These lesions depend upon the ductus arteriosus for systemic blood flow; shock ensues when the ductus closes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=see_link&amp;anchor=H6#H6\">",
"       \"Valvar aortic stenosis in children\", section on 'Critical AS'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=see_link&amp;anchor=H9#H9\">",
"       \"Clinical manifestations and diagnosis of coarctation of the aorta\", section on 'Neonates'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=see_link&amp;anchor=H22#H22\">",
"       \"Cardiac causes of cyanosis in the newborn\", section on 'Heart failure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Right heart obstructive lesions include pulmonary stenosis or atresia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the clinical presentation of neonatal shock may vary depending upon the type of shock and its cause, there are several features (cardinal findings) common in all cases of neonatal shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardinal findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical findings are usually present in neonatal shock regardless of the underlying etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cool extremities, acrocyanosis, and pallor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cool extremities, acrocyanosis, and pallor are initial signs of decreasing CO, as vasoconstrictive mechanisms compensate for decreased tissue perfusion by redirecting blood from the periphery to the vital organs (ie, coronary, cerebral and splanchnic perfusion). These signs may be difficult to differentiate from findings in the normal neonate who often have hands and feet that are cool to the touch with varying degrees of acrocyanosis. Pallor may also be an indication of anemia.",
"   </p>",
"   <p>",
"    A peripheral capillary refill greater than three or four seconds is suggestive of neonatal shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, the predictive value of capillary refill is poor, and it is not a reliable physical finding to either confirm the diagnosis of shock or to assess response of neonatal shock to resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/3,5\">",
"     3,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Changes in heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, tachycardia is a common but nonspecific finding in neonatal shock, which occurs when the infant tried to maintain cardiac output by a compensatory increase in heart rate when there is a limited capacity to increase stroke. In addition, variability of heart rate may be an early sign of septic shock [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/6\">",
"     6",
"    </a>",
"    ]. In contrast, bradycardia is a late sign of failing cardiac function, and is often a terminal finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Neurologic changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial stages of shock, neurologic changes vary from lethargy (including poor feeding) to irritability, and can progress to nonresponsiveness. Specific neurologic findings associated with shock include hypotonia at rest, decreased spontaneous movements of extremities, and deep tendon reflexes, and presence of developmental reflexes (also referred to as primitive reflexes), such as palmar grasp, Moro, and rooting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14505?source=see_link\">",
"     \"Neurological examination of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypotension is generally a late finding of shock. Ideally, shock should be diagnosed prior to the onset of hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/7\">",
"     7",
"    </a>",
"    ]. Blood pressure varies with gestational age, postmenstrual age, and weight (",
"    <a class=\"graphic graphic_figure graphicRef50321 \" href=\"mobipreview.htm?11/3/11312\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef71407 \" href=\"mobipreview.htm?38/24/39311\">",
"     figure 2",
"    </a>",
"    ). Both systolic and diastolic blood pressure increase approximately 1 to 2",
"    <span class=\"nowrap\">",
"     mmHg/week",
"    </span>",
"    for the first four weeks of life.",
"   </p>",
"   <p>",
"    There is a poor correlation between blood pressure (BP) and systemic blood flow in preterm infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/3,4,8\">",
"     3,4,8",
"    </a>",
"    ]. As a result, blood pressure measurements alone are imperfect tests to detect low blood flow in the early stages of shock. Two prospective studies of extremely premature infants (gestational age &le;25 weeks or birth weight &lt; 1000 g) showed mean arterial pressure below 25 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/9\">",
"     9",
"    </a>",
"    ] or 30 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/7\">",
"     7",
"    </a>",
"    ] was associated with poor neurologic outcome or mortality. In addition, cerebral autoregulation appears to fail when the mean arterial pressure falls below 30 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/10\">",
"     10",
"    </a>",
"    ]. In one retrospective study, infants with untreated low BP had similar survival rates as infants with normal BP, but were more likely to have neurodevelopmental impairment, including cerebral palsy and deafness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon this evidence, the American College of Critical Care Medicine guidelines suggest that a minimal threshold blood pressure of 30 mmHg be used in the care of extremely premature infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/7\">",
"     7",
"    </a>",
"    ]. However, this recommendation is based upon retrospective data on a relatively small number of patients. Further research is needed to determine the minimal threshold blood for extremely premature infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Oliguria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a strong correlation between low urinary output (oliguria) and low systemic blood flow. However, there may be a time delay between the development of circulatory compromise and the recognition of oliguria, because the upper normal range for the timing of first urination is the first 24 hours of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Other findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above described cardinal features of neonatal shock, other less common findings may suggest an underlying cause or type of shock based upon pathophysiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Respiratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following nonspecific respiratory findings may be seen in patients with neonatal shock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachypnea is generally seen in infants with septic or cardiogenic shock. Increased rate of breathing may also be seen as a compensatory response (compensatory respiratory alkalosis) to metabolic acidosis due to lactate production from poorly perfused tissue.",
"     </li>",
"     <li>",
"      Other signs of respiratory distress often accompany tachypnea, especially in patients with primary pulmonary disease (eg, pneumonia) or cardiopulmonary compromise with pulmonary edema. These include grunting, retractions, nasal flaring, and gasping.",
"     </li>",
"     <li>",
"      Periodic breathing and apnea are usually centrally-mediated and are more likely to be associated with decreased cerebral perfusion or significant metabolic acidosis that impairs cerebral function. As a result, these findings can present in all three types of neonatal shock.",
"     </li>",
"     <li>",
"      Hypoxemia may be present in infants with shock due to cardiac dysfunction or obstructed blood flow, resulting in pulmonary edema or primary pulmonary disease. Isolated hypoxemia is rare, especially in the early stages of shock. Hypoxemia associated with neonatal shock may be due to persistent pulmonary hypertension that may accompany bacterial infections, especially those caused by group B streptococcus (GBS), cyanosis due to cyanotic congenital heart disease, and severe anemia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link&amp;anchor=H7#H7\">",
"       \"Persistent pulmonary hypertension of the newborn\", section on 'Maladaptation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=see_link\">",
"       \"Cardiac causes of cyanosis in the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following nonspecific gastrointestinal (GI) findings may be seen in patients with neonatal shock:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poor feeding may be due to lethargy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory distress",
"     </li>",
"     <li>",
"      Vomiting may be a manifestation of decreased motility that results from nonmechanical disruption of the normal coordinated propulsive motor activity of the GI tract, which may progress to paralytic ileus",
"     </li>",
"     <li>",
"      Abdominal distension may also be a manifestation of ileus",
"     </li>",
"     <li>",
"      Diarrhea is",
"      <strong>",
"       NOT",
"      </strong>",
"      a common finding of neonatal shock",
"     </li>",
"     <li>",
"      Blood in the stool is also uncommon in neonatal shock, unless necrotizing enterocolitis is present (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=see_link\">",
"       \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Liver dysfunction due to decreased perfusion is manifested by increased serum bilirubin, resulting in jaundice; elevation in liver enzyme levels; and prolongation of PT, PTT, and iNR, which increases the possibility of bleeding",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common laboratory feature characteristic of neonatal shock is metabolic acidosis due to increased anaerobic metabolism and decreased clearance of",
"    <span class=\"nowrap\">",
"     lactate/lactic",
"    </span>",
"    acid.",
"   </p>",
"   <p>",
"    Other less common laboratory features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anemia due to significant blood loss, resulting in hypovolemic shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/12,13\">",
"       12,13",
"      </a>",
"      ] or hemolysis in septic shock.",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC) may be present in infants with septic shock or complications from pregnancy including fetal",
"      <span class=\"nowrap\">",
"       anoxia/birth",
"      </span>",
"      asphyxia (distributive shock) and abruptio placentae (hypovolemic shock). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=see_link&amp;anchor=H9#H9\">",
"       \"Disseminated intravascular coagulation in infants and children\", section on 'Neonates'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucose levels may be elevated or decreased during neonatal shock. The glucose level varies depending upon catecholamine release during the body's stress response (which affects insulin release and peripheral utilization of glucose), and the body stores of glucose and glycogen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=see_link\">",
"       \"Neonatal hyperglycemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=see_link\">",
"       \"Neonatal hypoglycemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyperkalemia is a result of release of intracellular potassium stores due to tissue injury and cell death, and decreased excretion with renal function impairment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Oliguria'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27114?source=see_link&amp;anchor=H30#H30\">",
"       \"Acute kidney injury (acute renal failure) in the newborn\", section on 'Hyperkalemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of the initial evaluation of neonatal shock include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid recognition and correction of circulatory compromise and other life-threatening conditions",
"     </li>",
"     <li>",
"      Classification of the type and cause of shock to guide treatment of the underlying condition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When a patient is suspected of having shock, diagnostic evaluation should occur at the same time as resuscitation. Resuscitative efforts should",
"    <strong>",
"     NOT",
"    </strong>",
"    be delayed for history, physical examination, or laboratory testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=see_link\">",
"     \"Neonatal resuscitation in the delivery room\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The type of shock and cause of shock can generally be determined from a focused history, physical examination, and selected diagnostic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The newborn history reviews maternal and fetal factors, including antepartum and delivery room complications. It often can identify the underlying cause of shock.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Significant blood loss from placental anomalies; hypovolemic shock",
"     </li>",
"     <li>",
"      Maternal chorioamnionitis; septic shock",
"     </li>",
"     <li>",
"      Hydrops fetalis; distributive shock",
"     </li>",
"     <li>",
"      Maternal history of systemic lupus erythematosus or Sj&ouml;gren's syndrome; cardiogenic shock",
"     </li>",
"     <li>",
"      Prior maternal history of still birth",
"     </li>",
"     <li>",
"      Foul-smelling or meconium-stained amniotic fluid; septic shock",
"     </li>",
"     <li>",
"      Antenatal asphyxia with abnormal heart rate pattern; cardiogenic shock",
"     </li>",
"     <li>",
"      Congenital heart disease detected by prenatal ultrasound; cardiogenic shock",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some cases, neonates who are more likely to require resuscitation can be identified prior to delivery. As a result, the neonatal team can be alerted and set up preparations for resuscitation in the delivery room. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=see_link&amp;anchor=H4#H4\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'High-risk delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings are neither sensitive nor specific for identifying the cause of shock, but an examination may provide suggestive initial findings for the etiology and degree of shock. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following tests may be helpful in identifying the cause and severity of shock and initial treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Blood tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood gas &mdash; Blood gas samples provide data on the oxygen (pO2) and carbon dioxide tensions, pH, calculated bicarbonate",
"      <span class=\"nowrap\">",
"       deficit/excess,",
"      </span>",
"      and in some settings, plasma electrolytes. In neonates with adequate peripheral perfusion, there is good correlation of all parameters, with the exception of pO2, in simultaneously-obtained samples of arterial, venous, and capillary blood gases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/14\">",
"       14",
"      </a>",
"      ]. Blood gas analysis will identify patients with metabolic acidosis, respiratory acidosis, and respiratory alkalosis. In addition, an arterial blood gas should detect hypoxemia.",
"     </li>",
"     <li>",
"      Complete blood count (CBC) with differential &mdash; Although abnormalities of any of the three cell lines may occur in neonatal shock, these findings have a low specificity and sensitivity for bacterial infections:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Both elevated",
"      <span class=\"nowrap\">",
"       (&gt;20,000/mm3)",
"      </span>",
"      and depressed",
"      <span class=\"nowrap\">",
"       (&lt;5,000/mm3)",
"      </span>",
"      total white blood counts (WBC) are associated with systemic bacterial infection.",
"     </li>",
"     <li>",
"      Thrombocytopenia may be suggestive of disseminated intravascular coagulation or neonatal septic shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anemia is seen in neonatal shock due to massive blood loss or hemolysis from overwhelming sepsis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic chemistry tests include electrolytes, glucose, blood urea nitrogen (BUN), and creatinine. As discussed previously, hyperkalemia and both hypoglycemia and hyperglycemia may occur in neonatal shock. Serum bicarbonate is usually depressed as an indication of metabolic acidosis. Both BUN and serum creatinine will begin to rise in infants with impaired renal function.",
"     </li>",
"     <li>",
"      Blood cultures should be obtained in any infant who may have septic shock or shock without an identifiable cause.",
"     </li>",
"     <li>",
"      Type and cross should be obtained for infants with hypovolemic shock due to blood loss who will require red blood cell transfusion. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/53/9048?source=see_link&amp;anchor=H3#H3\">",
"       \"Red blood cell transfusions in the newborn\", section on 'Acute blood loss'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A positive test for fetal cells in a sample of maternal blood can be indicative of fetomaternal hemorrhage as a cause for hypovolemic shock [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3800?source=see_link&amp;anchor=H7#H7\">",
"       \"Diagnosis and management of massive fetomaternal hemorrhage\", section on 'Kleihauer-Betke'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"   </p>",
"   <p>",
"    Doppler ultrasonography &mdash; Noninvasive Doppler echocardiography is the recommended initial method to measure CO and blood flow through the superior vena cava, as a reflection of systemic blood flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/3,4,7,17\">",
"     3,4,7,17",
"    </a>",
"    ]. Echocardiography identifies cardiac structural disease, and assesses ventricular size, global and regional systolic and diastolic function, and outflow from the heart to the lungs and to the systemic circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because blood pressure is not a reliable measurement of blood flow to critical organs (eg, brain and abdomen), Doppler ultrasonography has been used in research settings to assess blood flow to critical organs (eg, brain, gastrointestinal tract, and kidneys) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/10,18-23\">",
"     10,18-23",
"    </a>",
"    ]. Preliminary data suggest that decreased cerebral blood flow predicts poor neurologic outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/18,20\">",
"     18,20",
"    </a>",
"    ], but correlates poorly with blood pressure measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39975/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chest radiography &mdash; Neonates with respiratory distress, abnormal cardiopulmonary examinations, or who have not responded to initial management as expected should receive chest radiographs. Abnormal chest radiograph may be indicative of primary cardiac or pulmonary disease.",
"     </li>",
"     <li>",
"      In patients with significant hemorrhage, ultrasonography is useful in detecting bleeding into the brain, abdomen, or kidney. Although head imaging using either computed tomography or magnetic resonance can differentiate subgaleal hemorrhage, which has a high mortality rate, from other cranial pathologic conditions, subgaleal bleeding should be diagnosed clinically, as it is important to initiate treatment as quickly as possible. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22265?source=see_link&amp;anchor=H10#H10\">",
"       \"Neonatal birth injuries\", section on 'Subgaleal hemorrhage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shock is a dynamic and unstable pathophysiologic state characterized by inadequate tissue perfusion, resulting in",
"    <span class=\"nowrap\">",
"     tissue/cellular",
"    </span>",
"    damage that may cause end-organ failure and, in some cases, death.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased systemic tissue perfusion is a consequence of diminished cardiac output",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      systemic vascular resistance. Cardiac output is the product of heart rate and stroke volume. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of neonatal shock are classified into three pathophysiologic mechanisms. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypovolemic shock is due to significant fluid losses, impairing cardiac output. Significant placenta or postnatal bleeding, or twin-twin transfusion are causes of hypovolemic shock. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hypovolemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Distributive shock due to loss of fluid from the vascular to extravascular space reduces systemic vascular resistance. Causes of distributive shock include sepsis, hydrops fetalis, or toxic shock syndrome.",
"     </li>",
"     <li>",
"      Cardiogenic shock due to cardiac dysfunction may be caused by myocarditis; impaired cardiac blood flow from congenital heart defects; complete neonatal heart block; or secondary cardiac damage from asphyxia, inflammation, or other metabolic conditions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several cardinal findings are common in all three types of shock. They include cool extremities, acrocyanosis, pallor, changes in heart rate (especially tachycardia), neurologic changes (eg, lethargy, irritability, hypotonia, and nonresponsiveness), and metabolic acidosis. Late signs of shock include bradycardia, oliguria,",
"      <span class=\"nowrap\">",
"       hypoxemia/cyanosis,",
"      </span>",
"      and hypotension. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Cardinal findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a patient is suspected of having shock, diagnostic evaluation should occur at the same time as resuscitation. Resuscitative efforts should",
"      <strong>",
"       NOT",
"      </strong>",
"      be delayed for history, physical examination, laboratory testing, or imaging. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=see_link\">",
"       \"Neonatal resuscitation in the delivery room\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The history, physical examination, and laboratory testing may help determine the underlying cause of shock and guide further management decisions. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kourembanas, S. Shock. In: Manual of Neonatal Care, 6th ed, Cloherty, JP, Eichenwald, EC, Stark, AR (Eds), Lippincott 2008. p.176.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/2\">",
"      Takahashi N, Uehara R, Nishida H, et al. Clinical features of neonatal toxic shock syndrome-like exanthematous disease emerging in Japan. J Infect 2009; 59:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/3\">",
"      Miletin J, Pichova K, Dempsey EM. Bedside detection of low systemic flow in the very low birth weight infant on day 1 of life. Eur J Pediatr 2009; 168:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/4\">",
"      Osborn DA, Evans N, Kluckow M. Clinical detection of low upper body blood flow in very premature infants using blood pressure, capillary refill time, and central-peripheral temperature difference. Arch Dis Child Fetal Neonatal Ed 2004; 89:F168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/5\">",
"      LeFlore JL, Engle WD. Capillary refill time is an unreliable indicator of cardiovascular status in term neonates. Adv Neonatal Care 2005; 5:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/6\">",
"      Griffin MP, Lake DE, Moorman JR. Heart rate characteristics and laboratory tests in neonatal sepsis. Pediatrics 2005; 115:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/7\">",
"      Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/8\">",
"      Evans N. Assessment and support of the preterm circulation. Early Hum Dev 2006; 82:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/9\">",
"      Batton B, Zhu X, Fanaroff J, et al. Blood pressure, anti-hypotensive therapy, and neurodevelopment in extremely preterm infants. J Pediatr 2009; 154:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/10\">",
"      Munro MJ, Walker AM, Barfield CP. Hypotensive extremely low birth weight infants have reduced cerebral blood flow. Pediatrics 2004; 114:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/11\">",
"      Clark DA. Times of first void and first stool in 500 newborns. Pediatrics 1977; 60:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/12\">",
"      Reid J. Neonatal subgaleal hemorrhage. Neonatal Netw 2007; 26:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/13\">",
"      Kilani RA, Wetmore J. Neonatal subgaleal hematoma: presentation and outcome--radiological findings and factors associated with mortality. Am J Perinatol 2006; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/14\">",
"      Yildizda D, Yapiciolu H, Yilmaz HL, Sertdemir Y. Correlation of simultaneously obtained capillary, venous, and arterial blood gases of patients in a paediatric intensive care unit. Arch Dis Child 2004; 89:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/15\">",
"      Kermorvant-Duchemin E, Laborie S, Rabilloud M, et al. Outcome and prognostic factors in neonates with septic shock. Pediatr Crit Care Med 2008; 9:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/16\">",
"      Markham LA, Charsha DS, Perelmuter B. Case report of massive fetomaternal hemorrhage and a guideline for acute neonatal management. Adv Neonatal Care 2006; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     Evans, N, Seri, I. Cardiovascular compromise in the newborn infant. In: Avery's Diseases of the Newborn, 8th ed, Taeusch HW, Ballard RA, Gleason CA (Eds), Elsevier 2005. p.398.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/18\">",
"      Fukuda S, Mizuno K, Kakita H, et al. Late circulatory dysfunction and decreased cerebral blood flow volume in infants with periventricular leukomalacia. Brain Dev 2008; 30:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/19\">",
"      Lightburn MH, Gauss CH, Williams DK, Kaiser JR. Cerebral blood flow velocities in extremely low birth weight infants with hypotension and infants with normal blood pressure. J Pediatr 2009; 154:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/20\">",
"      Nishimaki S, Iwasaki S, Minamisawa S, et al. Blood flow velocities in the anterior cerebral artery and basilar artery in asphyxiated infants. J Ultrasound Med 2008; 27:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/21\">",
"      Romagnoli C, Giannantonio C, De Carolis MP, et al. Neonatal color Doppler US study: normal values of cerebral blood flow velocities in preterm infants in the first month of life. Ultrasound Med Biol 2006; 32:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/22\">",
"      Papacci P, Giannantonio C, Cota F, et al. Neonatal colour Doppler ultrasound study: normal values of abdominal blood flow velocities in the neonate during the first month of life. Pediatr Radiol 2009; 39:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39975/abstract/23\">",
"      Ilves P, Lintrop M, Talvik I, et al. Developmental changes in cerebral and visceral blood flow velocity in healthy neonates and infants. J Ultrasound Med 2008; 27:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5039 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-210.101.131.232-FFF4911520-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39975=[""].join("\n");
var outline_f39_2_39975=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Distributive shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiac dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardinal findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cool extremities, acrocyanosis, and pallor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Changes in heart rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Neurologic changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Oliguria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Other findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Respiratory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Blood tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5039\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5039|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/3/11312\" title=\"figure 1\">",
"      Neonatal BP gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/24/39311\" title=\"figure 2\">",
"      Neonatal BP birth weight",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/30/27114?source=related_link\">",
"      Acute kidney injury (acute renal failure) in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=related_link\">",
"      Cardiac causes of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/13/35032?source=related_link\">",
"      Clinical features, diagnosis, and course of placenta previa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3800?source=related_link\">",
"      Diagnosis and management of massive fetomaternal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/49/14104?source=related_link\">",
"      Initial evaluation of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/47/22265?source=related_link\">",
"      Neonatal birth injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37816?source=related_link\">",
"      Neonatal hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27594?source=related_link\">",
"      Neonatal outcome, complications, and management of multiple births",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14505?source=related_link\">",
"      Neurological examination of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29417?source=related_link\">",
"      Placental abruption: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/9/10393?source=related_link\">",
"      Postnatal care of hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/53/9048?source=related_link\">",
"      Red blood cell transfusions in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/51/10040?source=related_link\">",
"      Total anomalous pulmonary venous connection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_2_39976="Diphyllobothriasis life cycle";
var content_f39_2_39976=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72572&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Diphyllobothriasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 470px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Immature eggs are passed in feces",
"    <strong>",
"     (1)",
"    </strong>",
"    . Under appropriate conditions, the eggs mature (approximately 18 to 20 days)",
"    <strong>",
"     (2)",
"    </strong>",
"    and yield oncospheres, which develop into a coracidia",
"    <strong>",
"     (3)",
"    </strong>",
"    . After ingestion by a suitable freshwater crustacean (the copepod first intermediate host) the coracidia develop into procercoid larvae",
"    <strong>",
"     (4)",
"    </strong>",
"    . Following ingestion of the copepod by a suitable second intermediate host, typically minnows and other small freshwater fish, the procercoid larvae are released from the crustacean and migrate into the fish flesh where they develop into a plerocercoid larvae (sparganum)",
"    <strong>",
"     (5)",
"    </strong>",
"    . The plerocercoid larvae are the infective stage for humans. Because humans do not generally eat undercooked minnows and similar small freshwater fish, these do not represent an important source of infection. Nevertheless, these small second intermediate hosts can be eaten by larger predator species (eg, trout, perch, walleyed pike)",
"    <strong>",
"     (6)",
"    </strong>",
"    . In this case, the sparganum can migrate to the musculature of the larger predator fish and humans can acquire the disease by eating these later intermediate infected host fish raw or undercooked",
"    <strong>",
"     (7)",
"    </strong>",
"    . After ingestion of the infected fish, the plerocercoid develop into immature adults and then into mature adult tapeworms, which will reside in the small intestine. The adults of",
"    <em>",
"     D. latum",
"    </em>",
"    attach to the intestinal mucosa by means of the two bilateral groves (bothria) of their scolex",
"    <strong>",
"     (8)",
"    </strong>",
"    . The adults can reach more than 10 m in length, with more than 3000 proglottids. Immature eggs are discharged from the proglottids (up to 1,000,000 eggs per day per worm)",
"    <strong>",
"     (9)",
"    </strong>",
"    and are passed in the feces",
"    <strong>",
"     (1)",
"    </strong>",
"    . Eggs appear in the feces five to six weeks after infection. In addition to humans, many other mammals can also serve as definitive hosts for",
"    <em>",
"     D. latum",
"    </em>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Diphyllobothriasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/diphyllobothriasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/diphyllobothriasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39976=[""].join("\n");
var outline_f39_2_39976=null;
var title_f39_2_39977="Anesthesia for cesarean delivery";
var content_f39_2_39977=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anesthesia for cesarean delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39977/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39977/contributors\">",
"     Gilbert J Grant, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39977/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39977/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39977/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39977/contributors\">",
"     Kari G Doucette, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/2/39977/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either regional or general anesthesia is an acceptable approach to providing anesthesia for cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the use of general anesthesia has fallen dramatically in the past few decades and now accounts for only about 5 percent of cesarean deliveries in the United States and United Kingdom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF ANESTHETIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anesthetic plan for cesarean delivery should take into account the well-being of two patients: the mother and the fetus. Regional anesthesia is the most common method of anesthesia for delivery because it allows the mother to be awake and immediately interact with her baby. It is also safer for the mother than general anesthesia. In the most recent report of anesthesia-related maternal mortality in the United States (1991-2002 period), the majority of women who died were undergoing a cesarean delivery and there were no deaths associated with vaginal delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/3\">",
"     3",
"    </a>",
"    ]. Maternal mortality associated with general anesthesia was 6.5 per million, while that associated with regional anesthesia was 3.8 per million, a risk ratio of 1.7. Even though overall anesthetic-related maternal mortality continues to decrease, rates for regional anesthesia are rising.",
"   </p>",
"   <p>",
"    Regional anesthesia is used for 95 percent of planned cesarean deliveries in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/4\">",
"     4",
"    </a>",
"    ]. Spinal and combined spinal epidural (CSE) anesthesia are more commonly used than epidural anesthesia because spinal-based techniques have a more rapid onset and lower incidence of failed block than pure epidural techniques. The use of spinal anesthesia for cesarean delivery was facilitated by the popularization of pencil-point needles, which dramatically reduced the incidence of postdural puncture headache.",
"   </p>",
"   <p>",
"    Regional anesthesia for cesarean delivery differs from analgesia for labor and vaginal delivery in two major ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Operative anesthesia requires a more intense block because the nociceptive stimulus of surgery is more intense than the pain of labor. Relatively dilute concentrations of local anesthetics are administered for labor analgesia to avoid motor block and to minimize interference with second stage pushing efforts. However, motor block is desirable during cesarean delivery to obtain abdominal muscle relaxation. A more intense block is achieved by administering a high concentration of local anesthetic.",
"     </li>",
"     <li>",
"      The dermatomal level of anesthesia required for cesarean delivery is higher than that required for labor analgesia. A sensory block to the 10th thoracic dermatome is sufficient to achieve analgesia for labor, but for cesarean, the anesthetic level must be extended cephalad to at least the fourth thoracic dermatome to prevent nociceptive input from the peritoneal manipulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed description of regional anesthetic techniques, side effects, and complications can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37574?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Options\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25977?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General anesthesia is less desirable for cesarean delivery because the mother is unconscious, thus unable to interact with her newborn immediately. It also appears to increase the risk of postpartum hemorrhage. In a multivariate analysis of over 67,000 cesarean deliveries, the rate of postpartum hemorrhage was significantly higher in women who received general anesthesia than in women who received epidural anesthesia (5.1 versus 0.4 percent; OR 8.15, 95% CI 6.43-10.33) after adjustment of maternal and fetal risk factors for postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two potential serious complications associated with general anesthesia are failed intubation and pulmonary aspiration of gastric contents. Inhibition of upper airway reflexes and alterations of gastrointestinal function increase the risk of pulmonary aspiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=see_link\">",
"     \"Aspiration pneumonia in adults\"",
"    </a>",
"    .) Airway reflexes are compromised by the loss of consciousness that occurs with induction of general anesthesia. An advantage of regional anesthesia is that the parturient is awake and airway reflexes are maintained. However, aspiration may also occur during regional anesthesia if airway reflexes are compromised by injudicious sedation. Furthermore, if the regional anesthetic is inadequate, it may be necessary to induce general anesthesia. Deaths associated with regional anesthesia are more likely a result of high spinal or epidural block, respiratory failure, or a drug reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The choice of regional or general anesthesia is influenced by a variety of other factors, such as the urgency of the procedure, maternal hemodynamic status, and physician and patient preference. A general discussion of anesthesia choices can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Urgency factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;For scheduled cesareans, the rapidity of anesthetic induction is less of a concern, so all anesthetic options are available. If the cesarean must be performed urgently (eg, nonreassuring fetal heart rate pattern), an anesthetic technique that can be performed expeditiously is preferred. If the cesarean is a true emergency, the time required to achieve anesthesia and facilitate a rapid delivery may be of critical importance to the well-being of the fetus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mother.",
"   </p>",
"   <p>",
"    Most practitioners agree that inducing general anesthesia is the most reliable means of quickly achieving operative anesthesia for cesarean. However, highly skilled clinicians are usually able to rapidly induce spinal anesthesia. In fact, spinal anesthesia is increasingly being used as a substitute for general anesthesia in all but the most emergent situations.",
"   </p>",
"   <p>",
"    Spinal anesthesia is more desirable than epidural if time is of the essence because the onset of the block is faster with a spinal approach. However, if the parturient already has an epidural catheter in-situ (eg, placed previously for labor analgesia), then operative anesthesia may be achieved within a few minutes in almost all patients (&ge;97 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/6\">",
"     6",
"    </a>",
"    ]) by injecting a more concentrated local anesthetic. In this situation, anesthetic latency may be decreased by using a local anesthetic with a rapid onset, such as 3% 2-chloroprocaine, or by increasing local anesthetic pH by adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    . In one study, the addition of bicarbonate to 2%",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    decreased the time of onset of surgical anesthesia from 9.7",
"    <span class=\"nowrap\">",
"     +/-1.6",
"    </span>",
"    minutes to 5.2",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    1.5 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/7\">",
"     7",
"    </a>",
"    ]. The addition of bicarbonate to 3% 2-chloroprocaine results in the local anesthetic with the shortest latency and is the recommended choice in urgent cases. Adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    to local anesthetics may result in a significantly faster onset of the block, but does not affect the need for intraoperative supplementation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Maternal status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal medical factors also influence choice of optimum anesthetic. A discussion of anesthetic management of specific maternal disorders is beyond the scope of this review. In general, acute hemorrhage and hemodynamic compromise militate against the use of regional anesthesia since the accompanying sympathetic block will produce vasodilation, which will exacerbate maternal hypotension. The presence of a significant bleeding diathesis (eg, severe thrombocytopenia) is another contraindication to regional anesthesia because of the increased risk of causing a",
"    <span class=\"nowrap\">",
"     spinal/epidural",
"    </span>",
"    hematoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, if evaluation of the parturient's airway anatomy suggests that intubation may be difficult, then regional anesthesia may be a more desirable choice than general anesthesia. Other reasons a regional anesthetic may be preferable include a history of malignant hyperthermia, some types of cardiac or respiratory disease, and for the",
"    <span class=\"nowrap\">",
"     prevention/treatment",
"    </span>",
"    of autonomic hyperreflexia. There are also specific situations in which regional anesthesia may be contraindicated (eg, uncorrected coagulopathy, skin infection of the lower back).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANESTHESIA ISSUES IN PREGNANT WOMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy induces a variety of physiologic changes that have important clinical implications for anesthesia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intraabdominal pressure, relaxation of the lower esophageal sphincter, and assumption of a recumbent position during",
"      <span class=\"nowrap\">",
"       labor/delivery",
"      </span>",
"      increase the risk for pulmonary aspiration of gastric contents if upper airway reflexes are compromised. Pain, anxiety, sedatives, and opioids contribute by prolonging intestinal transit time. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9160?source=see_link\">",
"       \"Maternal gastrointestinal tract adaptation to pregnancy\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Therefore, all parturients are at risk for pulmonary aspiration, regardless of the time of their last meal, and insertion of a cuffed endotracheal tube is mandatory to protect the trachea if the woman is obtunded, as occurs with general anesthesia.",
"     </li>",
"     <li>",
"      Edema of upper airway tissues, especially in",
"      <span class=\"nowrap\">",
"       preeclamptic/eclamptic",
"      </span>",
"      parturients, may render tracheal intubation challenging.",
"     </li>",
"     <li>",
"      Pregnancy increases the basal metabolic rate and lowers pulmonary functional residual capacity. Thus, hypoxemia is likely to develop rapidly during the period of apnea that accompanies the induction of general anesthesia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=see_link\">",
"       \"Respiratory tract changes during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the supine position, the gravid uterus compresses the aorta and vena cava, thereby decreasing venous return, cardiac output, and blood pressure. Regional anesthesia mediated-vasodilation exacerbates this effect by promoting pooling of blood in capacitance vessels. Therefore, the uterus should be displaced off the great vessels by placing a wedge under the right hip (left uterine displacement) whenever the parturient is positioned supine. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=see_link&amp;anchor=H11#H11\">",
"       \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\", section on 'Supine hypotensive syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREOPERATIVE ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patient evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, pregnant women should meet with an anesthesiologist antepartum or in the early intrapartum period, whether or not a cesarean is planned. This meeting allows the patient to ask specific questions regarding anesthesia, and it also permits the anesthesiologist to identify medical problems that may have important implications for the anesthetic plan. This consultation is particularly important for women with known disorders that affect administration of anesthesia, such as coagulopathy, severe obesity, restriction or abnormality of the spine, and cardiovascular or respiratory disease. As an example, preoperative evaluation may find that the woman has an airway that will render intubation difficult (eg, short neck, limited jaw movement) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/9\">",
"     9",
"    </a>",
"    ]; thus, rapid-sequence induction would be relatively contraindicated because of the risk of losing control of the airway. In this situation, other techniques, including awake intubation, are preferable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society of Anesthesiologists recommends that patients abstain from solid food for at least six hours prior to elective cesarean delivery (8 hours for fried or fatty foods) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Clear liquids, which have a more rapid gastric transit time, may be ingested until two hours prior to surgery. The unpredictability of unplanned cesarean births requires that certain standards for oral intake be followed at all times during labor. To be prepared for the emergent use of anesthesia, laboring women should avoid solid food, and restrict their oral intake to clear liquids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Reduction of gastric acidity/volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acidic aspirate is especially injurious to the lungs. Prophylactic administration of a nonparticulate antacid (eg, sodium citrate 30 mL p.o.), histamine 2-receptor antagonist (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    , 50 mg i.v.), proton pump inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    , 20 mg p.o.), or prokinetic drug (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    10 mg i.v.), alone or in combination, prior to induction of general anesthesia is a standard procedure to mitigate the effects of aspiration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. There is some evidence that use of both an antacid and a histamine 2-receptor antagonist is superior to use of antacids alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal is to raise intragastric pH and, for some agents, lower intragastric volume and increase lower esophageal sphincter tone. Although these drugs have been shown to increase pH and some decrease gastric volume, they have not been proven to reduce the frequency of aspiration pneumonitis due to the low incidence of this event. Parturients at increased risk for aspiration (obese, anticipated difficult intubation) are candidates for these drugs.",
"   </p>",
"   <p>",
"    Even though some anesthesiologists administer these agents prior to regional anesthesia using the rationale that the cost and side effects are low and one cannot predict if induction of general anesthesia will be required, aspiration is very unlikely in this setting. The incidence of failed epidural has been estimated at 2 to 6 percent, and the incidence of failed spinal is even lower. Even if general anesthesia is required to perform a cesarean, the incidence of aspiration is approximately 15 per 10,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/15\">",
"     15",
"    </a>",
"    ]. Thus, the likelihood of aspiration occurring during a cesarean in which regional anesthesia is planned is very low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5492576\">",
"    <span class=\"h3\">",
"     Choice of medication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although sodium citrate has an unpleasant taste that may itself precipitate vomiting, it is used routinely in many practices because it decreases the acidity of gastric contents. If given within 30 minutes of induction of anesthesia to healthy, term parturients, it effectively increases mean gastric pH from 1.8",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    2.7 to 5.0",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    1.5 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other pharmacologic measures designed to lower the risk of aspiration or decrease its severity are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    (10 mg intravenously, slowly) to increase lower esophageal sphincter tone and promote gastric emptying, an H2 antagonist such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (150 mg orally or 50 mg intravenously) to alkalinize gastric contents, or a proton pump inhibitor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    40 mg intravenously) to decrease gastric acid secretion. Forty to 60 minutes is required to decrease secretion of gastric acid, and it is sustained for eight hours, providing prophylaxis against aspiration pneumonitis upon extubation.",
"   </p>",
"   <p>",
"    A very small amount of these drugs administered parenterally cross the placenta and enter breast milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prevention and management of hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal oxygenation depends upon placental perfusion; thus, a decrease in maternal blood pressure can compromise fetal oxygenation, which can be manifested by deterioration of the fetal heart rate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=see_link&amp;anchor=H6#H6\">",
"     \"Antepartum fetal heart rate assessment\", section on 'Cardiovascular response to hypoxia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Induction of anesthesia tends to reduce maternal blood pressure. This is particularly true for regional anesthesia, which results in pooling of blood in capacitance vessels due to sympathetic block mediated vasodilation. The onset of block is more rapid with spinal than epidural anesthesia; for this reason, hypotension occurs more commonly after spinal anesthesia than after epidural anesthesia.",
"   </p>",
"   <p>",
"    Prophylactic strategies to prevent regional anesthesia-induced hypotension include volume expansion using intravenous fluids, administration of vasopressors, and mechanical interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5492583\">",
"    <span class=\"h3\">",
"     Intravenous fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous fluid loading has been a standard prerequisite to regional anesthesia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/17\">",
"     17",
"    </a>",
"    ]. Crystalloid preload prior to spinal anesthesia does not reliably prevent maternal hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/18\">",
"     18",
"    </a>",
"    ], probably due to rapid redistribution of crystalloid from the intravascular space.",
"   </p>",
"   <p>",
"    A systematic review found that colloid prehydration (hydroxyethylstarch) was superior to crystalloid prehydration (lactated Ringer's, Hartman's solution) in reducing, but not eliminating, the incidence of spinal-induced hypotension in parturients (RR hypotension requiring intervention 0.68, 95% CI 0.52-0.89) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/19\">",
"     19",
"    </a>",
"    ]. Crystalloid prehydration appeared to be superior to no prehydration (RR of hypotension requiring intervention 0.78, 95% CI 0.60-1.00).",
"   </p>",
"   <p>",
"    Most anesthesiologists administer crystalloid solutions for cesarean delivery because they are less expensive and more readily available than colloid. Furthermore, the limited available data do not indicate a large absolute benefit of colloids over crystalloids. If crystalloid is chosen, glucose-free solutions should be used to prevent hyperinsulinemia in the fetus. Excessive placental glucose transfer can result in compensatory release of fetal insulin (fetal hyperinsulinemia) and neonatal hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5492590\">",
"    <span class=\"h3\">",
"     Vasopressor treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, hypotension in parturients was routinely treated with mixed alpha- and beta-adrenergic agonists (eg, ephedrine) due to concerns that selective alpha agonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    ) would produce uterine artery constriction and thus adversely affect the fetus. However, the evidence does not support this concern and the superiority of selective alpha agonists has become apparent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of seven randomized trials comparing use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    versus ephedrine for the prevention and treatment of hypotension during spinal anesthesia for elective cesarean delivery in healthy parturients, both drugs were effective in managing maternal hypotension, but phenylephrine was associated with significantly higher umbilical arterial pH values in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/23\">",
"     23",
"    </a>",
"    ]. There was no significant difference in true fetal acidosis (umbilical arterial pH value of &lt;7.2) and maternal bradycardia was more likely to occur with phenylephrine than with ephedrine.",
"   </p>",
"   <p>",
"    Subsequent randomized trials comparing the two drugs in non-elective cesarean deliveries demonstrated no significant difference in fetal acid base status when the drugs were administered as bolus injections (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    100 micrograms, ephedrine 10 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/24\">",
"     24",
"    </a>",
"    ], but superiority of phenylephrine when the drugs were administered as infusions (phenylephrine 100",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    ephedrine 8",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ephedrine crosses the placenta to a greater degree than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    , supporting the hypothesis that the lower fetal pH associated with use of ephedrine results from stimulation of fetal beta-adrenergic receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anesthesiologists continue to use both ephedrine (5 to 10 mg boluses) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    (50 to 100 mcg boluses or 25 to 100",
"    <span class=\"nowrap\">",
"     microgram/min",
"    </span>",
"    infusions) to treat maternal hypotension. The choice of therapy is often guided by the maternal heart rate: phenylephrine is preferred when the maternal heart rate is relatively fast (greater than 100 bpm) since it tends to slow the heart rate to a greater degree than ephedrine. A randomized trial found that phenylephrine infusion (120",
"    <span class=\"nowrap\">",
"     microgram/min)",
"    </span>",
"    and bolus (120 microgram) regimens resulted in similar clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/27\">",
"     27",
"    </a>",
"    ]. The bolus regimen maintained the blood pressure closer to its normal range during the first few minutes following a spinal anesthetic, while the infusion regimen required a higher dose of phenylephrine to maintain the blood pressure close to baseline. These findings suggest that a phenylephrine bolus may be preferable over an infusion.",
"   </p>",
"   <p>",
"    Prophylactic administration of vasopressors prior to, or coincident with, induction of regional anesthesia will minimize the incidence and severity of hypotension, and thereby also reduce the incidence of intraoperative nausea and vomiting. Ephedrine (25 to 50 mg intramuscularly) prior to induction of regional anesthesia is one option [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/28\">",
"     28",
"    </a>",
"    ]. However, prophylactic use has been demonstrated to produce \"overshoot\" (reactive) hypertension, leading to its decreased popularity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactive hypertension has also been reported with prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    infusion, in patients receiving relatively high doses (75 to 100",
"    <span class=\"nowrap\">",
"     micrograms/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/30\">",
"     30",
"    </a>",
"    ]. Therefore, prompt treatment with vasopressor administration at the first sign of hypotension is a more cautious approach. Phenylephrine may be associated with a lower incidence of intraoperative nausea and vomiting compared with ephedrine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5492597\">",
"    <span class=\"h3\">",
"     Cohydration and vasopressor infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cohydration or coload refers to the rapid administration of crystalloid at the same time that the spinal anesthetic is injected, in contrast to preloading, in which the fluid is administered prior to anesthetic administration. Cohydration is intended to reduce the incidence of spinal anesthesia-induced maternal hypotension; the rationale is that crystalloid will be present in the intravascular space at the precise moment that it is needed: when spinal-induced vasodilation occurs. It is not necessary to delay surgery in order to deliver a fluid preload, as the incidence of hypotension is similar whether fluid is given in advance or coincident with the spinal anesthetic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more promising approach is the combination of cohydration with prophylactic vasopressor administration. In a randomized trial involving 112 nonlaboring women scheduled for cesarean delivery, rapid cohydration combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    infusion (100",
"    <span class=\"nowrap\">",
"     mcg/min)",
"    </span>",
"    at the initiation of spinal anesthesia resulted in a significant reduction in the incidence of hypotension compared with no cohydration (1.9 versus 28.3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5492604\">",
"    <span class=\"h3\">",
"     Mechanical compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical interventions, such as use of leg wrapping or compression boots, have also been used to decrease the incidence and severity of regional anesthesia-induced hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/33\">",
"     33",
"    </a>",
"    ]. Moreover, sequential compression boots may help prevent thrombus formation in patients undergoing surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94808770\">",
"    <span class=\"h2\">",
"     Fetal surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;For low risk patients undergoing scheduled cesarean delivery, the presence of a normal fetal heart rate should be ascertained and documented before administration of anesthesia. For patients undergoing unscheduled cesarean delivery, continuous fetal heart rate monitoring is maintained until the abdominal sterile preparation has begun, at which time the external monitor is removed. If the patient has an internal fetal monitor, it is removed when abdominal sterile preparation is complete [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GENERAL ANESTHESIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Induction",
"    </span>",
"    &nbsp;&mdash;&nbsp;If examination of the upper airway suggests that intubation will not be problematic, the following sequence is used for providing general anesthesia to the gravida:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nonparticulate antacid is generally given preoperatively to alkalinize gastric contents. Some practitioners also administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      or an H2 blocker as prophylactic measures to minimize the risk and severity of aspiration (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Reduction of gastric acidity/volume'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Just prior to induction, 100 percent oxygen should be administered by face mask to denitrogenate the maternal lungs. Preoxygenation for three to five minutes establishes an oxygen reserve prior to the expected apneic interval that accompanies anesthetic induction and tracheal intubation. If there is insufficient time to accomplish this, an alternative is to administer 100 percent oxygen for four vital capacity breaths. This is important because of the reduced functional residual capacity of pregnant women.",
"     </li>",
"     <li>",
"      At this time, the obstetrician should prepare and drape the abdomen for incision.",
"     </li>",
"     <li>",
"      Following preoxygenation, a rapid-sequence induction is performed to minimize the likelihood of pulmonary aspiration. Anesthetic agents are administered intravenously, rapidly followed by tracheal intubation without intervening mask ventilation. Typically, an assistant applies continuous pressure to the cricoid cartilage to compress the esophagus and help prevent reflux of gastric contents into the pharynx from the moment the anesthetic agents are injected until proper endotracheal tube placement is confirmed, although the efficacy of this maneuver has been questioned [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/35,36\">",
"       35,36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The preferred muscle relaxant is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      (1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      because of its rapid onset of action. Various anesthetic induction agents may be used, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      (2 to 3",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/34/15908?source=see_link\">",
"       etomidate",
"      </a>",
"      (0.2 to 0.3",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg).",
"      </span>",
"      A once-popular induction agent,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/63/1015?source=see_link\">",
"       thiopental",
"      </a>",
"      , is no longer available in the United States. Since ketamine tends to increase arterial pressure, it is a reasonable choice for anesthetic induction in acutely hypovolemic patients. Etomidate is used in patients in whom avoidance of hypotension is important, as etomidate typically causes less hemodynamic perturbation than the other induction agents.",
"     </li>",
"     <li>",
"      Tracheal intubation is performed as the induction agent and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      exert their effects (approximately 45 seconds). The cuff of the tube is inflated immediately upon placement to protect the lungs from aspiration. Equipment for emergency airway management, including laryngeal mask airways, a video assisted laryngoscopy device such as a Glide Scope&reg;, a set-up to perform transtracheal jet ventilation, and cricothyrotomy, should be readily available at sites where cesarean delivery is performed.",
"      <br/>",
"      <br/>",
"      Once proper placement of the endotracheal tube is confirmed, the obstetrician is informed that surgery may commence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Difficult airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rates of difficult and failed intubation in pregnant women are higher than in nonpregnant patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/37\">",
"     37",
"    </a>",
"    ]. If the airway examination suggests that intubation may be difficult, a different approach to induction should be taken (eg, preparation for awake intubation). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34248?source=see_link\">",
"     \"Airway management of pregnant women at delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many anesthesiologists administer 100 percent oxygen prior to delivery of the fetus, especially in cases of nonreassuring fetal heart rate tracing. Anesthesia is maintained using low concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    (25 to 50 percent) and inhalation anesthetics (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    0.25 to 0.5 MAC [minimum alveolar concentration]) until delivery of the baby (if nitrous oxide is not used, then higher concentrations of inhalation agents are necessary). After the birth, higher concentrations of nitrous oxide may be used, while keeping in mind that inhalation anesthetics produce dose-dependent uterine atony. Opioids such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    may also be administered. The abdominal muscle relaxation provided by inhalation agents may obviate the need for a second dose of neuromuscular blocker.",
"   </p>",
"   <p>",
"    Intraoperative recall is a possibility during cesarean surgery because low doses of anesthetics are used to reduce drug transfer to the fetus. Awareness during anesthesia can be minimized by administering an amnestic agent, such as a benzodiazepine, during the time of anesthesia induction. Inhalation anesthetics also provide amnesia.",
"   </p>",
"   <p>",
"    At the end of surgery, the patient is awakened prior to extubation to be sure that airway reflexes are intact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neonatal effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;All anesthetic induction and maintenance agents cross the placenta and may result in neonatal depression if used in large doses or if the infant is delivered after eight minutes of induction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/38\">",
"     38",
"    </a>",
"    ]. Studies in immature animals have shown that a variety of sedatives and anesthetics may produce neurodegenerative effects. However, there is no strong evidence of adverse causal effects of anesthetics and related drugs on human brain development or risk of future learning disabilities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/39-43\">",
"     39-43",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     Succinylcholine",
"    </a>",
"    and other muscle relaxants have difficulty crossing the placenta because they are ionized. These drugs have no fetal or neonatal clinical effects at standard dosages.",
"   </p>",
"   <p>",
"    If anesthetics result in neonatal depression, appropriate resuscitative measures, including ventilatory assistance, should be instituted until the effects abate. Alternatively, specific reversal agents for opioids (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    )",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    benzodiazepines (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    ) may be administered to the neonate. Although anesthetics may result in temporary neonatal depression, there is no evidence of any long-term effects. Personnel other than the surgical team should be immediately available to assume responsibility for resuscitation of the depressed newborn as the anesthesiologist and obstetrician are responsible for the mother, and may not be able to leave her to care for the newborn, even when a regional anesthetic is functioning adequately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Complications and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy-specific complications and side effects of general anesthesia include neonatal depression (see above) and uterine relaxation, which is associated with increased blood loss. Two potential serious complications associated with general anesthesia in any patient are esophageal intubation and pulmonary aspiration of gastric contents.",
"   </p>",
"   <p>",
"    Potent inhalational agents, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/63/17397?source=see_link\">",
"     isoflurane",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/44/5830?source=see_link\">",
"     desflurane",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/47/23286?source=see_link\">",
"     sevoflurane",
"    </a>",
"    , decrease uterine tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/45\">",
"     45",
"    </a>",
"    ]. Inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    at any percentage mixture with oxygen has no effect on uterine tone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     REGIONAL ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques, medications, and complications associated with regional anesthesia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37574?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Options\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25977?source=see_link\">",
"     \"Neuraxial analgesia and anesthesia for labor and delivery: Drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional systemic medication may be required during the cesarean to enhance the comfort of women who received regional anesthesia. The surgeon should be notified when there is a need for such interventions.",
"   </p>",
"   <p>",
"    There are some situations in which the surgical incision is delayed while regional anesthesia is taking effect. This more commonly occurs with epidural, not spinal anesthesia, as epidural block has a slower onset than spinal block. In this situation, if the abdominal skin has been sterilely prepared, but the level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intensity of anesthesia is insufficient to commence surgery, a choice needs to be made: continue to wait for the regional anesthetic to take effect, inject additional local anesthetic, or convert to general anesthesia. This decision is best made after the obstetrician and the anesthesiologist have fully communicated their assessment of the situation with one another. In this setting, it may be helpful to continue monitoring the fetus by placing the transducer for monitoring the fetal heart rate in a sterile sleeve (with a liberal amount of conductive gel), and applying it to the sterile abdomen.",
"   </p>",
"   <p>",
"    In healthy women with a reassuring fetal heart rate pattern, supplemental oxygen is not necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/48\">",
"     48",
"    </a>",
"    ]. Recommendations for women with obstructive sleep apnea are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=see_link\">",
"     \"Intraoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94808869\">",
"    <span class=\"h2\">",
"     Restlessness&nbsp;and pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women become restless during cesarean delivery, and benefit from a low dose of a sedative. A benzodiazepine, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , is an excellent anxiolytic that can be administered in 1 to 2 mg doses, as needed. The effect on the fetus appears negligible, but midazolam's amnestic properties may prevent the mother from remembering the moment of birth. An advantage of benzodiazepines is that their effect may be reversed by administration of a specific antagonist,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    .",
"    <br/>",
"    <br/>",
"    Other agents used to supplement regional anesthesia include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , or small doses of opioids such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/50/5927?source=see_link\">",
"     remifentanil",
"    </a>",
"    . However, if an inadequate block results in pain, it is unwise to administer excessive doses of sedatives because they may obtund the patient and compromise airway reflexes, which may cause aspiration. Thus, the prudent approach is to intubate the trachea prior to administering large doses of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94808885\">",
"    <span class=\"h2\">",
"     Nausea and vomiting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nausea is a common complaint during cesarean delivery. An antiemetic may be indicated after other causes of nausea (eg, hypotension, surgical manipulation with an inadequate level of anesthesia) are excluded. A systematic review of randomized trials of interventions for preventing nausea and vomiting in women undergoing regional aesthesia for cesarean delivery concluded three interventions were effective: 5-HT3 antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ), dopamine antagonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ), and small doses of sedatives (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg/hour)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/49\">",
"     49",
"    </a>",
"    ]. For example, in one trial of cesarean under spinal anesthesia, administration of 4 mg ondansetron after umbilical cord clamping reduced the incidence of vomiting compared to placebo (by 58 and 36 percent, respectively); the severity of nausea was also significantly reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/50\">",
"     50",
"    </a>",
"    ]. Another trial showed that 4 mg ondansetron was superior to 10 mg metoclopramide and placebo in preventing nausea in parturients receiving epidural anesthesia for cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/51\">",
"     51",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/19/9527?source=see_link\">",
"     Droperidol",
"    </a>",
"    , a commonly used agent for treatment of nausea and vomiting, has been associated with cardiac dysrhythmias in nonpregnant women, even when used in doses as low as 2.5 mg. Since the potential for QT prolongation is dose dependent, initial doses of 0.625 to 1.25 mg are recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/52\">",
"     52",
"    </a>",
"    ]. If the benefit of droperidol treatment is felt to outweigh the risks of potentially serious arrhythmias, cardiac monitoring should be performed prior to therapy and continued for two to three hours after completing treatment to monitor for arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of complications from neuraxial anesthesia can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=see_link\">",
"     \"Adverse effects of neuraxial analgesia and anesthesia for obstetrics\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS AGAINST POSTPARTUM HEMORRHAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41639?source=see_link\">",
"     \"Uterotonic drugs for management of the third stage of labor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE ANALGESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery results in more acute and chronic postpartum pain than vaginal delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/53\">",
"     53",
"    </a>",
"    ]. Unrelieved pain causes maternal suffering and prevents optimal interaction with the newborn. The pathophysiological consequences of unrelieved pain may result in medical complications, as well. As an example, pain induced by movement may result in reticence to ambulate and thus increase the risk of formation of venous thrombi. Shallow breathing and splinting promotes atelectasis and predisposes to pneumonia. Good pain relief may help to prevent these effects.",
"   </p>",
"   <p>",
"    The risk of postpartum pain is not limited to untoward physiological effects; psychological sequelae may also occur. The presence of severe acute pain during the first 36 hours after delivery was noted to be associated with a three-fold increased likelihood of developing postpartum depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Options for postoperative analgesia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parenteral opioids &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H12#H12\">",
"       \"Management of postoperative pain\", section on 'Parenteral opioids'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Neuraxial opioids &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of postoperative pain\", section on 'Neuraxial (regional) analgesia'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Patient controlled epidural analgesia &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H21#H21\">",
"       \"Management of postoperative pain\", section on 'Patient controlled analgesia'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Oral analgesics &mdash; (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=see_link&amp;anchor=H26#H26\">",
"       \"Management of postoperative pain\", section on 'Oral opioids'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=see_link\">",
"       \"NSAIDs: Therapeutic use and variability of response in adults\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13311023\">",
"    <span class=\"h2\">",
"     Multimodal analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multimodal analgesia refers to the concurrent administration of different classes of analgesics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/55\">",
"     55",
"    </a>",
"    ]. The rationale of the multimodal approach is that each class of analgesic acts to inhibit pain at different sites of the pain pathway. Furthermore, the different analgesics potentiate one another, allowing use of relatively small doses of each agent. As each class of analgesic is associated with distinct side effects and only a relatively small dose of each agent is administered, the net effect is reduced incidence and severity of side effects and enhanced analgesia.",
"   </p>",
"   <p>",
"    Multimodal analgesia is the basis for current labor analgesia regimens, and it may also be used to provide effective analgesia after cesarean delivery. Patient-controlled epidural analgesia (PCEA) following delivery is rarely used as a single dose of intrathecal or epidural",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    may be administered proximate to the time of delivery to provide safe and effective analgesia in the immediate postoperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/56\">",
"     56",
"    </a>",
"    ]. Furthermore, the majority of hospitals lack coverage for PCEA use during the postpartum period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Local infiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have shown that injecting local anesthetics into the surgical site or using local anesthetics to perform an abdominal nerve block (transversus abdominis plane block) enhanced postoperative analgesia and decreased opioid consumption in patients who did not receive intrathecal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Local infiltration may be considered as an adjunct for post-cesarean analgesia, especially in patients who undergo general anesthesia for cesarean delivery, or who do not receive a dose of perioperative neuraxial opioid or postoperative patient-controlled epidural analgesia. A limitation of the efficacy of local infiltration is the relatively brief duration of action of standard local anesthetics. An increase in the duration of analgesic action may be achieved by the use of continuous local anesthetic wound infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/59,60\">",
"     59,60",
"    </a>",
"    ], or perhaps by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/52/27460?source=see_link\">",
"     liposomal bupivacaine",
"    </a>",
"    , an ultra-long acting local anesthetic formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/61\">",
"     61",
"    </a>",
"    ]. A concern of local infiltration is the potential for systemic local anesthetic toxicity due to the large mass of drug administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]; this concern may be diminished by the use of a slow-release depot local anesthetic formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39977/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Regional anesthesia for cesarean delivery requires a more intense block and a higher dermatomal level than analgesia for labor. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of regional or general anesthesia is influenced by factors such as the urgency of the procedure, maternal status, the presence of specific contraindications and physician and patient preference. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Choice of anesthetic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physiological changes associated with pregnancy can affect management of anesthesia. These include relative incompetence of the gastroesophageal sphincter, lowered pulmonary functional residual capacity, edema of upper airway tissues, and uterine compression of the aorta and vena cava. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Anesthesia issues in pregnant women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antepartum consultation with an anesthesiologist is particularly important in women with coagulopathy, severe obesity, restriction or abnormality of the spine, and cardiovascular or respiratory disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patient evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clear liquids may be ingested until two hours prior to surgery. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diet'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are to undergo general anesthesia, we suggest administration of drugs to reduce gastric acidity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Options include a nonparticulate antacid (eg, sodium citrate), histamine 2-receptor antagonist (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      ), proton pump inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      ), or prokinetic drug (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ). The goal is to raise intragastric pH and, for some agents, increase lower esophageal sphincter tone and lower intragastric volume. Due to the low incidence of aspiration pneumonitis, it is not possible to prove that prophylactic administration of these medications reduces the frequency of this event. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Reduction of gastric acidity/volume'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preoxygenation before general anesthesia is particularly important in pregnant women because of their reduced functional residual capacity. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'General anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic strategies to prevent regional anesthesia-induced hypotension include volume expansion using intravenous fluids, administration of vasopressors, and mechanical interventions. Nevertheless, hypotension often occurs, especially with spinal anesthesia, and should be promptly treated with vasopressor administration (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/36/39488?source=see_link\">",
"       phenylephrine",
"      </a>",
"      , ephedrine), intravenous fluids, and uterine displacement. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prevention and management of hypotension'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postoperative analgesia is important for patient comfort, as well as prevention of untoward physiological and psychological effects. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Postoperative analgesia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/1\">",
"      Afolabi BB, Lesi FE. Regional versus general anaesthesia for caesarean section. Cochrane Database Syst Rev 2012; 10:CD004350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/2\">",
"      Djabatey EA, Barclay PM. Difficult and failed intubation in 3430 obstetric general anaesthetics. Anaesthesia 2009; 64:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/3\">",
"      Hawkins JL, Chang J, Palmer SK, et al. Anesthesia-related maternal mortality in the United States: 1979-2002. Obstet Gynecol 2011; 117:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/4\">",
"      Bucklin BA, Hawkins JL, Anderson JR, Ullrich FA. Obstetric anesthesia workforce survey: twenty-year update. Anesthesiology 2005; 103:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/5\">",
"      Chang CC, Wang IT, Chen YH, Lin HC. Anesthetic management as a risk factor for postpartum hemorrhage after cesarean deliveries. Am J Obstet Gynecol 2011; 205:462.e1.",
"     </a>",
"    </li>",
"    <li>",
"     Russell, IF. Technique of anaesthesia for caesarean section, Chapter 8.8. In: Raising the Standards: A Compendium of Audit Recipies&mdash;Kinsella M, ed. (2006) Royal College of Anaesthetists.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/7\">",
"      Lam DT, Ngan Kee WD, Khaw KS. Extension of epidural blockade in labour for emergency Caesarean section using 2% lidocaine with epinephrine and fentanyl, with or without alkalinisation. Anaesthesia 2001; 56:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/8\">",
"      Hillyard SG, Bate TE, Corcoran TB, et al. Extending epidural analgesia for emergency Caesarean section: a meta-analysis. Br J Anaesth 2011; 107:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/9\">",
"      Munnur U, de Boisblanc B, Suresh MS. Airway problems in pregnancy. Crit Care Med 2005; 33:S259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/10\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 441: Oral intake during labor. Obstet Gynecol 2009; 114:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/11\">",
"      American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Practice guidelines for obstetric anesthesia: an updated report by the American Society of Anesthesiologists Task Force on Obstetric Anesthesia. Anesthesiology 2007; 106:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/12\">",
"      Pisegna JR, Martindale RG. Acid suppression in the perioperative period. J Clin Gastroenterol 2005; 39:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/13\">",
"      Paranjothy S, Griffiths JD, Broughton HK, et al. Interventions at caesarean section for reducing the risk of aspiration pneumonitis. Cochrane Database Syst Rev 2010; :CD004943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/14\">",
"      Rout CC, Rocke DA, Gouws E. Intravenous ranitidine reduces the risk of acid aspiration of gastric contents at emergency cesarean section. Anesth Analg 1993; 76:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/15\">",
"      Olsson GL, Hallen B, Hambraeus-Jonzon K. Aspiration during anaesthesia: a computer-aided study of 185,358 anaesthetics. Acta Anaesthesiol Scand 1986; 30:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/16\">",
"      Dewan DM, Floyd HM, Thistlewood JM, et al. Sodium citrate pretreatment in elective cesarean section patients. Anesth Analg 1985; 64:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/17\">",
"      Wollman SB, Marx GF. Acute hydration for prevention of hypotension of spinal anesthesia in parturients. Anesthesiology 1968; 29:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/18\">",
"      Morgan PJ, Halpern SH, Tarshis J. The effects of an increase of central blood volume before spinal anesthesia for cesarean delivery: a qualitative systematic review. Anesth Analg 2001; 92:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/19\">",
"      Cyna AM, Andrew M, Emmett RS, et al. Techniques for preventing hypotension during spinal anaesthesia for caesarean section. Cochrane Database Syst Rev 2006; :CD002251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/20\">",
"      Grylack LJ, Chu SS, Scanlon JW. Use of intravenous fluids before cesarean section: effects on perinatal glucose, insulin, and sodium homeostasis. Obstet Gynecol 1984; 63:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/21\">",
"      Kenepp NB, Kumar S, Shelley WC, et al. Fetal and neonatal hazards of maternal hydration with 5% dextrose before caesarean section. Lancet 1982; 1:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/22\">",
"      Smiley RM. Burden of proof. Anesthesiology 2009; 111:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/23\">",
"      Lee A, Ngan Kee WD, Gin T. A quantitative, systematic review of randomized controlled trials of ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean delivery. Anesth Analg 2002; 94:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/24\">",
"      Ngan Kee WD, Khaw KS, Lau TK, et al. Randomised double-blinded comparison of phenylephrine vs ephedrine for maintaining blood pressure during spinal anaesthesia for non-elective Caesarean section*. Anaesthesia 2008; 63:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/25\">",
"      Ngan Kee WD, Khaw KS, Tan PE, et al. Placental transfer and fetal metabolic effects of phenylephrine and ephedrine during spinal anesthesia for cesarean delivery. Anesthesiology 2009; 111:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/26\">",
"      Habib AS. A review of the impact of phenylephrine administration on maternal hemodynamics and maternal and neonatal outcomes in women undergoing cesarean delivery under spinal anesthesia. Anesth Analg 2012; 114:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/27\">",
"      Doherty A, Ohashi Y, Downey K, Carvalho JC. Phenylephrine infusion versus bolus regimens during cesarean delivery under spinal anesthesia: a double-blind randomized clinical trial to assess hemodynamic changes. Anesth Analg 2012; 115:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/28\">",
"      Hemmingsen C, Poulsen JA, Risbo A. Prophylactic ephedrine during spinal anaesthesia: double-blind study in patients in ASA groups I-III. Br J Anaesth 1989; 63:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/29\">",
"      Rout CC, Rocke DA, Brijball R, Koovarjee RV. Prophylactic intramuscular ephedrine prior to caesarean section. Anaesth Intensive Care 1992; 20:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/30\">",
"      Allen TK, George RB, White WD, et al. A double-blind, placebo-controlled trial of four fixed rate infusion regimens of phenylephrine for hemodynamic support during spinal anesthesia for cesarean delivery. Anesth Analg 2010; 111:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/31\">",
"      Banerjee A, Stocche RM, Angle P, Halpern SH. Preload or coload for spinal anesthesia for elective Cesarean delivery: a meta-analysis. Can J Anaesth 2010; 57:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/32\">",
"      Ngan Kee WD, Khaw KS, Ng FF. Prevention of hypotension during spinal anesthesia for cesarean delivery: an effective technique using combination phenylephrine infusion and crystalloid cohydration. Anesthesiology 2005; 103:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/33\">",
"      Adsumelli RS, Steinberg ES, Schabel JE, et al. Sequential compression device with thigh-high sleeves supports mean arterial pressure during Caesarean section under spinal anaesthesia. Br J Anaesth 2003; 91:695.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics and the American College of Obstetricians and Gynecologists. Guidelines for perinatal care, 7th ed, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/35\">",
"      Priebe HJ. Cricoid pressure: an expert's opinion. Minerva Anestesiol 2009; 75:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/36\">",
"      Lerman J. On cricoid pressure: \"may the force be with you\". Anesth Analg 2009; 109:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/37\">",
"      Samsoon GL, Young JR. Difficult tracheal intubation: a retrospective study. Anaesthesia 1987; 42:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/38\">",
"      Datta S, Ostheimer GW, Weiss JB, et al. Neonatal effect of prolonged anesthetic induction for cesarean section. Obstet Gynecol 1981; 58:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/39\">",
"      Istaphanous GK, Loepke AW. General anesthetics and the developing brain. Curr Opin Anaesthesiol 2009; 22:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/40\">",
"      Sprung J, Flick RP, Wilder RT, et al. Anesthesia for cesarean delivery and learning disabilities in a population-based birth cohort. Anesthesiology 2009; 111:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/41\">",
"      Bartels M, Althoff RR, Boomsma DI. Anesthesia and cognitive performance in children: no evidence for a causal relationship. Twin Res Hum Genet 2009; 12:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/42\">",
"      Flick RP, Lee K, Hofer RE, et al. Neuraxial labor analgesia for vaginal delivery and its effects on childhood learning disabilities. Anesth Analg 2011; 112:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/43\">",
"      Flood P. Fetal anesthesia and brain development. Anesthesiology 2011; 114:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/44\">",
"      ACOG Committee on Obstetric Practice. ACOG committee opinion No. 433: optimal goals for anesthesia care in obstetrics. Obstet Gynecol 2009; 113:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/45\">",
"      Vincent RD Jr. Anesthesia for the pregnant patient. Clin Obstet Gynecol 1994; 37:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/46\">",
"      Volmanen P, Akural E, Raudaskoski T, et al. Comparison of remifentanil and nitrous oxide in labour analgesia. Acta Anaesthesiol Scand 2005; 49:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/47\">",
"      Polvi HJ, Pirhonen JP, Erkkola RU. Nitrous oxide inhalation: effects on maternal and fetal circulations at term. Obstet Gynecol 1996; 87:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/48\">",
"      Van de Velde M. Emergency Caesarean delivery: is supplementary maternal oxygen necessary? Br J Anaesth 2009; 102:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/49\">",
"      Griffiths JD, Gyte GM, Paranjothy S, et al. Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section. Cochrane Database Syst Rev 2012; 9:CD007579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/50\">",
"      Abouleish EI, Rashid S, Haque S, et al. Ondansetron versus placebo for the control of nausea and vomiting during Caesarean section under spinal anaesthesia. Anaesthesia 1999; 54:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/51\">",
"      Pan PH, Moore CH. Comparing the efficacy of prophylactic metoclopramide, ondansetron, and placebo in cesarean section patients given epidural anesthesia. J Clin Anesth 2001; 13:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/52\">",
"      Wu JI, Lo Y, Chia YY, et al. Prevention of postoperative nausea and vomiting after intrathecal morphine for Cesarean section: a randomized comparison of dexamethasone, droperidol, and a combination. Int J Obstet Anesth 2007; 16:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/53\">",
"      Kainu JP, Sarvela J, Tiippana E, et al. Persistent pain after caesarean section and vaginal birth: a cohort study. Int J Obstet Anesth 2010; 19:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/54\">",
"      Eisenach JC, Pan PH, Smiley R, et al. Severity of acute pain after childbirth, but not type of delivery, predicts persistent pain and postpartum depression. Pain 2008; 140:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/55\">",
"      Kehlet H, Dahl JB. The value of \"multimodal\" or \"balanced analgesia\" in postoperative pain treatment. Anesth Analg 1993; 77:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/56\">",
"      Gadsden J, Hart S, Santos AC. Post-cesarean delivery analgesia. Anesth Analg 2005; 101:S62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/57\">",
"      Bamigboye AA, Hofmeyr GJ. Local anaesthetic wound infiltration and abdominal nerves block during caesarean section for postoperative pain relief. Cochrane Database Syst Rev 2009; :CD006954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/58\">",
"      Mishriky BM, George RB, Habib AS. Transversus abdominis plane block for analgesia after Cesarean delivery: a systematic review and meta-analysis. Can J Anaesth 2012; 59:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/59\">",
"      Liu SS, Richman JM, Thirlby RC, Wu CL. Efficacy of continuous wound catheters delivering local anesthetic for postoperative analgesia: a quantitative and qualitative systematic review of randomized controlled trials. J Am Coll Surg 2006; 203:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/60\">",
"      O'Neill P, Duarte F, Ribeiro I, et al. Ropivacaine continuous wound infusion versus epidural morphine for postoperative analgesia after cesarean delivery: a randomized controlled trial. Anesth Analg 2012; 114:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/61\">",
"      Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum 2011; 54:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/62\">",
"      Griffiths JD, Barron FA, Grant S, et al. Plasma ropivacaine concentrations after ultrasound-guided transversus abdominis plane block. Br J Anaesth 2010; 105:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/63\">",
"      Kato N, Fujiwara Y, Harato M, et al. Serum concentration of lidocaine after transversus abdominis plane block. J Anesth 2009; 23:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39977/abstract/64\">",
"      Davidson EM, Barenholz Y, Cohen R, et al. High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg 2010; 110:1018.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4480 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39977=[""].join("\n");
var outline_f39_2_39977=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF ANESTHETIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Urgency factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Maternal status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANESTHESIA ISSUES IN PREGNANT WOMEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREOPERATIVE ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Reduction of gastric acidity/volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5492576\">",
"      - Choice of medication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prevention and management of hypotension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5492583\">",
"      - Intravenous fluids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5492590\">",
"      - Vasopressor treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5492597\">",
"      - Cohydration and vasopressor infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5492604\">",
"      - Mechanical compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94808770\">",
"      Fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GENERAL ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Induction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Difficult airway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Maintenance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neonatal effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Complications and side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      REGIONAL ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94808869\">",
"      Restlessness&nbsp;and pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94808885\">",
"      Nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROPHYLAXIS AGAINST POSTPARTUM HEMORRHAGE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      POSTOPERATIVE ANALGESIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13311023\">",
"      Multimodal analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Local infiltration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/40/39562?source=related_link\">",
"      Adverse effects of neuraxial analgesia and anesthesia for obstetrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34248?source=related_link\">",
"      Airway management of pregnant women at delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31017?source=related_link\">",
"      Aspiration pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=related_link\">",
"      Intraoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9160?source=related_link\">",
"      Maternal gastrointestinal tract adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5703?source=related_link\">",
"      NSAIDs: Therapeutic use and variability of response in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25977?source=related_link\">",
"      Neuraxial analgesia and anesthesia for labor and delivery: Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/44/37574?source=related_link\">",
"      Neuraxial analgesia and anesthesia for labor and delivery: Options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41639?source=related_link\">",
"      Uterotonic drugs for management of the third stage of labor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_2_39978="HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels";
var content_f39_2_39978=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39978/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39978/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39978/contributors\">",
"     Paul Durrington, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39978/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39978/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/2/39978/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/2/39978/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/2/39978/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most trials of hypolipidemic therapy to prevent coronary heart disease (CHD) have evaluated therapies to lower low density lipoprotein (LDL) cholesterol. LDL-cholesterol lowering is associated with improvements in outcomes, particularly in trials of statin therapy, irrespective of whether it is attempted as primary or secondary prevention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The level of high density lipoprotein (HDL) cholesterol is inversely related to the presence or development of coronary heart disease, but a causal relationship has not been established (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Low HDL-C as a risk factor for coronary heart disease'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, the evidence that raising HDL is of benefit in reducing cardiovascular events has not been established. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Effect of increasing HDL-cholesterol on clinical outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Thus, for individuals with low HDL-cholesterol, the first priority of treatment is attempting to lower LDL-cholesterol using a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will address the role of HDL in cholesterol metabolism, its relation to coronary risk, and an approach to patients with low serum HDL-cholesterol levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE OF LIPID ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of different lipid disorders that can occur as either a primary event or secondary to some underlying disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43621?source=see_link\">",
"     \"Secondary causes of dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One definition of dyslipidemia is total cholesterol, LDL-cholesterol, triglyceride, apo-B, or Lp(a) concentrations above the ninetieth percentile or HDL-cholesterol or apo A-1 concentrations below the tenth percentile for the general population (",
"    <a class=\"graphic graphic_table graphicRef71803 \" href=\"mobipreview.htm?18/63/19453\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The prevalence of dyslipidemia varies with the population being studied. The incidence is highest in patients with premature coronary disease, which can be defined as occurring before 55 to 60 years of age in men and before 65 years in women. In such patients, the prevalence of dyslipidemia is as high as 80 to 88 percent compared to approximately 40 to 48 percent in age-matched controls without coronary disease (",
"    <a class=\"graphic graphic_figure graphicRef59944 \" href=\"mobipreview.htm?15/40/16014\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A disturbance in lipoprotein metabolism is often familial. In one study of 102 kindreds in which the proband had premature coronary disease, 54 percent of all probands (and 70 percent of those probands with a lipid abnormality) had a familial lipid disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common lipid abnormalities were lipoprotein(a) excess (alone or with other dyslipidemia), hypertriglyceridemia with hypoalphalipoproteinemia, and combined hyperlipidemia.",
"   </p>",
"   <p>",
"    Because of the association of familial dyslipidemia with premature CHD and a family history of CHD, a screening lipid analysis is recommended for first-degree relatives of patients with premature CHD. Screening should begin with a standard lipid profile. Further testing may include measurement of Lp(a) and apolipoprotein (apo) B levels. Approximately 25 percent of patients with premature CHD and a normal standard profile will have an abnormality of one of these lipoproteins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=see_link\">",
"     \"Screening guidelines for dyslipidemia\"",
"    </a>",
"    .) There are also nonlipid familial metabolic disorders that need to be considered, such as hyperhomocysteinemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HDL METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Much of the antiatherogenic effect of HDL is thought to be mediated by macrophage cholesterol efflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/5\">",
"     5",
"    </a>",
"    ]. The steps involved in the removal of excess cholesterol from macrophage to its ultimate disposition in the feces is known as reverse cholesterol transport. The cholesterol transported by HDL particles is derived from multiple sources (",
"    <a class=\"graphic graphic_figure graphicRef51253 \" href=\"mobipreview.htm?5/4/5199\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83853 \" href=\"mobipreview.htm?39/56/40839\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. These processes are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, the following steps are involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic and intestinal synthesis of small nascent HDL particles composed of phospholipid and apolipoproteins.",
"     </li>",
"     <li>",
"      Procurement of surface components (phospholipids, cholesterol, and apolipoproteins) from triglyceride-depleted chylomicron and VLDL remnants.",
"     </li>",
"     <li>",
"      Acquisition of free (unesterified) cholesterol from tissue sites (such as the liver and arterial wall) and other lipoproteins, as the initial HDL particles contain relatively little cholesterol. Apo A-I on the surface of HDL plays a central role in this process. It serves as a signal transduction protein to mobilize cholesterol esters from intracellular pools.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the peripheral tissues, nascent HDL particles promote the transfer of intracellular cholesterol to the cell membrane through the action of another protein known as ABCA1 (also called cholesterol efflux regulatory protein [CERP]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. ABCA1 expression on the cell surface is induced by cholesterol loading and reduced after the cholesterol has been removed by apolipoproteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mutations in the gene encoding for ABCA1 are associated with low serum HDL-cholesterol concentrations in familial HDL deficiency and Tangier disease. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Familial HDL deficiency and Tangier disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast, one common variant of this gene, R219K, is associated with higher HDL-cholesterol and lower triglyceride concentrations; carriers of this variant have a reduced severity of coronary disease, a slower progression of disease, and fewer coronary events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/11\">",
"     11",
"    </a>",
"    ]. Other genetic variations in the ABCA1 gene may also contribute to determining HDL concentrations in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After acquisition of free cholesterol by HDL, the cholesterol is esterified to cholesterol esters by lecithin:cholesterol acyl transferase (LCAT), a plasma enzyme that is activated primarily by apo A-I. By a similar mechanism, HDL can act as an acceptor for cholesterol released during lipolysis of triglyceride-containing lipoproteins.",
"     </li>",
"     <li>",
"      Lipid transfer proteins, such as cholesteryl ester transfer protein (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Cholesteryl ester transfer protein'",
"      </a>",
"      below), facilitate movement of the cholesterol esters to apo B-containing lipoproteins (VLDL, IDL, and LDL). This cholesterol can then be delivered to the tissues for steroid synthesis or storage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HDL subfractions",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-density lipoprotein can be subcategorized into subclasses based on physicochemical properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. The HDL2 density range is comprised of apo A-I HDL particles and the HDL3 density range is comprised of particles containing apo A-l and A-II. In some studies, apo A-I HDL particles are strongly associated with the cholesterol efflux-promoting effects of HDL, whereas the particles containing both apoproteins are less effective for mobilization of cholesterol from nonhepatic cells and appear to have other functions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. As an example, apo A-II appears to promote visceral fat accumulation and to impair the metabolism of large VLDL, which is rich in triglycerides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another method used to quantify HDL particle size is nuclear magnetic resonance (NMR) spectroscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. With this technique, large HDL particles are those between 8.8 nm and 13 nm and small HDL particles are 7.3 nm to 8.2 nm. Large HDL particles correspond to the gradient gel electrophoresis (GGE) HDL subclass designation HDL2b and 2a, and small HDL particles correspond to the GGE designation HDL 3b and 3c, respectively. The NMR approach also provides a measure of total HDL particle concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/16\">",
"     16",
"    </a>",
"    ], which has been shown to be more strongly associated with carotid intima media thickness, a surrogate measure of atherosclerosis, and ischemic cardiovascular events than HDL cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/20\">",
"     20",
"    </a>",
"    ]. Ion mobility (IM) is a newer method that quantifies HDL particle concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical importance of the different HDL subfractions is uncertain. Many case-control and prospective studies have demonstrated that the HDL2 subfraction and the plasma apo A-I concentration are better predictors of coronary atherosclerosis than total HDL-cholesterol or HDL3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. In contrast, the Physicians' Health Study and some other reports have shown similar associations of total HDL and HDL3 with CHD as HDL2 and apo A-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. This may reflect the participation of both HDL2 and HDL3 in reverse cholesterol transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cholesteryl ester transfer protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of cholesteryl ester transfer protein (CETP) in lipoprotein metabolism is complex, and the impact of CETP (",
"    <a class=\"graphic graphic_figure graphicRef51253 \" href=\"mobipreview.htm?5/4/5199\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef83853 \" href=\"mobipreview.htm?39/56/40839\">",
"     figure 3",
"    </a>",
"    ) on cardiovascular disease is not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating CETP mediates the transfer of cholesteryl esters from HDL particles to the triglyceride-rich lipoproteins LDL and VLDL; at the same time, triglycerides are transferred in the opposite direction. In this process, HDL-cholesterol is decreased, the cholesterol content in VLDL is increased, and LDL particles become smaller and denser. Intracellular CETP in both the periphery and the liver appears to promote cholesterol removal from peripheral cells and uptake by the liver.",
"   </p>",
"   <p>",
"    The potential cardiovascular effect of CETP inhibition is discussed below. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'CETP inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     LOW HDL-C AS A RISK FACTOR FOR CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An inverse relationship between the level of HDL-cholesterol (HDL-C) and the presence or development of coronary heart disease (CHD) is well established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, primary reductions in HDL-cholesterol are common in patients with premature CHD (usually defined as men less than 55 to 60 years of age and women less than 65 years of age) (",
"    <a class=\"graphic graphic_figure graphicRef59944 \" href=\"mobipreview.htm?15/40/16014\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/3,26,30-33\">",
"     3,26,30-33",
"    </a>",
"    ]. For example, low HDL-cholesterol levels are more common in patients with a first myocardial infarction than in age-matched controls without CHD (19 versus 4 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/26\">",
"     26",
"    </a>",
"    ]. The risk of low HDL-C is independent of the risk attributed to elevated levels of low-density lipoprotein cholesterol (LDL-C) in most analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Low serum HDL-cholesterol can occur as the sole abnormality or, more often, in association with hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H96329583\">",
"     'Isolated low HDL-C'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     HDL-C and coronary events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of CHD events in a normal population appears to be inversely related to the serum HDL-cholesterol concentration, with low levels (hypoalphalipoproteinemia) being associated with increased coronary risk (",
"    <a class=\"graphic graphic_table graphicRef57480 \" href=\"mobipreview.htm?0/2/35\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70170 \" href=\"mobipreview.htm?21/49/22302\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Based upon data from the Framingham Heart Study, the risk for myocardial infarction increases by about 25 percent for every 5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.13",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    decrement in serum HDL-cholesterol below median values for men and women.",
"   </p>",
"   <p>",
"    HDL levels are also predictive of coronary events in patients with known CHD across a broad range of LDL-cholesterol levels as demonstrated in the following two post hoc analyses of randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 13,173 patients in the LIPID and CARE trials found that low serum HDL-cholesterol was a significantly stronger predictor of CHD events in patients with an LDL-cholesterol &lt;125 than &ge;125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/37\">",
"       37",
"      </a>",
"      ]. For a 10",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.26",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      increase in HDL-cholesterol the event rate decreased by 29 percent in those with LDL-cholesterol &lt;125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      compared to 10 percent in those with an LDL-cholesterol &ge;125",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"     </li>",
"     <li>",
"      This relationship was also evaluated in a post hoc analysis of the Treating to New Targets trial (TNT) in which nearly 10,000 patients with established CHD were treated with either high or low dose statin therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/38\">",
"       38",
"      </a>",
"      ]. HDL-cholesterol levels were inversely predictive in multivariate analysis of the time to a first major cardiovascular event across the spectrum of LDL-cholesterol levels, including patients with treated LDL-cholesterol levels below 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.8",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Improvement in clinical outcome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H96329583\">",
"    <span class=\"h3\">",
"     Isolated low HDL-C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated low HDL-C, a condition that occurs when HDL-C is low and triglycerides and LDL-C are normal, predicts an increased risk for cardiovascular events in population studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/39\">",
"     39",
"    </a>",
"    ]. A 2011, individual-participant-data (over 200,000 individuals) meta-analysis of 23 studies in the Asia-Pacific region evaluated the prevalence and predictive ability (for CHD events) of isolated low HDL-C [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/39\">",
"     39",
"    </a>",
"    ]. The following findings were noted (low HDL-C was defined as values &lt;39.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;1.03",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    in men and 50.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [&lt;1.30",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    in women):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A low value of HDL-C (with or without associated co-lipid abnormalities) was seen significantly more often in Asians than non-Asians (33.1 versus 27.0 percent).",
"     </li>",
"     <li>",
"      The prevalence of isolated low HDL-C was significantly higher in Asians (22.4 versus 14.5 percent).",
"     </li>",
"     <li>",
"      There was a significant correlation between low HDL-C and CHD events in all individuals (hazard ratio 1.57; 95% CI 1.31-1.87).",
"     </li>",
"     <li>",
"      In Asians, isolated low levels of HDL-C were as strongly associated with CHD risk as low levels of HDL-C combined with other lipid abnormalities (HR 1.67, 95% CI1.27-2.19). This was not true in non-Asians.",
"     </li>",
"     <li>",
"      This study suggests that isolated low HDL-C in Asians is a distinct phenotype, which is strongly associated with an increased risk of CHD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HDL and atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The protective effect of HDL on atherosclerosis is suggested by the observation in humans that plasma HDL-cholesterol concentrations above 75",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    are associated with prolonged life (called the longevity syndrome) and relative freedom from coronary heart disease (",
"    <a class=\"graphic graphic_table graphicRef57480 \" href=\"mobipreview.htm?0/2/35\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/36,40\">",
"     36,40",
"    </a>",
"    ]. In a review of 18 kindreds with familial hyperalphalipoproteinemia, for example, men and women lived five and seven years longer than the general United States white population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further evidence comes from experimental models as atherosclerosis can be prevented in transgenic mice or rabbits expressing high levels of human apo A-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], by somatic gene transfer of apo A-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/43\">",
"     43",
"    </a>",
"    ], by the administration of oral apo A-1 mimetic peptides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/44\">",
"     44",
"    </a>",
"    ], or the administration of apo A-I Milano, which is a natural variant of apo A-I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/45\">",
"     45",
"    </a>",
"    ]. Furthermore, liver-directed gene transfer of human apo A-I results in significant regression of pre-existing atherosclerosis after four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HDL has a variety of vascular actions that can counteract atherogenesis in addition to macrophage cholesterol efflux described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HDL may promote maintenance of endothelial function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/27,47\">",
"       27,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HDL protects against oxidation of LDL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HDL protects against inflammation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HDL may, via a variety of actions, interfere with the thrombotic component of atherosclerosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/49-52\">",
"       49-52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, not all disorders associated with low HDL-cholesterol are accompanied by a predisposition to premature CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/53\">",
"     53",
"    </a>",
"    ]. Examples in which there is not a strong association with atherosclerosis include most patients with LCAT deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/54,55\">",
"     54,55",
"    </a>",
"    ], and patients with the apo A-I Milano variant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. A familial history of premature CHD is often helpful in distinguishing high-risk from low-risk patients with low HDL-cholesterol levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196198349\">",
"    <span class=\"h2\">",
"     Low HDL-C as a cause of coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the substantial body of evidence of an inverse relationship between levels of HDL-C and cardiovascular risk presented above, low levels of HDL-C have not been established as causative of this relationship or with the development of atherosclerosis. The argument for lack of causality for low levels of HDL-C comes from Mendelian randomization analyses, and the difficulty in demonstrating improved outcomes with therapies to raise HDL-C. The absence of premature coronary heart disease (CHD) in individuals with rare disorders such as Tangier disease, who have very low levels of HDL-C but not the predicted increase cardiovascular disease, provides some further support for the lack of association. As will be discussed, other components or functions of the HDL particle may be causative. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Familial HDL deficiency and Tangier disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Early Mendelian randomized analyses found that genetically decreased HDL-C levels were not associated with an increased risk of coronary heart disease events and that genetically increased HDL-C levels were not associated with a decreased risk. However, due to limitations of these studies, including small size and the use of single nucleotide polymorphisms (SNPs) that affect multiple lipid fractions, their conclusions were not definitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of whether higher levels of HDL-C cause a lower risk of coronary heart disease events was directly addressed in a 2012 Mendelian randomization study, which evaluated the relationship between HDL-C level and the risk of coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11335?source=see_link\">",
"     \"Mendelian randomization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The study had three principle components: case-control studies of the relationship between single nucleotide polymorphisms (SNPs) related to plasma low density lipoprotein cholesterol (LDL-C) risk of myocardial infarction (MI); case-control and prospective evaluations of the role of an uncommon SNP (LIPG Asn396Ser) that leads to elevated plasma HDL-C (a loss of function coding polymorphism at the endothelial lipase gene) but not to changes in other lipid or on-lipid risk factors; and a case-control study (of 12,482 individuals with MI and 41,331 controls) of a genetic score consisting of 14 common SNPs, each of which is associated (at p &lt;5x10",
"    <sup>",
"     -8",
"    </sup>",
"    ) with a small increase in HDL-C.",
"   </p>",
"   <p>",
"    For 9 of the 10 SNPs related to plasma LDL-C, the allele related to increased LDL-C was also associated with an increased risk of MI; this established the validity of the methodology. However, neither the uncommon variant for HDL-C, nor the risk score, was associated with a decreased risk of MI. Limitations of this study include an inconsistent relationship between endothelial lipase and atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/5\">",
"     5",
"    </a>",
"    ] and the fact that cholesterol-depleted HDL particles retain more anti-atherogenic functions than cholesterol-enriched HDL particles. Thus, the use of HDL-C as an intermediate between SNPs and cardiovascular end points does not address the issue of whether other modifications of the HDL particle might be of clinical use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/5,16\">",
"     5,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When evaluating the studies looking at HDL-C as a potential cause of CHD events, it should be kept in mind that the cholesterol component is only one of many structural or functional components of the HDL particle. Thus, if HDL-C is found not to be causally associated with CHD, it is possible that other attributes of HDL could be causal. For instance, it is possible that some component of the HDL particle or one of its functions may protect against CHD events or atherosclerosis. The genetic determinants of this component or function may or may not be linked to the HDL-C composition of the HDL particle. As an example, two polymorphisms in phospholipid transfer protein are associated with increased concentrations of smaller, cholesterol-depleted HDL particles and a lower cardiovascular event rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/61\">",
"     61",
"    </a>",
"    ]. The genetic studies presented in this section, and their seemingly different conclusions, underscore the complexity of the HDL particle as well as the importance of considering more than the cholesterol content of the HDL particles.",
"   </p>",
"   <p>",
"    Additional evidence that may explain why HDL-C has not been shown to be causal comes from the Multi-ethnic Study of Atherosclerosis (MESA) cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/20\">",
"     20",
"    </a>",
"    ]. In this study, the associations between HDL-C and HDL particle (HDL-P) number determined by NMR spectroscopy with carotid intimal medial thickness (a known predictor of cardiovascular risk) and coronary events (such as MI, CHD death, and angina) were evaluated in a group of nearly 6000 individuals without known CHD who were not taking lipid-lowering medication. After adjusting for each other (HDL-C or HDL-P) and for other known predictors of CHD events such as low density lipoprotein particle number, age, sex, hypertension, and smoking, a significant inverse relationship between HDL-P, but not HDL-C, and CHD risk (as measured by carotid thickness CHD events) persisted.",
"   </p>",
"   <p>",
"    This study adds to the concept that the inverse relationship between HDL and cardiovascular risk may be determined more by some structural or functional component of the HDL particle than by its cholesterol content. The role of measurement of HDL-P in cardiovascular risk assessment needs to be studied further before we recommend its routine use.",
"   </p>",
"   <p>",
"    In summary, HDL-C is a biomarker inversely associated with CHD risk, and it may still be of considerable use in assessing patients&rsquo; CAD risk. However, HDL-C is not likely causally responsible for that risk relationship.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H265590575\">",
"    <span class=\"h1\">",
"     CETP AND CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesteryl ester transfer protein (CETP) is integrally involved in HDL metabolism. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cholesteryl ester transfer protein'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The impact of circulating CETP on the risk of cardiovascular disease has been evaluated in a number of clinical studies. The prognostic role of CETP remains uncertain and may vary with triglyceride concentrations. The following studies demonstrate the potential relationship between CETP and CHD risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nested case-control study found that higher CETP levels were associated with an increased risk of CHD, particularly among adults with higher triglyceride levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/62\">",
"       62",
"      </a>",
"      ]. CETP was also directly associated with LDL-C concentrations and inversely associated with HDL-cholesterol concentrations. This is a potentially important observation since some have suggested that the association between CETP and CHD is attenuated after adjusting for HDL and LDL-cholesterol concentrations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second nested case-control study concluded that in men with low triglyceride levels, a higher CETP concentration was associated with a decreased risk of CHD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Polymorphisms affecting the activity of CETP, such as an isoleucine for valine substitution at codon 405 (I405V) are common. In a study from Denmark, for example, 43 percent of people studied were heterozygous for I405V and 11 percent were homozygous for I405V [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/65\">",
"     65",
"    </a>",
"    ]. Polymorphisms such as I405V that reduce the activity of CETP typically increase plasma HDL-cholesterol concentrations, although this has not been found consistently in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies that have looked at individuals with other polymorphisms that increase rather than decrease CETP activity have had conflicting results about the effect on risk of CHD. At least one CETP inhibitor has been associated with an increase in cardiovascular risk. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Elevated CETP activity'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H29\">",
"     'CETP inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CAUSES OF LOW PLASMA HDL-CHOLESTEROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, apo A-I plays an important role in HDL function. Low HDL-cholesterol levels due to hypoalphalipoproteinemia can occur in one of three ways: impaired synthesis of apo A-I (apo A-I deficiency, apo",
"    <span class=\"nowrap\">",
"     A-I/C-III",
"    </span>",
"    deficiency, apo A-I structural variants); increased catabolism (familial HDL deficiency and Tangier disease); or enzymatic changes affecting HDL metabolism (",
"    <a class=\"graphic graphic_table graphicRef70239 \" href=\"mobipreview.htm?27/61/28635\">",
"     table 3",
"    </a>",
"    ). The enzymatic changes are either genetically determined or, as with decreased activity of lipoprotein lipase, secondary to insulin resistance.",
"   </p>",
"   <p>",
"    A number of rare genetic disorders, which are described below, are associated with low HDL-cholesterol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the genes that account for the variation in serum HDL-cholesterol in the general population have not been identified. A locus on chromosome 9p has been noted in Mexican Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Familial hypoalphalipoproteinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial hypoalphalipoproteinemia is an autosomal dominant disorder that has been linked to premature CHD and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. Affected patients have a primary depression in HDL-cholesterol to below the tenth percentile compared with age and sex-matched controls. The defect appears to be due to mutations in the apo A-I gene; it accounts for 6 percent of Japanese subjects with low HDL-cholesterol concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Familial HDL deficiency and Tangier disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other familial forms of low serum HDL-cholesterol concentrations are familial HDL deficiency and Tangier disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familial HDL deficiency is an autosomal dominant disorder associated with very low serum HDL concentrations and premature coronary heart disease, but none of the systemic findings in Tangier disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tangier disease is an autosomal codominant condition in which homozygotes have no serum HDL-cholesterol and heterozygotes have HDL-cholesterol concentrations about one-half those in normal individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/76\">",
"       76",
"      </a>",
"      ]. HDL-mediated cholesterol efflux from macrophages and intracellular lipid trafficking are impaired in this disorder, leading to the presence of foam cells throughout the body and hepatosplenomegaly, peripheral neuropathy, and frequently premature coronary disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/77\">",
"       77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link&amp;anchor=H6#H6\">",
"       \"Hereditary neuropathies associated with generalized disorders\", section on 'Tangier disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      However, several studies have found a lower than expected rate of premature coronary artery disease in patients with Tangier disease, considering the very low HDL-C levels in these individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/77,78\">",
"       77,78",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The defect in both familial HDL deficiency and Tangier disease appears to involve mutations in the ATP-binding cassette transporter (ABCA1) gene, which, as noted above, encodes for the cholesterol efflux regulatory protein (CERP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/8,10,74,76,79\">",
"     8,10,74,76,79",
"    </a>",
"    ]. The above observations suggest that ABCA1 plays a central role in intracellular cholesterol transport, which is impaired in both disorders and is associated with increased HDL catabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/75,79\">",
"     75,79",
"    </a>",
"    ]. It has been suggested that reduced cholesterol efflux onto nascent HDL particles leads to lipid depleted particles that are then rapidly catabolized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H451293472\">",
"    <span class=\"h2\">",
"     Familial combined hypolipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial combined hypolipidemia is a rare inherited disorder in which affected members have low plasma levels of HDL-cholesterol, LDL-cholesterol, and triglycerides. Affected individuals do not appear to get premature coronary heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/80\">",
"     80",
"    </a>",
"    ]. Familial combined hypolipidemia is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H26#H26\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Low LDL-cholesterol levels'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Elevated CETP activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesteryl ester transfer protein (CETP) facilitates transfer of cholesteryl esters from HDL to triglyceride-enriched lipoproteins. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cholesteryl ester transfer protein'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Elevated CETP activity has been documented in normotriglyceridemic men with low HDL-cholesterol levels. In one series of 109 such men, 27 had increased CETP activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/81\">",
"     81",
"    </a>",
"    ]. The patients with normal CETP activity had 20 percent lower concentrations of lipoprotein lipase and 25 percent higher concentration of hepatic triglyceride lipase, other changes that can lower HDL-cholesterol.",
"   </p>",
"   <p>",
"    The plasma concentration and activity of CETP is associated with polymorphism of the CETP gene, referred to as TaqIB. The presence of a gene variant, termed B1, is associated with a higher CETP concentration and a lower HDL cholesterol level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/82\">",
"     82",
"    </a>",
"    ]. In an angiographic study of 807 men with documented coronary atherosclerosis, progression of the coronary disease was greatest in patients with the B1B1 genotype, intermediate in those with the B1B2 genotype, and least for those with B2B2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/82\">",
"     82",
"    </a>",
"    ]. Therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    slowed the progression of coronary atherosclerosis in the high-risk B1B1 carriers, but not in those with B2B2.",
"   </p>",
"   <p>",
"    However, other studies have found that higher CETP concentrations and lower HDL concentrations reduce the risk of coronary atherosclerosis, suggesting that the TaqIB polymorphism is probably not the causative mutation responsible for the lower HDL concentrations that result in an increased risk of CHD. Support for this comes from a report that evaluated two other common mutations in CETP, A373P and R451Q, in 8467 healthy subjects and 1636 patients with CHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/83\">",
"     83",
"    </a>",
"    ]. Compared to noncarriers, those who were heterozygous or homozygous for the",
"    <span class=\"nowrap\">",
"     A373P/R451Q",
"    </span>",
"    polymorphism had lower HDL-cholesterol concentrations. Women with this allele had a 36 percent lower risk of CHD (odds ratio 0.64); there was a similar trend in men (odds ratio 0.86). Similarly, some (but not all) studies have suggested an increased risk of CHD in patients with reduced CETP activity. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cholesteryl ester transfer protein'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The potential cardiovascular effect of CETP inhibition is discussed below. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'CETP inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lipoprotein lipase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipoprotein lipase normally lowers triglyceride levels through hydrolysis of triglyceride enriched lipoproteins and facilitation of cholesterol transfer from these lipoproteins to HDL. Most mutations of the LPL gene lead in heterozygotes to impaired LPL activity, low HDL levels, and hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. In one report, this pattern was present in 15 percent of patients with premature coronary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/3\">",
"     3",
"    </a>",
"    ]. Homozygotes have complete LPL deficiency with chylomicronemia and severe hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Elevated hepatic triglyceride lipase activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic triglyceride lipase lowers HDL by hydrolyzing triglycerides and phospholipids from HDL particles. Increased activity of this enzyme is frequently found in patients with low HDL-cholesterol levels with or without hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     LCAT deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;After acquisition of free cholesterol onto HDL, the cholesterol is esterified to cholesterol esters by lecithin:cholesterol acyltransferase (LCAT). Patients with homozygous mutations of the LCAT gene have very low serum HDL-cholesterol concentrations and typically present with severe corneal opacities, called the fish eye syndrome, and target cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9305?source=see_link\">",
"     \"Spiculated cells (echinocytes and acanthocytes) and target cells\"",
"    </a>",
"    .) Premature coronary disease is usually not part of the phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/54\">",
"     54",
"    </a>",
"    ], but can occur with some mutations even in heterozygotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low HDL-cholesterol is a component of the atherogenic lipid phenotype that is characterized by obesity, insulin resistance, type 2 diabetes mellitus, dyslipidemia, and hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/88\">",
"     88",
"    </a>",
"    ]. The atherogenic dyslipidemia consists of low HDL-cholesterol, moderate elevations in triglyceride-enriched remnant particles, and borderline to high LDL-cholesterol levels with a predominance of small, dense LDL particles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low serum HDL-cholesterol concentrations can be induced by certain drugs. Included in this group are beta blockers, benzodiazepines, and anabolic steroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/89-91\">",
"     89-91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low HDL-cholesterol concentrations can occur secondarily as a consequence of acute infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/92,93\">",
"     92,93",
"    </a>",
"    ] or other inflammatory conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Measurements of HDL-cholesterol can also be artifactually low in patients with gammopathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     EFFECT OF INCREASING HDL-CHOLESTEROL ON CLINICAL OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of increasing concentrations of HDL-cholesterol have been suggested by two randomized trials and by multivariate analyses of observations from clinical trials in which the goal was lowering LDL-cholesterol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Trials designed to increase HDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have found that raising HDL-cholesterol in patients with a low baseline serum concentration may be effective for secondary prevention of CHD:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     VA-HIT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VA-HIT trial included 2531 with CHD who had an LDL-cholesterol (&le;140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 3.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    an HDL-cholesterol (&le;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 1.0",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    and triglycerides &le;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.4",
"    <span class=\"nowrap\">",
"     mmol/L);",
"    </span>",
"    the patients were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/97\">",
"     97",
"    </a>",
"    ]. At one year, the following differences were noted in the gemfibrozil group:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The mean HDL-cholesterol level was 6 percent higher (34 versus 32",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      for placebo [0.9 versus 0.8",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      The mean total cholesterol was 4 percent lower (170 versus 177",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.4 versus 4.6",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      The mean triglyceride concentration was 31 percent lower (115 versus 166",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.3 versus 1.6",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These differences persisted throughout the study and the mean LDL-cholesterol concentration was the same in both groups. At five years, the combined primary end point of cardiac death and nonfatal myocardial infarction occurred less often in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    -treated group (17.3 versus 21.7 percent for placebo). The risk reduction was similar for both components of the composite end point, but the beneficial effect did not become apparent until two years after randomization. Patients taking gemfibrozil also had a lower rate of stroke (4.6 versus 6 percent for placebo), transient ischemic attacks (1.7 versus 4.2 percent), and carotid endarterectomy (1.3 versus 3.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/98\">",
"     98",
"    </a>",
"    ]. The reduction in stroke risk was evident after 6 to 12 months of therapy.",
"   </p>",
"   <p>",
"    Multivariable analysis of the VA-HIT trial found that the reduction in nonfatal myocardial infarction and CHD death was strongly correlated with the serum HDL-cholesterol concentration achieved with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    therapy, but was independent of changes in LDL-cholesterol or triglycerides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Trial of simvastatin plus niacin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second study suggested that additional benefits may be observed in patients with low HDL-cholesterol by combining a statin (which not only lowers LDL-cholesterol but may have additional cardiovascular benefits beyond lipid lowering) with a drug that increases HDL-cholesterol. This three year trial included 160 patients with clinical and angiographic evidence of CHD who had an HDL-cholesterol less than 35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and an LDL-cholesterol less than 145",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.75",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/100\">",
"     100",
"    </a>",
"    ]. Patients were randomly assigned to one of four regimens:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    plus niacin; antioxidants; simvastatin plus niacin plus antioxidants; or placebo. The mean serum LDL and HDL-cholesterol concentrations were unaltered in the antioxidant and placebo groups, but changed substantially (-42 and +26 percent, respectively) in the simvastatin plus niacin group. Compared with placebo, patients receiving simvastatin plus niacin were significantly less likely to sustain a cardiovascular event (death, myocardial infarction, stroke, or revascularization) and experienced angiographic regression (compared with progression for the placebo group) of the most significant coronary stenosis.",
"   </p>",
"   <p>",
"    The magnitude of the reduction of clinical events with drug therapy (relative risk 0.1 to 0.4 compared with placebo) in this study was greater than that typically observed with studies of statins alone, suggesting that treatment designed to raise HDL-cholesterol provides additional protection beyond that attributable to simply lowering LDL-cholesterol. However, caution should be exercised when comparing results of different study populations. In addition, the study group was relatively small and the confidence intervals wide, suggesting that larger studies comparing combination therapies with statins alone may be warranted. Antioxidants did not provide any additional benefits in this study of secondary prevention (and even appeared to attenuate the positive effects of combination drug therapy), which is consistent with most other clinical trial data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1481450550\">",
"    <span class=\"h3\">",
"     AIM-HIGH trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of the AIM-HIGH trials are presented elsewhere (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H708622578#H708622578\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'AIM-HIGH trial'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     ARBITER 2 study",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial examined the effects of extended-release (ER) niacin 1000 mg daily in 167 patients with known CHD and an HDL-cholesterol concentration below 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.16",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    who were already receiving a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'ARBITER 2 study'",
"    </a>",
"    .) Patients treated with ER niacin experienced a mean increase in HDL-cholesterol of 8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.21",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and, compared with those receiving placebo, had a trend toward decreased progression of carotid intima-media thickness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Investigational therapies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Infusion of apo A-I Milano",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the intravenous administration of apo A-I Milano to cholesterol-fed rabbits significantly reduced intimal thickening and macrophage content after balloon injury to the femoral and iliac arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/45\">",
"     45",
"    </a>",
"    ]. Based upon this and related observations, a pilot trial of intravenous therapy with recombinant apo A-1 Milano phospholipid complexes (ETC-216) was conducted in 57 patients who were within two weeks of onset of an acute coronary syndrome (ACS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/102\">",
"     102",
"    </a>",
"    ]. Subjects were randomly assigned to five weekly infusions of ETC-216 at 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 45",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or to placebo. Intracoronary ultrasonography (IVUS) was performed at baseline and repeated after completion of the study treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34234?source=see_link\">",
"     \"Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients treated with ETC-216 (combining both dosing groups) had a significant decrease in the mean percentage of coronary artery volume occupied by atheroma (from 38.96 to 37.91 percent), while there was no significant change for the placebo group (from 34.80 to 34.94 percent). Total atheroma volume also decreased significantly with ETC-216 but not placebo (-14.1 versus -2.9 mm3), as did mean maximum atheroma thickness (-0.042 versus -0.008 mm).",
"   </p>",
"   <p>",
"    The rapidity and magnitude of decrease in atheroma burden seen in this preliminary trial are of interest, but further study is required to confirm these findings and to assess the efficacy, safety, and cost-effectiveness of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Infusion of reconstituted HDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ERASE trial randomly assigned 183 patients with CHD to four weekly infusions of either placebo or one of two doses of reconstituted human HDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/103\">",
"     103",
"    </a>",
"    ]. The primary end point of the percentage change from baseline in coronary atheroma volume, as measured with IVUS two to three weeks after the last infusion, was not statistically different among the three groups. The higher of the two HDL doses was associated with a high incidence of liver function test abnormalities, which led to early study discontinuation in this group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     CETP inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Torcetrapib, anacetrapib, evacetrapib, and dalcetrapib inhibit cholesteryl ester transfer protein (CETP) and raise HDL-cholesterol levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. Investigation of torcetrapib has stopped due to the finding of an increased risk of cardiovascular events in the ILLUMINATE trial; dal-OUTCOMES, the major trial of dalcetrapib, was terminated early for futility. Anacetrapib and evacetrapib are under active investigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/28,107\">",
"     28,107",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Cholesteryl ester transfer protein'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Torcetrapib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical investigation of torcetrapib has stopped principally because of the finding of an increase in adverse in cardiovascular events associated with its use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/108\">",
"     108",
"    </a>",
"    ]. Failure of efficacy has also been noted for prevention of progression of atherosclerosis in imaging trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/109-112\">",
"     109-112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the randomized ILLUMINATE trial of over 15,000 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    , a significant increase in HDL-cholesterol (72 percent) and a decline in LDL-cholesterol (25 percent) were seen after 12 months of torcetrapib therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/108\">",
"     108",
"    </a>",
"    ]. However, the trial was stopped early because, at a mean follow-up of 550 days, torcetrapib therapy was associated with a significant increase in the risk of cardiovascular events (6.2 versus 5.0 percent with atorvastatin alone, HR 1.25, 95% CI 1.09-1.44) and death from any cause (1.2 versus 0.8 percent, HR 1.58, 95% CI 1.14-2.19, respectively). The increase in mortality was due to both cardiovascular and noncardiovascular causes (primarily cancer and infection).",
"   </p>",
"   <p>",
"    The mechanism(s) by which torcetrapib produced adverse effects are unknown, but may have been related in part to a significant 5.4 mmHg increase in systolic blood pressure (compared with 0.9 mmHg with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    alone) and a significant reduction in serum potassium (below 3.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in 2.3 versus 0.6 percent with atorvastatin alone), which may have reflected mineralocorticoid excess, a known cardiovascular risk factor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features of primary aldosteronism\", section on 'Cardiovascular risk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Anacetrapib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anacetrapib has been shown in two randomized clinical trials to significantly lower LDL-cholesterol by about 40 percent and raise HDL-cholesterol by over 130 percent, without causing a significant increase in systolic blood pressure as was seen with torcetrapib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. In the DEFINE trial, 1623 patients with coronary heart disease or at high risk and on statin therapy were randomly assigned to either anacetrapib 100 mg or placebo daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/114\">",
"     114",
"    </a>",
"    ]. By 24 weeks, anacetrapib, compared with placebo, was associated with a significantly lower level of LDL-cholesterol (45 versus 77",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.2 versus 2.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and a significantly higher level of HDL-cholesterol (101 versus 46",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.6 versus 1.2",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"   </p>",
"   <p>",
"    By",
"    76 weeks, there were no significant changes in blood pressure or electrolyte or aldosterone levels compared with placebo. Although the study was not powered to evaluate the impact of anacetrapib on overall safety and efficacy, there was no evidence of an adverse impact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Dalcetrapib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dalcetrapib has been investigated in several dose-ranging studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/115-119\">",
"     115-119",
"    </a>",
"    ]. In May of 2012, all clinical trials of the drug were stopped due to an absence of clinically meaningful efficacy at interim analysis.",
"   </p>",
"   <p>",
"    For example, the dal-Outcomes trial randomly assigned 15,871 patients with a recent acute coronary syndrome to receive dalcetrapib or placebo in addition to the best available evidence-based care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/120\">",
"     120",
"    </a>",
"    ]. The trial was terminated early for futility at a prespecified interim analysis when 71 percent of the projected total number of adverse events had occurred. Although dalcetrapib significantly increased HDL&ndash;cholesterol compared to placebo, there was no significant difference between the two groups (8.3 versus 8.0 percent, respectively) in the risk of the primary composite end point of death from coronary heart disease, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest with resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14681998\">",
"    <span class=\"h3\">",
"     Evacetrapib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evacetrapib has been found to not have demonstrable effects on blood pressure or adrenal synthesis of aldosterone or cortisol in preclinical studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/121\">",
"     121",
"    </a>",
"    ]. In a study of nearly 400 patients with elevated low-density lipoprotein (LDL) cholesterol or low HDL-cholesterol, patients were randomly assigned to either placebo, evacetrapib monotherapy at 30, 100, or 500, or 500 mg daily, or statin therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    , 40 mg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    20 m, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    , 10 mg daily) with or without evacetrapib 100 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/107\">",
"     107",
"    </a>",
"    ]. Evacetrapib monotherapy increased HDL-cholesterol by 54 to 129 percent and lowered LDL-cholesterol by from 14 to 36 percent in dose dependent manners. In combination with statin therapy, evacetrapib produced increase in HDL-C from 79 to 89 percent compared to placebo and decreases in LDL-C from 11 to 14 percent compared with statin monotherapy. Although the study was not powered to detect adverse clinical effects, none were observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Trials of LDL-cholesterol lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible support for the treatment of low HDL-cholesterol is provided by inference from clinical trials of LDL lowering strategies in which patients were further stratified by change in HDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/122,123\">",
"     122,123",
"    </a>",
"    ]. The importance of HDL-cholesterol was best illustrated in an analysis from the 4S trial in which 4444 patients with coronary disease and a baseline serum total cholesterol levels between 212 and 309",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.5 and 8.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were treated with a lipid-lowering diet and then randomly assigned to therapy with placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (20 to 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in an attempt to reduce total cholesterol below 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    There",
"    was an overall benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    therapy, the degree of which was related to the baseline serum HDL-cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/123\">",
"     123",
"    </a>",
"    ]. Patients with the lowest serum HDL-cholesterol (&lt;39",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and highest serum triglycerides (&gt;159",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    quartiles were compared to those with the highest HDL-cholesterol and lowest triglyceride quartiles (isolated high LDL-cholesterol). At five years, patients with low HDL-high triglycerides had a significantly higher major cardiac event rate on placebo (36 versus 21 percent for isolated high LDL) and derived greater benefit from simvastatin (relative risk 0.48 versus 0.86). The patients with low HDL-cholesterol and high triglycerides were also more likely to have other features of the metabolic syndrome (hypertension, diabetes, increased body mass index). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the Heart Protection Study, 20,536 patients with coronary disease, other occlusive arterial disease, or diabetes, and baseline plasma total cholesterol level of at least 135",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    were treated with a lipid-lowering diet and then randomly assigned to therapy with placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/124\">",
"     124",
"    </a>",
"    ]. The vascular event rate in patients in the placebo arm with baseline HDL-cholesterol concentrations below 35",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    was 29.9 percent, whereas patients with HDL-cholesterol concentrations of 42",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or higher had an event rate of 20.9 percent. The relative reduction in risk for patients treated with simvastatin was similar in patients with low and high baseline HDL-cholesterol concentrations, resulting in a higher absolute risk reduction in patients with low baseline HDL-cholesterol concentrations (7.3 versus 3.9 percent absolute reduction). Although the authors did not discuss whether this difference was statistically significant, the greater reduction in absolute risk in patients with low HDL-cholesterol concentrations is consistent with what was seen in other studies.",
"   </p>",
"   <p>",
"    A post-hoc subset analysis of 2073 patients in the LIPID study with a recent myocardial infarction or unstable angina who had a low LDL-cholesterol (140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.6",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less) and low HDL-cholesterol (40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less) who also had a triglyceride level of 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.4",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or less found that absolute and relative risk reductions for cardiovascular events and mortality with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    40 mg daily were similar to those seen in the overall cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/125\">",
"     125",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'LIPID trial'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the indirect evidence in support of benefit from raising HDL-cholesterol presented above, a 2009 meta-analysis of 108 randomized trials involving nearly 300,000 patients at risk for cardiovascular events of therapy (drugs or diet) failed to come to the same conclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/126\">",
"     126",
"    </a>",
"    ]. After adjustment for changes in LDL-cholesterol, there was no association between treatment-induced increases in HDL-cholesterol with risk ratios for CHD deaths, CHD events, or total deaths. It should be noted that this meta-analysis included clinical trials of CETP inhibition with torcetrapib, which has been shown to have off-target toxicity. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'CETP inhibition'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     TREATMENT GUIDELINES FOR LOW HDL DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the above studies, therapy aimed at raising HDL-cholesterol levels into the normal range has been advocated by some investigators in patients with overt CHD and those at high risk because of a strong family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/127-129\">",
"     127-129",
"    </a>",
"    ]. The separate issue of how elevated HDL impacts treatment decisions is discussed elsewhere. (See",
"    <a class=\"local\" href=\"#H38\">",
"     'Patients with high HDL'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The National Cholesterol Education Program (Adult Treatment Program [ATP] III) guidelines, published in 2001, identified the following HDL-cholesterol levels as high risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/130\">",
"     130",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HDL-cholesterol less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      For patients with the metabolic syndrome (insulin resistance syndrome or syndrome X), gender adjusted HDL-cholesterol levels of less than 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.0",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in men and 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in women. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The goals of treating patients with low HDL-cholesterol have not been firmly established; although clinical trial data suggest that raising HDL-cholesterol will reduce risk, the currently available evidence is not sufficient to specify a therapeutic goal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. Nevertheless, ATP III recommends the following approach to the management of patients with low HDL-cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/130\">",
"     130",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary target of therapy is LDL cholesterol; this goal should be reached before treating low HDL-cholesterol. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=see_link\">",
"       \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intensify weight management, increase physical activity, and encourage smoking cessation.",
"     </li>",
"     <li>",
"      When a low HDL-cholesterol is associated with high triglycerides (200 to 499",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.3 to 5.6",
"      <span class=\"nowrap\">",
"       mmol/dL]),",
"      </span>",
"      first achieve non-HDL goals. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=see_link&amp;anchor=H14#H14\">",
"       \"ATP III guidelines for treatment of high blood cholesterol\", section on 'Non-HDL-cholesterol'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If triglycerides are &lt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&lt;2.3",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      ie, isolated low HDL-cholesterol, consider treatment with nicotinic acid or a fibrate (see",
"      <a class=\"local\" href=\"#H37\">",
"       'Lipid lowering drugs'",
"      </a>",
"      below), although treatment in these circumstances should primarily be reserved for patients with CHD or CHD equivalents. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=see_link\">",
"       \"Lipid lowering with drugs other than statins and fibrates\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although not mentioned in ATP III, drug therapy can also be considered in patients with isolated low HDL-cholesterol who have first-degree relatives with a similar lipid profile and early onset CHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned, the therapy of hypoalphalipoproteinemia involves both lifestyle modifications and appropriate medications. Exercise, weight loss (in overweight subjects) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/132,133\">",
"     132,133",
"    </a>",
"    ], smoking cessation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/134\">",
"     134",
"    </a>",
"    ], and substitution of monounsaturated for saturated fatty acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/135\">",
"     135",
"    </a>",
"    ] all can raise HDL-cholesterol (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=see_link\">",
"     \"Fish oil and marine omega-3 fatty acids\"",
"    </a>",
"    ). In addition, medications that lower HDL-cholesterol (beta blockers, benzodiazepines, and androgens) should be discontinued, if possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/89-91\">",
"     89-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials produced conflicting data on the effect of calcium supplementation on serum HDL-cholesterol. A significant 7 percent increase in serum HDL was noted in a trial of normal postmenopausal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/136\">",
"     136",
"    </a>",
"    ], while no change was noted in a trial of middle-aged men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/137\">",
"     137",
"    </a>",
"    ]. Although more data are needed, it is possible that these disparate findings are due in part to differences in the populations tested. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=see_link&amp;anchor=H17#H17\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Calcium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The different classes of hypolipidemic drugs have different effects on HDL-cholesterol (",
"    <a class=\"graphic graphic_table graphicRef75715 \" href=\"mobipreview.htm?21/47/22268\">",
"     table 4",
"    </a>",
"    ). Nicotinic acid (niacin),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , and estrogen replacement therapy in postmenopausal women produce the most pronounced elevations (15 to 30 percent). Gemfibrozil, for example, raises the HDL-cholesterol concentration via both direct stimulation of the hepatic synthesis of apo A-I and reduced cholesterol transfer from HDL to VLDL due to a decline in VLDL levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Lipid lowering drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal drug therapy of hypoalphalipoproteinemia is determined in part by the presence or absence of other lipid abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/35\">",
"     35",
"    </a>",
"    ]. In patients who also have high LDL-cholesterol levels, attainment of goal LDL-cholesterol should first be achieved, usually with a statin. A persistent reduction in HDL-cholesterol can be most effectively treated with nicotinic acid.",
"   </p>",
"   <p>",
"    When the low HDL-cholesterol is accompanied by a high triglyceride level, fibrate therapy can be beneficial. However, combined therapy with a statin and a fibrate is associated with an increased risk of muscle toxicity.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    is the fibrate of choice in this setting because, unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , it does not compete with the glucuronidation elimination pathway for statins. The risk of myopathy with combined statin and nicotinic acid therapy appears to be low. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, monotherapy with fibrate therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    ) can be used initially in patients with hypertriglyceridemia and low HDL-cholesterol levels if LDL-cholesterol levels are normal or minimally elevated (100 to 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.6 to 3.4",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    After the hypertriglyceridemia is reversed, residual elevations of LDL-cholesterol should be addressed with a statin or, in statin-intolerant patients, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    or a bile acid sequestrant.",
"   </p>",
"   <p>",
"    Nicotinic acid is the most effective therapy for high risk patients who have low HDL-cholesterol levels without any other lipid abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/138-141\">",
"     138-141",
"    </a>",
"    ]. In one study of 37 such patients, for example, nicotinic acid (in a mean dose of 4.5",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    raised serum HDL-cholesterol by 30 percent versus only 10 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/140\">",
"     140",
"    </a>",
"    ]. The combination of gemfibrozil and nicotinic acid is more effective than monotherapy, raising HDL-cholesterol by as much as 45 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/141\">",
"     141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who cannot tolerate nicotinic acid should be treated with a fibrate or, if necessary, a statin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/140\">",
"     140",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/36/17993?source=see_link\">",
"     Simvastatin",
"    </a>",
"    at a dose of 40 or 80",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    may be more effective for raising HDL-cholesterol than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/142,143\">",
"     142,143",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    may be even more effective, raising HDL-cholesterol by up to 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/35,144\">",
"     35,144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of cholesterol ester transfer protein is another way to raise serum HDL-cholesterol. Such drugs remain investigational and one of these drugs, torcetrapib, has been associated with a significant increase in mortality and morbidity. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'CETP inhibition'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     PATIENTS WITH HIGH HDL",
"    </span>",
"    &nbsp;&mdash;&nbsp;High serum HDL-cholesterol (&gt;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.6",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    is associated with a lower risk of CHD, implying that an elevated LDL-cholesterol level may be less important in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/145\">",
"     145",
"    </a>",
"    ]. This pattern is most likely to occur in women. However, the",
"    <span class=\"nowrap\">",
"     AFCAPS/TexCAPS",
"    </span>",
"    trial, which is the only primary prevention study that included women, all of whom were postmenopausal, specifically excluded women and men with serum HDL-cholesterol above 47 and 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.2",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    respectively.",
"   </p>",
"   <p>",
"    The reason(s) for this association is not well understood. HDL-cholesterol levels are positively associated with HDL particle size, and these same individuals most often have large LDL particles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=see_link&amp;anchor=H22#H22\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Small dense LDL (LDL phenotype B)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In order to evaluate whether elevated LDL-cholesterol is associated with increased numbers of LDL particles in patients with an elevated HDL-cholesterol, we advocate measurements of apolipoprotein B or NMR LDL particle concentration. In situations when the LDL particle concentration is not elevated, we do not recommend LDL cholesterol lowering therapy. However, if the LDL particle concentration is elevated for that particular individual's cardiovascular risk profile, we do recommend LDL-cholesterol lowering therapy.",
"   </p>",
"   <p>",
"    A separate issue is whether the HDL particles are functional in patients with high HDL-cholesterol levels. In one series of patients with elevated HDL-cholesterol levels who had coronary artery disease, it was found that the HDL particles were functionally impaired with regard to anti-oxidant and anti-inflammatory activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/146\">",
"     146",
"    </a>",
"    ]. In the future, we anticipate that HDL biology will extend beyond static measures of concentration to functional measures of their anti-atherothrombotic properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, there are limited data concerning the optimal approach to patients with elevations in both LDL-cholesterol and HDL-cholesterol. We follow the ATP III guidelines, in which the combination of the LDL-cholesterol value and risk factors for CHD are used to determine the need for cholesterol-lowering therapy independent of HDL-C (ie, one risk factor is subtracted for serum HDL-cholesterol &ge;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.6",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several issues need to be addressed in premenopausal women with LDL-cholesterol &ge;160",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and HDL-cholesterol &ge;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.6",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    including planned pregnancy, regular use of effective contraception, and family history of early onset cardiovascular disease or type 2 diabetes mellitus. Even though the cardiovascular event rate is very low, the individual patient may express concerns about long-term risk of hypercholesterolemia. In these settings, we provide nutritional counseling and suggest dietary complementary approaches that include diets high in soluble fiber, soy, phytoestrogens, flaxseed, and garlic. If pharmacologic therapy is desired in those patients adherent to a low-fat and cholesterol diet, a nonsystemic agent (bile acid sequestrant) is advisable if pregnancy is a possibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of increasing the concentration of HDL-cholesterol in patients with low HDL-cholesterol levels have been suggested by two randomized trials and multivariate analyses of observations from clinical trials in which the goal was lowering LDL-cholesterol. However, a meta-analysis of studies in which therapies were used to raise HDL-cholesterol failed to show benefit. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Meta-analysis'",
"    </a>",
"    above.) In addition, a causal relationship between HDL-C and coronary heart disease events has not been established. (See",
"    <a class=\"local\" href=\"#H196198349\">",
"     'Low HDL-C as a cause of coronary heart disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Thus, we do not recommend drug treatment directed specifically at low HDL-cholesterol. This is consistent with the 2006",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    update on the guidelines for secondary prevention of patients with coronary and other atherosclerotic vascular disease that did not address the issue of treating low HDL-cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/2/39978/abstract/148\">",
"     148",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Treatment guidelines for low HDL disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Exercise, weight loss (in overweight subjects), smoking cessation, and substitution of monounsaturated for saturated fatty acids raise HDL-cholesterol. As health benefits are associated with each of these, we recommend their use in patients with low HDL-cholesterol. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Medical therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following summarizes other important points in this topic:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HDL particles possess multiple anti-atherothrombotic properties. Reverse cholesterol transport is considered the most important of the anti-atherothrombotic properties of HDL (",
"      <a class=\"graphic graphic_figure graphicRef51253 \" href=\"mobipreview.htm?5/4/5199\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'HDL metabolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low levels of HDL-cholesterol remain an important predictor of CHD events even among statin-treated patients who achieve LDL cholesterol levels less than 70",
"      <span class=\"nowrap\">",
"       mg/dL.",
"      </span>",
"      High HDL-cholesterol levels are associated with a decreased risk of CHD events. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Low HDL-C as a risk factor for coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CETP inhibitors represent a new class of lipid altering drugs, which raise HDL-cholesterol as one of their effects. The future role for these agents remains under investigation in randomized clinical trials, although studies of dalcetrapib and torcetrapib have stopped. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'CETP inhibition'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Irrespective of HDL-cholesterol level, all adults should have a low density lipoprotein cholesterol target set and an attempt should be made to reach that target with statin therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/1\">",
"      Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/2\">",
"      Gotto AM Jr, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000; 101:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/3\">",
"      Genest JJ Jr, Martin-Munley SS, McNamara JR, et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992; 85:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/4\">",
"      Roncaglioni MC, Santoro L, D'Avanzo B, et al. Role of family history in patients with myocardial infarction. An Italian case-control study. GISSI-EFRIM Investigators. Circulation 1992; 85:2065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/5\">",
"      Rosenson RS, Brewer HB Jr, Davidson WS, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation 2012; 125:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/6\">",
"      Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J Am Coll Cardiol 2004; 43:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/7\">",
"      Tall AR. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest 1990; 86:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/8\">",
"      Marcil M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/9\">",
"      Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008; 451:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/10\">",
"      Lawn RM, Wade DP, Garvin MR, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/11\">",
"      Clee SM, Zwinderman AH, Engert JC, et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation 2001; 103:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/12\">",
"      Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. J Clin Invest 2004; 114:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/13\">",
"      Pajukanta P. Do DNA sequence variants in ABCA1 contribute to HDL cholesterol levels in the general population? J Clin Invest 2004; 114:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/14\">",
"      Albers JJ, Aladjem F. Precipitation of 125 I-labeled lipoproteins with specific polypeptide antisera. Evidence for two populations with differing polypeptide compositions in human high density lipoproteins. Biochemistry 1971; 10:3436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/15\">",
"      Puchois P, Kandoussi A, Fievet P, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis 1987; 68:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/16\">",
"      Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/17\">",
"      Huang Y, von Eckardstein A, Wu S, Assmann G. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 1995; 15:1412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/18\">",
"      van 't Hooft FM, Ruotolo G, Boquist S, et al. Human evidence that the apolipoprotein a-II gene is implicated in visceral fat accumulation and metabolism of triglyceride-rich lipoproteins. Circulation 2001; 104:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/19\">",
"      Barter PJ, Nicholls S, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res 2004; 95:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/20\">",
"      Mackey RH, Greenland P, Goff DC Jr, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 2012; 60:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/21\">",
"      Krauss RM, Wojnooski K, Orr J, et al. Changes in lipoprotein subfraction concentration and composition in healthy individuals treated with the CETP inhibitor anacetrapib. J Lipid Res 2012; 53:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/22\">",
"      Salonen JT, Salonen R, Sepp&auml;nen K, et al. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991; 84:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/23\">",
"      Maciejko JJ, Holmes DR, Kottke BA, et al. Apolipoprotein A-I as a marker of angiographically assessed coronary-artery disease. N Engl J Med 1983; 309:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/24\">",
"      Miller NE, Hammett F, Saltissi S, et al. Relation of angiographically defined coronary artery disease to plasma lipoprotein subfractions and apolipoproteins. Br Med J (Clin Res Ed) 1981; 282:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/25\">",
"      Stampfer MJ, Sacks FM, Salvini S, et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/26\">",
"      Buring JE, O'Connor GT, Goldhaber SZ, et al. Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction. Circulation 1992; 85:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/27\">",
"      Oram JF, Johnson CJ, Brown TA. Interaction of high density lipoprotein with its receptor on cultured fibroblasts and macrophages. Evidence for reversible binding at the cell surface without internalization. J Biol Chem 1987; 262:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/28\">",
"      Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-&beta;-HDL formation and increases reverse cholesterol transport. J Lipid Res 2010; 51:3443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/29\">",
"      Gordon DJ, Rifkind BM. High-density lipoprotein--the clinical implications of recent studies. N Engl J Med 1989; 321:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/30\">",
"      Genest J Jr, McNamara JR, Ordovas JM, et al. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol 1992; 19:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/31\">",
"      Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged &lt; or = 50 years) and women (&lt; or = 60 years) with coronary artery disease. Am J Cardiol 1993; 71:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/32\">",
"      Genest J Jr, Bard JM, Fruchart JC, et al. Familial hypoalphalipoproteinemia in premature coronary artery disease. Arterioscler Thromb 1993; 13:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/33\">",
"      Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation 1992; 86:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/34\">",
"      Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/35\">",
"      Rosenson RS. Low HDL-C: a secondary target of dyslipidemia therapy. Am J Med 2005; 118:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/36\">",
"      Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980s. Am Heart J 1983; 106:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/37\">",
"      Sacks FM, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation 2002; 105:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/38\">",
"      Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/39\">",
"      Huxley RR, Barzi F, Lam TH, et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation 2011; 124:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/40\">",
"      Glueck CJ, Gartside P, Fallat RW, et al. Longevity syndromes: familial hypobeta and familial hyperalpha lipoproteinemia. J Lab Clin Med 1976; 88:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/41\">",
"      Rubin EM, Krauss RM, Spangler EA, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/42\">",
"      Duverger N, Kruth H, Emmanuel F, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996; 94:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/43\">",
"      Benoit P, Emmanuel F, Caillaud JM, et al. Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation 1999; 99:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/44\">",
"      Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/45\">",
"      Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994; 90:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/46\">",
"      Tangirala RK, Tsukamoto K, Chun SH, et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999; 100:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/47\">",
"      Kuhn FE, Mohler ER, Satler LF, et al. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol 1991; 68:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/48\">",
"      Kontush A, Chantepie S, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003; 23:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/49\">",
"      Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/50\">",
"      Griffin JH, Kojima K, Banka CL, et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/51\">",
"      Epand RM, Stafford A, Leon B, et al. HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity. Arterioscler Thromb 1994; 14:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/52\">",
"      Aoyama T, Yui Y, Morishita H, Kawai C. Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris. Circulation 1990; 81:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/53\">",
"      Rader DJ, Ikewaki K, Duverger N, et al. Very low high-density lipoproteins without coronary atherosclerosis. Lancet 1993; 342:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/54\">",
"      Funke H, von Eckardstein A, Pritchard PH, et al. A molecular defect causing fish eye disease: an amino acid exchange in lecithin-cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A 1991; 88:4855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/55\">",
"      Klein HG, Lohse P, Pritchard PH, et al. Two different allelic mutations in the lecithin-cholesterol acyltransferase gene associated with the fish eye syndrome. Lecithin-cholesterol acyltransferase (Thr123----Ile) and lecithin-cholesterol acyltransferase (Thr347----Met). J Clin Invest 1992; 89:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/56\">",
"      Bekaert ED, Alaupovic P, Knight-Gibson CS, et al. Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles. J Lipid Res 1993; 34:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/57\">",
"      Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/58\">",
"      Haase CL, Tybj&aelig;rg-Hansen A, Grande P, Frikke-Schmidt R. Genetically elevated apolipoprotein A-I, high-density lipoprotein cholesterol levels, and risk of ischemic heart disease. J Clin Endocrinol Metab 2010; 95:E500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/59\">",
"      Haase CL, Tybj&aelig;rg-Hansen A, Qayyum AA, et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab 2012; 97:E248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/60\">",
"      Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/61\">",
"      Vergeer M, Boekholdt SM, Sandhu MS, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010; 122:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/62\">",
"      Boekholdt SM, Kuivenhoven JA, Wareham NJ, et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004; 110:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/63\">",
"      Wolfe ML, Rader DJ. Cholesteryl ester transfer protein and coronary artery disease: an observation with therapeutic implications. Circulation 2004; 110:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/64\">",
"      Borggreve SE, Hillege HL, Dallinga-Thie GM, et al. High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007; 28:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/65\">",
"      Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. Circulation 2000; 101:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/66\">",
"      Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990; 323:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/67\">",
"      Kuivenhoven JA, de Knijff P, Boer JM, et al. Heterogeneity at the CETP gene locus. Influence on plasma CETP concentrations and HDL cholesterol levels. Arterioscler Thromb Vasc Biol 1997; 17:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/68\">",
"      Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003; 290:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/69\">",
"      Cohen JC, Kiss RS, Pertsemlidis A, et al. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/70\">",
"      Arya R, Duggirala R, Almasy L, et al. Linkage of high-density lipoprotein-cholesterol concentrations to a locus on chromosome 9p in Mexican Americans. Nat Genet 2002; 30:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/71\">",
"      Vergani C, Bettale G. Familial hypo-alpha-lipoproteinemia. Clin Chim Acta 1981; 114:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/72\">",
"      Glueck CJ, Daniels SR, Bates S, et al. Pediatric victims of unexplained stroke and their families: familial lipid and lipoprotein abnormalities. Pediatrics 1982; 69:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/73\">",
"      Yamakawa-Kobayashi K, Yanagi H, Fukayama H, et al. Frequent occurrence of hypoalphalipoproteinemia due to mutant apolipoprotein A-I gene in the population: a population-based survey. Hum Mol Genet 1999; 8:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/74\">",
"      Brooks-Wilson A, Marcil M, Clee SM, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999; 22:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/75\">",
"      Emmerich J, Verg&egrave;s B, Tauveron I, et al. Familial HDL deficiency due to marked hypercatabolism of normal apoA-I. Arterioscler Thromb 1993; 13:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/76\">",
"      Rust S, Rosier M, Funke H, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet 1999; 22:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/77\">",
"      Serfaty-Lacrosniere C, Civeira F, Lanzberg A, et al. Homozygous Tangier disease and cardiovascular disease. Atherosclerosis 1994; 107:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/78\">",
"      Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis 2010; 208:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/79\">",
"      Bodzioch M, Ors&oacute; E, Klucken J, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet 1999; 22:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/80\">",
"      Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010; 363:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/81\">",
"      Tato F, Vega GL, Grundy SM. Bimodal distribution of cholesteryl ester transfer protein activities in normotriglyceridemic men with low HDL cholesterol concentrations. Arterioscler Thromb Vasc Biol 1995; 15:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/82\">",
"      Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998; 338:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/83\">",
"      Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, et al. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. Circulation 2000; 102:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/84\">",
"      Nordestgaard BG, Abildgaard S, Wittrup HH, et al. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997; 96:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/85\">",
"      Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999; 99:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/86\">",
"      Blades B, Vega GL, Grundy SM. Activities of lipoprotein lipase and hepatic triglyceride lipase in postheparin plasma of patients with low concentrations of HDL cholesterol. Arterioscler Thromb 1993; 13:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/87\">",
"      Kuivenhoven JA, van Voorst tot Voorst EJ, Wiebusch H, et al. A unique genetic and biochemical presentation of fish-eye disease. J Clin Invest 1995; 96:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/88\">",
"      Abate N, Vega GL, Garg A, Grundy SM. Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. Atherosclerosis 1995; 118:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/89\">",
"      Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/90\">",
"      Wallace RB, Hunninghake DB, Reiland S, et al. Alterations of plasma high-density lipoprotein cholesterol levels associated with consumption of selected medications. The Lipid Research Clinics Program Prevalence Study. Circulation 1980; 62:IV77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/91\">",
"      Bagatell CJ, Heiman JR, Matsumoto AM, et al. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J Clin Endocrinol Metab 1994; 79:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/92\">",
"      van Leeuwen HJ, Heezius EC, Dallinga GM, et al. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003; 31:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/93\">",
"      Khovidhunkit W, Kim MS, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004; 45:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/94\">",
"      McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/95\">",
"      van Leuven SI, Hezemans R, Levels JH, et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 2007; 48:2640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/96\">",
"      Murali MR, Kratz A, Finberg KE. Case records of the Massachusetts General Hospital. Case 40-2006. A 64-year-old man with anemia and a low level of HDL cholesterol. N Engl J Med 2006; 355:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/97\">",
"      Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/98\">",
"      Bloomfield Rubins H, Davenport J, Babikian V, et al. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 2001; 103:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/99\">",
"      Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001; 285:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/100\">",
"      Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/101\">",
"      Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/102\">",
"      Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/103\">",
"      Tardif JC, Gr&eacute;goire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/104\">",
"      Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/105\">",
"      Forrester JS, Makkar R, Shah PK. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 2005; 111:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/106\">",
"      Brewer HB Jr. Increasing HDL Cholesterol Levels. N Engl J Med 2004; 350:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/107\">",
"      Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/108\">",
"      Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/109\">",
"      Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007; 356:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/110\">",
"      Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008; 118:2515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/111\">",
"      Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/112\">",
"      Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 2008; 118:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/113\">",
"      Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/114\">",
"      Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/115\">",
"      de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/116\">",
"      Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005; 95:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/117\">",
"      Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009; 104:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/118\">",
"      Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/119\">",
"      Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/120\">",
"      Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/121\">",
"      Cao G, Beyer TP, Zhang Y, et al. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure. J Lipid Res 2011; 52:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/122\">",
"      Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988; 260:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/123\">",
"      Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/124\">",
"      Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/125\">",
"      Colquhoun D, Keech A, Hunt D, et al. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J 2004; 25:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/126\">",
"      Briel M, Ferreira-Gonzalez I, You JJ, et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009; 338:b92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/127\">",
"      Rosenson RS. Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess. Arch Intern Med 1996; 156:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/128\">",
"      Harper CR, Jacobson TA. New perspectives on the management of low levels of high-density lipoprotein cholesterol. Arch Intern Med 1999; 159:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/129\">",
"      Ashen MD, Blumenthal RS. Clinical practice. Low HDL cholesterol levels. N Engl J Med 2005; 353:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/130\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/131\">",
"      Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation 2001; 103:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/132\">",
"      Wood PD, Stefanick ML, Dreon DM, et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1988; 319:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/133\">",
"      Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991; 325:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/134\">",
"      Moffatt RJ. Effects of cessation of smoking on serum lipids and high density lipoprotein-cholesterol. Atherosclerosis 1988; 74:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/135\">",
"      Gerasimova E, Perova N, Ozerova I, et al. The effect of dietary n-3 polyunsaturated fatty acids on HDL cholesterol in Chukot residents vs muscovites. Lipids 1991; 26:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/136\">",
"      Reid IR, Mason B, Horne A, et al. Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. Am J Med 2002; 112:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/137\">",
"      Bostick RM, Fosdick L, Grandits GA, et al. Effect of calcium supplementation on serum cholesterol and blood pressure. A randomized, double-blind, placebo-controlled, clinical trial. Arch Fam Med 2000; 9:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/138\">",
"      Guyton JR, Blazing MA, Hagar J, et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000; 160:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/139\">",
"      Lavie CJ, Mailander L, Milani RV. Marked benefit with sustained-release niacin therapy in patients with \"isolated\" very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992; 69:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/140\">",
"      Vega GL, Grundy SM. Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia. Arch Intern Med 1994; 154:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/141\">",
"      Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol 2000; 35:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/142\">",
"      Kastelein JJ, Isaacsohn JL, Ose L, et al. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol 2000; 86:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/143\">",
"      Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/144\">",
"      Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003; 92:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/145\">",
"      Rahilly-Tierney CR, Spiro A 3rd, Vokonas P, Gaziano JM. Relation between high-density lipoprotein cholesterol and survival to age 85 years in men (from the VA normative aging study). Am J Cardiol 2011; 107:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/146\">",
"      Ansell BJ, Navab M, Hama S, et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003; 108:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/147\">",
"      Rosenson RS. Functional assessment of HDL: Moving beyond static measures for risk assessment. Cardiovasc Drugs Ther 2010; 24:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/2/39978/abstract/148\">",
"      AHA, ACC, National Heart, Lung, and Blood Institute, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006; 47:2130.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4560 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39978=[""].join("\n");
var outline_f39_2_39978=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE OF LIPID ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HDL METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HDL subfractions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cholesteryl ester transfer protein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LOW HDL-C AS A RISK FACTOR FOR CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HDL-C and coronary events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H96329583\">",
"      - Isolated low HDL-C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HDL and atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H196198349\">",
"      Low HDL-C as a cause of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H265590575\">",
"      CETP AND CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CAUSES OF LOW PLASMA HDL-CHOLESTEROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Familial hypoalphalipoproteinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Familial HDL deficiency and Tangier disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H451293472\">",
"      Familial combined hypolipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Elevated CETP activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lipoprotein lipase deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Elevated hepatic triglyceride lipase activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LCAT deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      EFFECT OF INCREASING HDL-CHOLESTEROL ON CLINICAL OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Trials designed to increase HDL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - VA-HIT trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Trial of simvastatin plus niacin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1481450550\">",
"      - AIM-HIGH trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - ARBITER 2 study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Investigational therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Infusion of apo A-I Milano",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Infusion of reconstituted HDL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      CETP inhibition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Torcetrapib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Anacetrapib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Dalcetrapib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14681998\">",
"      - Evacetrapib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Trials of LDL-cholesterol lowering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      TREATMENT GUIDELINES FOR LOW HDL DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Lipid lowering drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      PATIENTS WITH HIGH HDL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4560\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4560|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/40/16014\" title=\"figure 1\">",
"      Lipids and premature CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/4/5199\" title=\"figure 2\">",
"      HDL metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/56/40839\" title=\"figure 3\">",
"      Metabolic pathways that regulate high-density lipoprotein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/49/22302\" title=\"figure 4\">",
"      HDL-C and LDL-C levels and CHD risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4560|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/63/19453\" title=\"table 1\">",
"      Normal values for lipid levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/2/35\" title=\"table 2\">",
"      HDL-C and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/61/28635\" title=\"table 3\">",
"      Causes of low HDL-C levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/47/22268\" title=\"table 4\">",
"      Effects of lipid altering drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/23/10613?source=related_link\">",
"      ATP III guidelines for treatment of high blood cholesterol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34234?source=related_link\">",
"      Intravascular ultrasound, optical coherence tomography, and angioscopy of coronary circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/4/11335?source=related_link\">",
"      Mendelian randomization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33241?source=related_link\">",
"      Screening guidelines for dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/38/43621?source=related_link\">",
"      Secondary causes of dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/5/9305?source=related_link\">",
"      Spiculated cells (echinocytes and acanthocytes) and target cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_2_39979="Diagnosis autonomic neuropathy";
var content_f39_2_39979=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used techniques for the diagnosis of diabetic autonomic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reflex cardiovascular testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tests of predominantly parasympathetic integrity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Heart rate variability to deep breathing (ie, supine position with the subject breathing at a fixed rate of 5 breaths per minute during a six minute period)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Analysis technique:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Spectral analysis [mid (0.05-0.15 Hz) and high (0.15-0.5 Hz) frequency fluctuations]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Mean circular resultant of vector analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Expiratory: inspiratory difference and ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maximum/minimum 30:15 ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Tests of predominantly sympathetic integrity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Valsalva ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postural systolic blood pressure fall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Heart rate variability to deep breathing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Analysis technique:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Spectral analysis [low (0.01-0.05 Hz) frequency fluctuations on standing]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Galvanic skin potentials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Blood pressure response to sustained handgrip",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Direct assessment of cardiac autonomic integrity by scintigraphic imaging",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39979=[""].join("\n");
var outline_f39_2_39979=null;
var title_f39_2_39980="Procedural bleeding risk";
var content_f39_2_39980=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Procedural bleeding risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        High bleeding risk procedure&nbsp;(two-day risk of major bleed 2 to 4 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart valve replacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary artery bypass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal aortic aneurysm repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurosurgical/urologic/head and neck/abdominal/breast cancer surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral knee replacement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laminectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transurethral prostate resection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kidney biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polypectomy, variceal treatment, biliary sphincterectomy, pneumatic dilatation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PEG placement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endoscopically guided fine-needle aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple tooth extractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular and general surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any major operation (procedure duration &gt;45 minutes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Low bleeding risk procedure (two-day risk of major bleed 0 to 2 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholecystectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal hysterectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal endoscopy &plusmn; biopsy, enteroscopy, biliary/pancreatic stent without sphincterotomy, endonosonography without fine-needle aspiration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pacemaker and cardiac defibrillator insertion and electrophysiologic testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simple dental extractions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carpal tunnel repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knee/hip replacement and shoulder/foot/hand surgery and arthroscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilatation and curettage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin cancer excision",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal hernia repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemorrhoidal surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Axillary node dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrocele repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cataract and noncataract eye surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Noncoronary angiography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchoscopy &plusmn; biopsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central venous catheter removal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous and bladder/prostate/thyroid/breast/lymph node biopsies",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This table is based on definitions derived from surgical/subspecialty societies in anticoagulant bridging or anticoagulant bridging management studies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood 2012; 120:2954. Copyright &copy; 2012 the American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39980=[""].join("\n");
var outline_f39_2_39980=null;
var title_f39_2_39981="Elbow hypermobility";
var content_f39_2_39981=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elbow hypermobility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 274px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Laxity of the elbow with greater than 10 degrees of joint extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sheon, RP, Moskowitz, RW, Goldberg, VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed. Williams &amp; Wilkins, Baltimore 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39981=[""].join("\n");
var outline_f39_2_39981=null;
var title_f39_2_39982="Algorithm II VT versus SVT";
var content_f39_2_39982=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Diagnosis of wide QRS tachycardia in preexcitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 531px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for distinguishing ventricular tachycardia (VT) from supraventricular tachycardia (SVT) in the setting of preexcitation syndrome.",
"    <div class=\"footnotes\">",
"     sens: sensitivity; spec: specificity.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39982=[""].join("\n");
var outline_f39_2_39982=null;
var title_f39_2_39983="Metaphyseal lesions";
var content_f39_2_39983=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metaphyseal lesions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 289px; height: 392px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGIASEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDpPHPxX1DSfi8n2bUTH4V0m7ttN1C3EBZJWlD+bMZNvy+UWiG3Iyfxr6FrMk8PaLJYXljJpGnNZXsrT3Vu1shjnkYgl3XGGYkAknJyBWiiLGipGoVFGFVRgAegoAdRRRQAUVBfXltp9pLdX1xDbW0Q3SSzOERB6kngVyA8Z3us/L4M0O41GE8DULxjaWn1VmBeQe6qR70AdtRXGDw/4q1P5ta8VGyjbrb6NarEB7ebLvY/UBaX/hW/h6bB1RNQ1WTu2oX80+f+Altv6UAdHd61pdln7ZqVlb4/56zqn8zWbJ448JxnEnifQlPo2oRD/wBmpLTwN4UtAPs3hvRkI7iyjJ/PGa0otF0qIYi0yxQeiwIP6UAZg8d+EScDxToJP/YRh/8AiquWvifQLsgWuuaXOT0Ed3G38jVo6TpzAhtPtCPQwr/hVG58JeHLoEXOgaTNn+/Zxt/MUAbMbpIoaNlZT0KnIp1cfJ8NfCRcvbaQljJ2ewlktSP+/bLTD4R1fT/m0DxfqkWP+WOpKt9EfbLYk/8AH6AOzorim8R+ItC/5GjQftVov3tQ0UtMqj1eA/vFH+7vrptE1jTtdsEvdHvYLy1fgSRNuAPcH0I7g8igC/RRRQAV86fHDxn4t0bx7q1t4e1a6tbTT9Fh1AJG1uERvOKuzrKpMg28bFIJOPevousXVfCnh3V79L7VtB0m+vUAVbi5s45ZFAOQAzAkYJOKANDSbyPUdKs72Fi0VzCkyMV2khlBBx269KtUAYGB0ooAKKKzte1zTPD9ibzWb2G0twdoaQ8s3ZVHVmPYAE0AaNFcSNc8Ua//AMi7o0elWTdL7Wgwdh6pbKd3/fbJ9KePBE9983iTxNrWpE/ehgm+xQfTZDhsfVjQB1V5f2dim69ure3X1lkCD9TWNN458JwsRN4o0KMjs2oRD/2aoLL4e+EbNt0fh3TZJP8AnpPCJnP/AAJ8n9a2oNG0u3GLfTbKIDskCr/IUAZSePfCDnCeKtAY+g1GE/8As1athrOl6h/x4ajZXWf+eM6v/I0+TS9PlXElhaOPRoVP9KyL7wN4VvgftXhzSHY/xfZEDfmBmgDo6K4z/hX1lac+H9W1vRXHIW2vWkiz7xS70x9AKabjxroPN1b2fiexXq9oBa3YHr5bExufoyfSgDtaKxPDfijSvEQmTT52W7g4uLOdDFcQH0eNsMPr0PYmtugAooooAKKKKACiiigArC8V+JIPD9vAoglvdTu2MVlYQY8y4fGTjPCqByznhR17A6Os6la6PpN3qWoSiK0tYmmlc9lUZP1PtXNeBNJuppZvFHiCIrrmpINkL8/YbbOUgX0PRnPdiewFAEemeD5tTuotV8czRanqCHfDYrn7FZHtsQ/fcf8APR8n0C9K7UcUUUAFFFFABRRRQAUUUUAFFFFABXJ6/wCD1mv31nw1cjR/EGMtPGuYbrH8NxH0cf7XDDse1dZRQBzfhLxMdYkudO1O2Ona/ZAfa7Jm3DB6Sxt/HG3ZvwIBGK6SuW8caBcajFb6rohSHxHpmZLOVjhZR/FBJ6xuBg+hww5FafhXXLfxHoNrqdorxrMCHifh4ZFO142HZlYEH6UAa1FFFABRRXOeNtfm0Wzt7fTIVutc1GT7PYWzHhnxku/pGgyzH0GOpFAEPijxPLZ38eieH7ZNR8RTp5iwM22K2j6edOw+6noB8zHgdyE8PeD4bK+Gr63ctrPiAjBvZ1wsIPVII+kS/Tk9yaueEPDkPh3T5FMrXepXT+dfX0g/eXMp6sfQDoqjhQABW9QAUUUUAFFFFABRRRQAUUUUAYHifwpp/iAxTzebaanb/wDHtqNq3l3EB/2W7j1U5U9xWXofiK/07V4fD3jHylv5six1GJdkGoADOMf8s5QOSnQ9VyOB2dZniTQ7HxFpE2nanGXgkwQyHa8bg5V0bqrKcEEdDQBp0VyXgjWL03F34d8QuH1zTVVvPxtF7bnISdR6nBVgOjA9iK62gAooooAKKKKAOK8eL/a2veGfDh5trm4a/vF7NDb4YKfYytF+ANdrXHRjzvjDOTyLXQo9vt5tw+f/AESK7GgAooooAKKKKACiiigAooooAKKKKACiiigAriNOX/hHfiTd2K/Lp3iGJr6FeyXcYAmA/wB9Cj/VWNdvXG/EoeSvhrUV4ks9atfm77ZSYWH4iWgDsqKKKACuG8DL/wAJDreo+MJxuhlLWOlA9EtUbDSD3kcFs/3VSr3xPvriz8G3kNg5S/1Bo9OtiOokmcRhh9Axb8K6HSbCDStLtNPs0CW1rEkESjsqgAfoKALVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcZ8SbSW0trTxTp0bNqOhsZmROs9qcefF75Ubh/tItdbZ3MN5aQXVrIslvOiyRuvRlIyCPqDUrKrKVcBlIwQRkEVxvwuJsdL1Lw9ISW0O+ks48nnyDiSH8o3Vf+A0AdnRRRQAUUUUAcdbnZ8YNQB/5a6FbEf8AALifP/oYrsa43Vz9j+Kvh64/hvtOu7M/7ytFKv6B67KgAooooAKKKKACiiigAooooAKKKKACiiigArjvied2l6Lb/wAU+t2CD8J1c/oprsa4zxaft3jnwbpg+ZYpp9TlHosURjX/AMfmX8qAOzooooA43xri68X+CLBuYzfTXjD18qB9v/jzqa7KuN8Ufu/iL4Jkb7rfboQf9oxKw/SNq7KgArO1vW9M0G0+06zf21lBnAaZwu4+ijqT7DmuK17xxdajNPZeEGgWCFilzrM43QxkcFYV/wCWjDuc7AfXpXnF7r+j6VqYe2S517xDKMC5nzPO/wDuAD5V9lCrUTqRhubUqE6t+VaLrsl6vY9PuPiI9yceHvD+oXyHpcXWLOE+43/OfwSsm88S+LZFJnv/AA/pCHskT3Dj/gTsg/8AHa4sW3jbXfmuJYNGtm/hkO+TH+4h4/Fqng+Hdq53anq+qXjnqEdYFP8A3yM/rUc9SXwxt6v/ACua+yoQ+Od/Rfq7fkzWuNevz/x9ePrv6WtrboP/AEWx/WqLa7ED8/jnxAzezoP5RVPF4B8MJ97SknPrPLJIf/HmNWV8GeGVGBoGmfjbqaLVe6+5/wCYubDL7Mn81/8AIlGLXhn9z4615f8AfETj9Yq0LfxHrCkfZfHMM3ot7YQkH6ldhpkngrwxJ97QNOH+7CF/lVOb4feHHB8m0uLU+ttdSp+m4j9KLVl1X3P/ADHzYZ/Zkvmn+iOqtPF3iyAbpbHRNXi9bSd7Zz+Db1/8eFatn8SdHDrFrsN7oUrHAOoRYhJ9plJj/NhXmEvgK6tW8zRPEF1C46JdRiQf99Ltb+dQyat4r8Pow1vThqFjjDzW375cf7QwHA+qkUvaTj8cfu1/4I/YUp/w569pK346r72j6JhljnhSWCRJInG5XRgVYeoI60+vAvC2pWchF14I1MaRcudzWZ+eznPcGLOAfdNrfWvT/CfjOPVbz+ytXtv7M10KWFuz7o7hR1eF+N49Rww7jvWsJxmrxZz1KU6T5ZqzOurjbDFl8W9WhXhdR0q3uj7vFI8ZP/fLp+VdlXHXWD8X9M29RoV3u/8AAi3x/wCzVRmdjRRRQAUUUUAcZ8Tj9is9E1wcDSdUgmkb0hkJhk/DbLn8K7OuB+M/nT+GLPTY7iS3h1S/isblo1UsYnDbgNwIB4HPWuXv7nVdJtFe58Z6yqABEURWzM59B+6yTSlJRV3sVCEptRirtns1FeEf2t4tcZh1LxKV7F0tF/8AaVL9v8bkfLqWtj/ea0/+NVj9Yh5/c/8AI6fqVXrZf9vR/wAz3aivCReeOz/zFdVH1e0/+NUG58e441jUfxe1/wDjVHt49n9z/wAg+pT/AJo/+BR/zPdqK8I+0+P/APoMah/33a//ABqkM/xAPTW74D03Wv8A8ao9vHs/uf8AkH1Of80f/Ao/5nvFFeEC4+IA+9rV+30a1/8AjVL9p8ff9BjUP++7X/41R7ePZ/c/8g+pT/mj/wCBR/zPdqK8K+1ePB11fUv+/lr/APGqQ3vjoddU1Y/R7T/41R9Yj2f3P/IPqU+8f/Ao/wCZ7tRXhP8AaHjYD5tS1w/7rWh/9pUf2t4tX/W6j4mH+7HaN/7So+sQ8/uf+QfUqvS3/gUf8z3auK8MH+1/H/iXWOsFkI9Gtm9Sn7yY/wDfbqv/AGzrjdJv9X1JHMHi/W0ljOJIpILYOh9x5VdR8Fkkt/DepWclxJcLa6tdRLLKBvYF9xLEAZJZmOfetYyUleOxzzpypycZqzO/oooqiDjfiN+5uPCV4PvQa5ApPoJVeI/+jBWD8SvEX267udAtrl7fTLZVOr3MTEO24ZW1QjozDliOQpA/i41vjZcvYfDu91KKPzJdOuLW8RM43GO4jbH44rxaxs7nxRqSaQ07m0hJu9VuUODLLISzAH+85yB/dRfpWVWbjaMd3/Vzow9JTvOekY7/AKJeb/4JdthqPjNlttK26X4btj5QljUYIXjZEvRiOhY/KO2TXc6DoOnaDbtFplsI2fmSVjullPq7nk/yq/bQQ2tvFb20SQwRKEjjQYVVHQAVJTp01DXd9wrV5VdNorZLZf8AB89wooorQwCiiigAooooAKM4PFFFAHLeJPBdlqkj3lg39m6qeftEK/LIf+midG+vDD1rCtNUkmnHh3xlG9tfRES213G+GQj7s0UnXg9+o6MMV6NWP4p0C28Q6b9muCYp4zvt7lR80EnZh6jsR0IrKdK75oaP8/U6aVey9nU1h+Xmu35Pqdf4B8S3N9JNomusn9t2aBxKo2pew5wJlHY54ZezexFLpuLv4s65N2sdLtbUf70kksjfoErx/RNW1FU8uWMJ4n8OSGaJAf8AXIB+8iB7pJH0/wCA91r1f4YX1vrl74q16ycSW19qCJC47xx28Sj9S361VOfOrmdak6Urbro+6O7oooqzEKKK81+Lfxh8PfDm2aG5kF/rbLmLToGG72Mh/gX68nsDzQBY+NN1HZaLoVzNny4tZt2YKMno9c3o2nz3dyNW1WM/aGH7iEjiBO341ifA++vPjLoviXU/HYN1YG/hjtLOJniitmiUt8hUg5/ejJJycDPQY0vEvg3TNI8c29pi/wD7N1GzLW6nULg7J4j84B35+ZHU8/3DWcqfNJN7Lp5m9Ot7ODjFavr5dvn1+46ba390/lRtb+6fyrnv+EQ0f+5ff+DC4/8Ai6P+EQ0f+5ff+DC4/wDi60MTodrf3T+VG1v7p/Kue/4RDR/7l9/4MLj/AOLo/wCEQ0f+5ff+DC4/+LoA6Ha390/lRtb+6fyrnv8AhENH/uX3/gwuP/i6P+EQ0f8AuX3/AIMLj/4ugDodrf3T+VG1v7p/Kue/4RDR/wC5ff8AgwuP/i6P+EQ0f+5ff+DC4/8Ai6AOh2t/dP5UbW/un8q57/hENH/uX3/gwuP/AIuj/hENH/uX3/gwuP8A4ugDodrf3T+VG1v7p/Kue/4RDR/7l9/4MLj/AOLo/wCEQ0f+5ff+DC4/+LoAm16wnjlXVtNQ/bYB+8QDiaPup966L4K3KXug6zcxAiOXWLlgGHI+7XDHwhZat4nsNC0xr+EgC8v7hb+cmG3BwFGXxukYbR6AMewq34t8aaR8GfGnhnQra2+zeGdSSeW8+ZpDFIzqFm3MSxAwdwz0ORyKzjT5ZOS2f59zadbnpqElqtn5dv8AI9wopkMqTRJLC6yROoZXU5DA8gg9xXA/GzxF4t8N+EJLvwRon9p3hyJZR85tV/viLrIfp06kEVoYFf48a3pVp4C1fSru9hTUru0kltrXdmSQRjzGIA6ABDyeM8dSBXN/D/Szpnhm2M6gXl5/pdye+9+Qv/AV2r+FfOfwtGp+L9a8b63rVxPfXdvodxNJNMSzFiUXHt8hfAHQDAFfVyFWRTHjYQCuPTtS5Ve5ak+Xl6C0UUUyQooooAKKKKACiiigAooooAKKKKAOF+IVs+m6lpfiW0+WSCVLW5I/iRj8jH6McfRzXo3wNtoYPhxYy20XkxXc9zdrH/dV5nKj/vnFcz42tVvfB2t278BrOUg+hVSwP4EA1w/wZ+LKaN46k8Ea9ME010t4LCZnyIJhDGpiJ7KzAkejHHfiFC0nLuaSq81NQfS/49P67n05RRRVmQV4/wDHHwB4e8b6ho2mSWKJ4jv5Dt1CEbZILaMAySPj76jKIAf4pFxjmvYK5rw/pF2PEut67qyKtzcOLSzjDBvKtI87end3LufYoD92gDF+CPgOX4deCjolzcw3U5u5Z2mhBAcMQFOD0O1VyOcHuetWPi9aO3hQatbqWudFnTUVAHJRciVfxjZ/0rt6juYI7m3lgnQPFKhR1PRlIwR+VAHnCssiK8bBkYBlYdCD0NLWH4OWS20dtMuGLT6TcS6c7HqwibCH8U2H8a3KBhRRRQAUUUUAFFFFABRRRQAVFd3MNnaT3Vy4jt4EaWRz/CqjJP5CpaxvEFt/a13o2gDldUvFWcf9O8Y82UfiFC/8DoA6/wCFWlS2vh99W1CMpqmtOL2dT1jQjEUX/AU2jHqW9a8i/aV+Ffinx94wg1HRYbVdNsNJwZJpcNJKHkYxqoyScbMZAHPWvpEDAwOlFAjiPgxoTeHfhxo9kNan1m2aFZ7a4ljCbYnUMqKAT8ozxknGcdABVz4iX9ymmW2jaTK0Wr63L9it5E+9AhBMs3/AIwxH+1sHepPh7ZXGk6NdaRcQSRxafezQWrMMB7ct5kW31Co6p9UNazaPat4iXWn8x7xLU2ke5srGhfc20dixCZPoi+nIBl6b4F8N6Wb46dpUFs99aLZXLx5BmiUFQG7E4Jy3U9ya4Hwo00WmNpl6Sb/SpDYXGepKfcf6Mmxvxr2OvOfiNpkmkaiPFdjEz2/liDVokGSYR9ycAdTHk59UJ/uigCOimxyJLGkkTrJG4DK6nIYHkEHuKdQMKKKKACiiigAooooAKKKKACiimTSxwQyTTyJFDGpd3c4VVAyST2FAGR4uElzpQ0q2P+l6vIunwgdt/Dt9FTex+lec+Kv2flTxZP4i8S6sDpN9rgRrWyXa0VvNKUiJkYcEM0QI29M/N3r2X4daVLquonxXqETxwmMw6TBIuGWFvvTsD0aTAx6IB/eNdf4t0ga/4Y1TSi2xru3eJJOhjcj5XHuGwfwoEc9/wrfTv+gz4n/8HE3+NFYX9t/FT/oU7H/wNi/+KooA9UooooAKKKKAPJmT7P4+8X24GFea2ugP9+AKf1jNX6g8QJ5XxS1LjifSbWT8VlmX+oqegYUUUUAFFFFABRRRQAUUUUAFR+EIftnxNuJWGU0zSlVfZ55CSf8AvmEfnUlT/DBfM8R+MbnsLi2th/wCBW/nIaAPQ6KKKBBRRRQAUhAYEEAg8EGlooA8kn02Pw14yn0WwYrpU9p9vt7c9LdvM2uiHsnKkL2JOOOBo1J8QE8rx54cm/572V5AfwaFx/I1HQMKKKKACiiigAooooAKKKKADvVPw3ojeNLt7zUgq+G7S5eOK0zk30sTlS8v/TNWU4T+IjJ4wKtvIsSNI5wqAsfoOa3vhNA0Hw50EyDDz2/2pvrKxkP/AKHQB1o4ooooEFFFFABRRRQAUUUUAeZeMRs+KFo2P9dozj/vidf/AIun07x8pT4heHnHSTTrxD+DwGm0DCiiigAooooAKKKKACiiigAq/wDCNd2n+ILk/wDLfWbgg+yBI/8A2SqKcuv1rU+Di58A2c/e5uLq4PHXfcSMP0IoA7WiiigQUUUUAFFFFAHn/wAUU2at4QuvS+ltyf8Aft5D/NBVWtH4uLt0fRrntb6xasT6BmMf/s9Z1AwoooAyeOaACioLq8tbMZu7q3tx/wBNZVT+ZrPPifQAcHW9L/8AApP8aANeis+21vSbpgLXVLCYntHcox/Q1oY4z2PQ0AFFFFAGP4yuGtfCWsyocOLSRU/3mUqP1Ir1bR7NdO0ixsk+7bQJCPoqgf0ryjxTH9ptNPsT0vdStLcj1UzKzf8AjqmvY6BBRRRQAUUUUAFFFFABRRRQB518RwR408IsO8V8h/74jP8ASoqm+JwI8UeDXH/Pa7Q/jAT/AOy1DQMKKKKACiiigAooooAKKKKAIruUW9pPMxwIo2ck+wJrp/hdbm1+HHhmI8N/Z8Ln6sgY/qa4TxnMbfwfrkqkhlspsY9ShA/nXq2iWwstGsLUDAgt44sf7qgf0oAu0UUUCCiiigAooooA4z4wL/xb7UZR1t5Le4HtsnRv5A1kyEAsSQFGSSegFdL8S7f7X8PfEsIGSdOnI+oQkfqK8vhYeLnAds6DAFEiqeL2bAJUn/nmucEfxNkHgcgy1/blzqbMnhq1S4iBwdQuCUtgf9jHzS/8Bwv+1Tv+EfluxnWtWvrwnrDC/wBlh+m1PmI/3mNbqqFVVUBVUYCgYAHoKWgDJtPDeiWhzb6RYK398wKzf99EE1orbW6jC28Kj0EYH9KlooApXOk6bdKRdadZTA/89LdG/mKzv+EU0yIltN+1aXJ/esZ2iH/fHKH8VreooAwC2v6Xy3l63aDrsUQXSj6fcf8A8dNaWlanaarbtNYy7wjbJEZSrxN3V1PKn2NXaxdc0mSWcanpBWHWYVwrHhLlB/yyl9Qex6qeR3BALmz7V438JWp5UXM12w9o4GA/8ekWvWK8m+H97Frvj21voFZY7bR3Yo/3opJZgpVvceSwP0r1mgQUUUUAFFFFABRRRQAUUUUAeffFL5dZ8HP638yfnbS/4VWq58VB/pvhBvTVGH5201U6BhRRRQAUUUUAFFFFABRRRQBgeOlMvhm4txybqWC2H/bSZF/rXtNePa+vm3nhy26+frNpkeoRjIf/AECvYaBBRRRQAUUUUAFFFFAFLW4xNot/Eylle3kUqO+VPFeRfD62is/AugQW4AjFlEeO5KhifzJr2rr1rx7TrdvDurXPhi6+UQl59Oc9JrUtkAHu0ZOwj02noaBmvRRRQAUUUUAFFFFABRRVTVtRt9K0+W8uy3lJgBVGWkYnCoo7sxwAPU0AS/CTTY7Xxd46u4/uzXNuuOynyd7AfUyE/jXqFct8OdFudH8Pl9TULqmoTNe3ag5CO+MRg99qhV/4DXU0CCiiigAooooAKKKKACiiigDi/idpmp6hb6HNo1ib6Wx1EXEkImSIlPKkQ4LEDq4rnPL8Vf8AQnXP/gxtv/iq9XooA8o8vxV/0J1z/wCDG2/+Ko8vxV/0J1z/AODG2/8Aiq9XooA8o8vxV/0J1z/4Mbb/AOKo8vxV/wBCdc/+DG2/+Kr1eigDyjy/FX/QnXP/AIMbb/4qjy/FX/QnXP8A4Mbb/wCKr1eigDyjy/FX/QnXP/gxtv8A4qjy/FX/AEJ1z/4Mbb/4qvV6KAPKtN0jxFqHivw/NqGgSafY2FzJcyyyXkMmT5MiKAqEn7zivVaKKACiiigAooooAKKKKACsbxT4csfEunrbXwkSSJ/Nt7mFtstvIOjo3Y/oRwQRWzRQB5HfrrfhklPEFo99YL93VbCEsMes0IyyH1K7l+nSrOnX9nqcAn066gu4f78LhwPrjp+Nep1zeteB/Dms3JubzS4VvD/y9W5aCb/vtCGP4mgDmaKuy/Dpox/xLfFGuW47LM0Vyo/77Qt+tQHwLr4Py+Llx/taXGT+jCgZDQeFLHhR1J6CrUfgDU5D/pni+/K9xa2kEX6lWNXLf4aeHtwfU1vdYcHP/EyunmT/AL95Cf8AjtAHIjXor25a08PW82t3ynaUs8GKM/8ATSY/In5k+xrqvC3guaPUIdZ8UTRXeqRZNtbQg/ZrLPBKA8u+ODIeewC9+ztLWCzt0gtIIoIEGFjiQKqj2A4FS0CCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqvbXtrdSSpa3MEzxHbIscgYofQgdKw/iTY6pqXgHX7Lw/IY9VnspI7cq+wlivQN2J6A9ie1cb8F7XQ7ZLWLTfA2peHtTt9OWC7u7rTvswkYFdybz/rSWG7dzwOozigD1aiiigAoJABJOAO9cbqHi+e+1CfS/BlkmrX0LeXcXcjlLK0buHkGS7j+4mT6laYvgU6qRL401W61xzybQE29kvsIVPzf8DLUAXNR8f8AhmyuTa/2pHd3g4NtYI11Ln0KxhiPxxVb/hMNUux/xKfBmuzjs935Nov5O+7/AMdrqNN06y0u2W202zt7S3XpFBGsaj8AMVaoA44an45uP9T4b0W1H/TzqrufySE/zpN3xBbpF4Uj/wC2lw//ALKK7KigDjf+LhD/AKFRvb/SB/jS/a/H0PL6R4buh6RahNGf/HojXY0UAcb/AMJP4ktedR8EXxQdW0+9guP0Yox/KnRfEbw+kiRatLd6JMxwE1a1ktR/32w2H8GrsKZNFHNE0cyLJGwwysMgj3FACW88N1Ak1tLHNC4yskbBlYeoI61JXHXXgDTYZ3u/DM9x4cvmO4vpxCwuf9uA5jb/AL5B9xUMXirUfDtxHaeOreCK3dgkWtWgItXJ4AlU5MDH3JU/3u1AHb0UAggEEEHkEUUAFRR3MEkrRRzRPKudyK4JGOuRUtfLSeGNSm1PxJDpnhnVLbxfN41nvrDWW094o4rPzFy5uCAGjIEnyAnO7IBzQB9S0UUUAFFNkdIo2kkZUjUFmZjgADqSa4g+J9V8USND4GhhWwBKvrl4hMB7HyI+DMf9rIT3bpQB2N/e2un2r3N/cwWtsnLSzSBEX6k8Vyh+ImlXR26BZ6rrxzjfp1ozRZ/66vtj/Jql0/wFpSXSX2uNPr+qLyLnU2EoQ/8ATOPAjj/4CoPvXWgBQAoAA4AHagDjhrfjK6/49PCNraqejahqiqfxWJH/AJ0bviC/Ij8KQ+xe4kx+i12VFAHG/wDFwV7+FJPbFwn+NB1Pxzaj/SPDekXo/wCnPVGRvykiA/WuyooA4w+PFsv+Rh8P69pKj70zWv2mFf8AgcJfA9yBXRaJrula9bfaNG1G1voR1aCUPtPocdD7GtGub13wVoes3P2yS1NpqY+7qFi5t7hT/vrgn6Nke1AHSUVwr6h4j8H862H8Q6EvW/tocXlsvrLEvEijuyAH/ZPWuw0zULTVbCC+025iurOdd8c0TBlceoIoAtUUUUAFFFFABRRRQAVwesXV54z1q60DSLiW00OyfytVv4W2ySydTawsOhwRvccjO0YJJGv8QdXutK0Dy9K2/wBr6hMlhY7hkCaTjefZFDOfZa0vDOi2vh3QrTS7EN5NumC7HLSMeWdj3ZmJJPqTQBZ0vTrPSdPgsdMtorWzgUJHDEu1VHsKtUUUAFFFFABRRRQAUUUUAFFFFABUdzBFdW8kFzEk0EilHjkUMrKeCCDwRUlFAHn1sZfh5qdvZyyvJ4OvJRDbSSMWOlzMcLEzHrCx4Un7hwp4Ix6DVTVtOtdW0y60/UYVns7mNopY2HDKRgiua+Hd9dRw3/hzV5mm1TRJFhMz/euLdhmGY+5UbT/tI1AHYUUUUAFMmljhieWZ1jiRSzu5wFA5JJ7Cn1wnijPi7xMvhWMn+yLNUutZYHHmg8xWuf8Aaxuf/ZAH8VAFe3gm+JEou74SQ+C0bNtaHKtqmD/rZe/k/wB1P4urcYFegxxpFGkcSKkaAKqqMBQOgApUVURURQqqMAAYAFLQAUUUUAFFFFABRRRQAUUUUAFcJrWj3fhO+uPEHhS3eW1kbzNT0aL7s4/imhHRZh1IHD9D82DXd0UAU9H1Kz1jS7bUdNnS4s7lBJFInRgf5H1HY1crg4k/4QvxokMY2eHvEMx2L/Da35GSB6LKATj++P8AarvKACiiigAooooA4zVQNQ+K2hWrcx6bp9xf4/6aOyxIf++fN/Ouzrj7UA/F/VCeq6FaY/G4uc/yFdhQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxXilf7J8eeGdaj+VL1n0a6/wBpXBkhP4OhH/bQ12tcd8UeNF0qQffj1nT2T6/aUH8iaAOxooooAoa9qlvomiX+qXhxb2cDzyepCgnA9+KxvhxpVxpvhmOfUh/xNtSdtQvj/wBNpOSv0UbUHsoqp8Tx9ss9E0XqurarBBKvrEhM0g+hWLH412dABRRRQAUUVk6r4l0LSCRqmsadZsP4Z7lEP5E5oA1qK41vib4RBIi1f7Rj/n2tpph+aIab/wALL8PH7g1dx6rpVz/8boA7SiuLHxM8ND/Wy6lF/wBdNLuR/wC06mt/iR4PncJ/wkFlCx7XLGD/ANDAoA66iqthqNlqMXm6fd291F/fglVx+YNWqACiiigDF8Y6GniPw1faYz+VJKm6GYdYplO6Nx7qwU/hTPA+tP4g8K6fqE6CO7dDHcx/8850JSRfwdWFbtcZ4NH9neMvGGkdImuItUhH+zOmHx/20ic/8CoA7OiiigAooooA40/ufjCM8C70LA9zFcf/AG6uyrjPGB+xeNfBmpHiNrifTZD7TRFl/wDH4VH412dABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXG/EY+fceE7BeXudbgfb/sxK8xP/kMV2VcXd/8AE0+LGnwjmLRNOkuXI7S3DbEH12Ry/wDfVAHaUUUUAcb4n+f4jeCYz91RfTAf7QiVR+jmuyrjfGg+z+L/AARfH7ovprNvpLbyEf8Aj0a1seLPEVp4a0v7XdK8ssjiK2tohmS4lP3UQevv0ABJ4FAF/VdSstIsJb3VLqG0tIhl5ZnCqPxP8q4O+8c6rqgI8MaclrZ/9BHVVZQw9UgGGI93KfQ1w3ifXUtrpNV8XTR3urqc21hGS1vYk9FQfxSf7eCx7ACqceleJvFbCbVrhtH09uVhCgzsP937qf8AAtx9hWLq3fLBXf4fedUMNaKnVfKnt3fov1dkXte1XTgjP4p8Tahqv96FZ/s9v9Nke1T/AMCLVj6f4m0uM48K+EzN6SW9mWz/AMCC4/8AHq6vSPBuhaW6yxWKXFyP+Xi7PnSfm3T8AK6HJwB2HQUclSXxSt6f8G4/a0YfBC/q3+St+pwo1zxvcD/RvDxhXt50kafoXP8AKg3HxBfkWNivsbpP/iTXdUUexXVv72H1qS2jH/wFfrc5vT9S8TQWiLqGhC4nBO54L+IA88cECppNen2ldQ8O6wqd9sUdwv5I5P6VvUVqlZWOaT5m2zjP+KKvrsBo7OxvyeCyNYT59j8jZ+hro7X/AISLScNo3iCa4h6i21ZftKH6SDEg+pLfSrlzBDdQmG6ijniPVJUDqfwNYp8NRWhL6DdXGkydfLiO+3Y+8TfL/wB87T70xHXaX8Q7dJo7XxVZtolw5CpOz+ZaSnsFmAG0n0cKfTNd0CCAQcg968Tk1eSzU2niu0git5f3f2yMb7SXPGHB5jJ9Gyv+1V/S72/8EkPpqz3/AIcHMunZLyWq93tyeSo6mI9vu46EA9drjpAYfjDAR0utCk3e/lXCY/8ARxrqNMv7TVdPt77TriO5s7hBJFLGcqynuK5dyZ/jBCF6WmhPu+s1wmP/AEQaBHY0UUUAFFFFAHC/Ge6gsfA8t1JL5d3b3MFxZDazGS4jcSIgABOW2lfxqZPid4UZFY6hOpIB2mxnyPY/JUHxb/48fDmP+g3b/wAnrl9S1a6kvTp2j4e7AzLK/wByAe/qfaonNQV2a0aMqrtH/gJd2dj/AMLM8J/9BGb/AMArj/4ij/hZnhP/AKCM3/gFcf8AxFcZ/ZWrN/rPEFzn/YjUCkGjX38XiDUfwwKz9pP+R/ev8zb2FHrVX3S/yO0/4WZ4T/6CU3/gFcf/ABFL/wALM8Kf9BGb/wAArj/4iuLOiXZH/Ie1P/vsUn9hXP8A0HdU/wC+xR7Sp/J+KD2FD/n6vuf+R2v/AAszwp/0EZv/AACuP/iKP+FmeFP+gjN/4BXH/wARXFf2Fc/9B3VP++xR/YVz/wBB3VP++xR7Sp/J+KD2FD/n7+D/AMjtf+FmeFP+gjN/4BXH/wARR/wszwp/0EZv/AK4/wDiK4r+wrn/AKDuqf8AfYo/sK5/6Duqf99ij2lT+T8UHsKH/P38H/kdp/wszwn/ANBKb/wCuP8A4ij/AIWZ4T/6CU3/AIBXH/xFcYNEugONe1P/AL7FH9i3fbXtT/76FHtKn8n4oPYUf+fq+5/5HZ/8LM8J/wDQRm/8Arj/AOIo/wCFmeE/+gjN/wCAVx/8RXGf2Le/9B/UvzFJ/Y1//wBDBqH6Ue0qfyfiv8w9hR/5+r7pf5Haf8LM8J/9BKb/AMAp/wD4iqvwmu4dbtte8RKxM+palICrKVaKOLEcUbAjg7V3Y9XNcr/Y+o/9DDff98ium+DMckOia3HLM08i6zchpXGCx+Xk1cJylvG33GdWnCCvGal8n+qR6BRRRWhgcd8UAI9K0a8JAFprVjKSewMyof0c15T4u8YNeapJrcavPPMzWei26jJSEnb5ij+/KwyPRAvbNek/HeHz/hL4iQEg+UjZBwRiRDn9K8w+HOli/vJdfuVBihzaaeuOFVfleQflsHsp9axquUmoR69fL/M6sOoRi609bbLu3+i6/ca3hDwn/Z8i6prRW61t8nOdyW2eqpnqfV+p9hXW0UVpGKguWOxjOpKpJzm7thRRRVEBRRRQAUUUUAFFFFADZEWSNo5FV43BVlYZDA9QR3Fc06yeEmEsJeTw5n95Hks1h/tL3MXqv8PUcZA6eggEEMAQRggjIIoAo+HdQHhPxHEFYf8ACO6zMFZQfktbp/uuvokh4PbcQf4jXTeGP9J+IvjO6PIhFnYqfTbGZSPzmrzuHT4oze+E7st/Z13A8mnvnmNM/NGD6xsVZf8AZI/u12XwOe+u/C+oalq4Uahe6lO0xXoWj2w5/Hys/jQB6JRRRQIKiuriG1t5bi6ljhgiUvJJIwVUUdSSeAKlr5G/a1j+IZvM6hIjeDWfFtHYMQpIBbM6/eLYBPdRjjBzQB674u1//hYfg6O/+H0U2qHTdbjXegVBJ5aZZ03kZUeYBk4yQcZGCcHS9Tk0eaXSf+Ec1w6hEiT3AZYdzb84cnzOQSrD2xXT/sx6Z/ZnwV8Ph1IkuRLdP775GK/+O7au/E22/s/xF4f11BiOVm0q6P8AsyfNET9JFx/20qeROXN1NFVkoezWz1Oc/wCEgvP+hZ1z/vmD/wCOUf8ACQXn/Qs65/3zB/8AHK36KogwP+EgvP8AoWdc/wC+YP8A45R/wkF5/wBCzrn/AHzB/wDHK36KAMD/AISC8/6FnXP++YP/AI5R/wAJBef9Czrn/fMH/wAcrfooAwP+EgvP+hZ1z/vmD/45R/wkF5/0LOuf98wf/HK36KAMD/hILz/oWdc/75g/+OUf8JBef9Czrn/fMH/xyt+igDA/4SC8/wChZ1z/AL5g/wDjlH/CQXn/AELOuf8AfMH/AMcrfooA5i+8WSWMcb3Xh3W0EkqQoNkJLyOcKoAkySTXe/CqyvrPR9UfUrGexkutTnuUhnK7wjbcE7SR29aw/A9gPEPi241mYbtN0Z2tLJT0kucYml/4CD5Y999eoUCCq9/e22nWU15f3EVtawqXkmmcIiKO5J4AqxXzh+1b4K8Wa7Ba32ma0brSfNjhj0PHls0zHAKY/wBax54PKjOM80AdH4j+Iml/ET4c/ESHw9HM1hptqIUvpBtW4kbcfkXqANq8nk7ugxzraNYR6VpFlYQjEdtCkQ/Acn8Tk1wv7PvhG5b9nzxPZy28kWoalPdBY5FKurIioqkHoQ6H867rR75NT0iyvoj8lzCko9sgEj86BlyiiigAooooAKKKKACiiigAooooAKKKKAMHxnm20lNWjBM2kyrejHUovEq/jGX/AErufhJCYvhzobt964hN0c+srNJ/7PXHeL5Uh8J61JLygspgR65QgD8SQK9P8N2Z07w7pdky7WtrWKEj02oBj9KANGiiigQVxOiqvifxrqOsyqJNM0kSaXYAjKySkj7TL78hYh6bJOzV21VNK0600nToLDToFgtIF2xxrk4HXqeSc5JJ5JNAEtna29laxW1lBFb20ShI4okCIijoABwBWP480VvEHhDVdNjO24mhJgb+7MvzRt+DqpreooA8m0HUV1fRLHUFXb9phWRl/utj5l/A5H4VfrJ0aH7BrHibS1AEdpqkjxqP4UmVZgPpmRq1qBhRRRQAUUUUAFFFFABRRRQAVl+J7+bTtFuJbNd99IVt7VP708jBIx/30wP0BrUqjbW/9qfEHw7YsN0Nms2qSj3QCOP/AMekJ/4DQB6H4V0WHw74c0/SbYlktYghc9ZG6s592Ykn3NatFFAgrirX/ipfiFLdH5tL8N5t4fSS+kX94/8A2zjYID6yyDqtdrUcEENurLbxRxKztIQihQWYksxx3JJJPcmgCSvIltD4c8T3+guNtpOz3+mnsY2bMsQ90dicf3XX0r12uf8AGvhtPEmkrFHL9l1G2cT2V2BkwSgcHHdSCVYdwTQBytFZukajJdPPZ6hb/Y9XtCFu7UnO0no6H+KNuqt+B5BFaVAwooooAKKKKACiiigAooooAKKKzNW1GWC4t9O0uAXmtXmRbW2cAAdZZD/DGvc9+gyTQANaHxH4nsdCjG61t2S/1Juyxq2Yoj7u6g4/uo3rXrtYHgzw5F4b0owGU3N9cOZ7y7YYaeU9Wx2AwAF7AAVv0CCiiigAooooAKKKKAPKtSQwfEvxInae2srn8cSIf/QBVuovFIEfxTcgf67RYzn/AHJ3/wDi6loGFFFFABRRRQAUUUUAFFFFABTvh7GJ/HniW5Yc21pZ2qH0z5kjf+hLTat/ClN934uuv7+qCEfSOCIfzJoA7+iiigQUUUUAFFFFAHmnjRPK+JdhJ/z86RKn1McyH/2oaWp/iSvl+LfCU/ZheW5P+9Grj/0XUFAwooooAKKKKACiiigAooooAVRlgPU1d+EFlA3h2TXGjDX+q3E0kk7cuYhK6xJnsoQDAHHJPc1j6rdCx0q9u2OBbwSS/wDfKk/0rtPh9ZHTvAvh+0Iw8VhCG/3tgz+uaAOgooooEFFFFABRRRQAUUUUAeaeOF2fErSXzjzdJuE+u2aI/wBTS1J8QwF8d+FnPV7S+jH/AJBP9KjoGFFFFABRRRQAUUUUAFFFFAABkgVo/B5d3hi9uv8An71W8lz6gTMg/RBWeCFIY9BzWx8Hoynw10Jm6zQtcH/to7P/AOzUAdjRRRQIKKKKACiiigDg/iuuz/hFrnvHq6IT7PDKn8yKo1qfF9MeEorn/n11Gymz6f6Qin9GNZjDBIoGJRTXdY42kkZUjUZZmOAB6k9qxD4ospmKaTBeas4OM2UW6PP/AF1bCfrQBu0VhfbPEU/+o0axtl9bu+3N+UaEfrSgeKCOX0FfbbM365FAG5RWF5viePlrTRbgekdxLEf1RhQdeurb/kKaFqNuo6y2+26Qf98Hd/47QBu0VT0zVLDVY2fTruG5CcOEb5kPoy9VP1Aq5QBheOQX8KX9un37oJaL7mV1j/8AZq9ljRY0VEGFUAAegryPV0Nzq3hmyHPn6tCxH+zEGmP/AKLFevUCCiiigAooooAKKKKACiiigDzv4lYXxf4Pc9/tqfnEp/8AZahqx8UFH/CQ+DnPa6uV/O3f/Cq9AwooooAKKKKACiiigAooooAo67cfZNC1K5PHk2ssn5ITXeeBrX7F4J0C1xgw6fAhHuI1BrzLx8xXwXrIX70lu0I+rkIP/Qq9mgiEMEcSfdRQo+gGKBD6KKKACiiigAooooA5D4uRGT4beICv3orYzj/tmQ//ALLXI61rC2PkR28LXeoXefs1qhwX9WY/woM8sf1JAr0Xxla/bvCGuWoGTPYzxgfWNhXkfw8SW80O312/TF/qMEbYPPlQgfJGPb+I+pY0DLcPh83si3HiSZdRnB3LbAEWsJ/2Y/4iP7z5P0rfACqFUAKBgADAA9qKKACiiigAooooAzNV0Ow1ORZp4mivE+5dwMY5k+jjn8Dke1UoNQvNIuorTXnWe2mYR2+pKoQFj0SZRwrHsw+Unjg8HoKhvbWC+tJrW7iWW3mQpIjdGU0AM0yM3PxJ8PxdrW2u7xvY4SIf+jGr1OvH/g6LqfxpryX5eSbRbSHTRO/WYM7yB/qUEefcGvYKBBRRRQAUUUUAFFFFABRRRQB598VAf7T8HMO2pSKfxtpv8KrVd+KvFx4SbH/MWx+dvMKpYPoaBhRRg+howfQ0AFFGD6GjB9DQAUUYPoaMH0NABRRg+howfQ0AYni1PPsLK1/5+tSsoMeoNwhP6A17LXkOpxmfxD4Rtsf6zVkkPHaOKV//AGUV69QIKKKKACiiigAooooAhvIftFpPBnb5kbJn0yMV5B4JcnwppsMi7ZrWIWkyd0ki/dup/FTXsteaeMtEutA1e51/SbeS60y7IfUrOFd0kTgY+0RqPvcAB1HJwGGTkEAWioLG8ttQtIrqxnjuLaUZSWNtytU9AwooooAKKKKACijGTgVkNLeeIb+TRfDT/vlOy91FRmOxXuAejTY6KOnVsDqAdF8KIhNP4n1RAPJutQEMbY++IY1jJ+m8OPwrv6paJpdpouk2mm6dH5VpbRiONc5OB3J7k9Se5NXaBBRRRQAUUUUAFFFFABRRRQBj+J/DmneJbS3t9VSYpBMJ4mhneF0cArkMhB6MR+NYP/CstA/5661/4N7n/wCLoooAP+FZaB/z11r/AMG9z/8AF0f8Ky0D/nrrX/g3uf8A4uiigA/4VloH/PXWv/Bvc/8AxdH/AArLQP8AnrrX/g3uf/i6KKAD/hWWgf8APXWv/Bvc/wDxdH/CstA/5661/wCDe5/+LoooAP8AhWWgf89da/8ABvc//F0f8Ky0D/nrrX/g3uf/AIuiigC3pHgDQ9K1a11K3GoS3dtuMJub+aZULKVJCuxGcEjOO9dXRRQAUUUUAFFFFABRRRQAUUUUAcbrvgGzu7ybUNEupdE1OU7pZLdQ0M7essJ+Vj/tDDe9c5c2XizSsi+0WLVIR/y8aVMAxHvDIQR9AzUUUAZ8viawtjjUYtS05u4vLCaMD/gW3b+tRHxp4YH3tf01T6NOAfyNFFAxy+L9BkOLbUBdN2W1iknJ/wC+FNXILvV9QO3R/DOqzZ6S3iizjHv+8+f8lNFFAGtZ+BdV1TnxRqqw2p66fpRaNWHo85+dh7KEru9K02y0mwhstMtYbS0iG1IYUCqo+goooEW6KKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diagrammatic representation of the relationship of the subperiosteal bone collar to a metaphyseal lesion. A: A tangential view of the metaphyseal margin, demonstrating a fracture line that extends adjacent to the chondro-osseous junction centrally. Peripherally, the fracture line (arrows) veers away from the growth plate to undermine a larger peripheral fragment, incorporating the subperiosteal bone collar. B: When the fracture line (arrows) is projected obliquely, the thicker peripheral fragment, including the subperiosteal bone collar, is projected as a curvilinear fragment or a bucket-handle lesion. C: When the fracture line (arrow) is incomplete (it extends across only a portion of the metaphysis), the appearance suggests a focal, triangularly shaped peripheral fragment encompassing the subperiosteal bone collar. D: When the fracture line (arrow) is tipped obliquely, the peripheral margin of the fragment is projected as curvilinear density.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kleinman, PK, Marks, SC Jr. Relationship of the subperiosteal bone collar to metaphyseal lesions in abused infants. J Bone Joint Surg Am 1995; 77:1471. Copyright &copy; 1995 The Journal of Bone and Joint Surgery, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_2_39983=[""].join("\n");
var outline_f39_2_39983=null;
